日本臨牀　81/増刊6　臨床前立腺癌学

出版社： 日本臨牀社
発行日： 2023-06-30
分野： 臨床医学：一般  >  雑誌
ISSN： 00471852
雑誌名：
特集： 臨床前立腺癌学―基礎・臨床の最新知見―
電子書籍版： 2023-06-30 （初版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：4～8営業日

24,200 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

24,200 円(税込)

購入する

目次

  • 特集　臨床前立腺癌学
    　　　―基礎・臨床の最新知見―

    I．総　論
    　１．前立腺癌研究の歴史的変遷と展望

    II．基礎研究
    　1．発癌・進展機序の解明
    　　（1）アンドロゲン受容体およびそのシグナル伝達の異常
    　　（2）前立腺癌再燃時の副腎性アンドロゲンの役割
    　　（3）ドライバー遺伝子の同定
    　　（4）神経内分泌分化
    　　（5）前立腺癌骨転移機序
    　　（6）前立腺癌におけるエピジェネティクス制御
    　　（7）エクソソームの役割
    　2．臨床応用を目指した基礎研究
    　　（1）バイオマーカー開発: 前立腺癌診断マーカーS2,3PSA%検査の開発経緯とその臨床有用性
    　　（2）リキッドバイオプシーの進歩
    　　（3）遺伝子多型と薬剤感受性
    　　（4）去勢抵抗性前立腺癌に対する免疫療法
    　　（5）前立腺がんに対するウイルス療法　～臨床応用に向けて～

    III．診　断
    　1．検診
    　　（1）本邦における現況
    　　（2）前立腺がん検診をめぐる国際的動向
    　2．PSAおよび関連パラーメーター
    　3．生検
    　　（1）至適生検手技の確立
    　　（2）前立腺再生検
    　　（3）MRI-US fusion生検
    　4．画像診断
    　　（1）MRIによる病巣検出
    　　（2）MRIによる局所病期診断
    　　（3）マルチパラメトリックMRIによる治療後の再発診断
    　　（4）骨シンチグラフィーとその定量的評価
    　　（5）PSMA-PETとその臨床的有用性

    IV．治　療
    　1．手術療法
    　　（1）手術療法概論：現況と将来展望
    　　（2）開腹前立腺全摘除術
    　　（3）腹腔鏡下前立腺全摘除術
    　　（4）ロボット支援前立腺全摘除術
    　　（5）リンパ節郭清術
    　　（6）術後合併症とその対策
    　　　　1）周術期合併症とその対策
    　　　　2）尿禁制改善の工夫
    　　　　3）性機能改善の工夫
    　　　　4）人工尿道括約筋植込術
    　　　　5）鼠経ヘルニアの予防と治療
    　　（7）外科治療に関する諸問題
    　　　　1）国産手術支援ロボットの導入
    　　　　2）レチウス腔温存アプローチの有用性と問題点
    　　　　3）局所進行癌に対する拡大摘除術
    　　　　4）前立腺癌局所再発に対する救済前立腺全摘除術の治療成績とその適応
    　　　　5）術後再発診断とその問題点
    　　　　6）術後再発に対する治療
    　2．放射線療法
    　　（1）放射線療法概論：現状と将来展望
    　　（2）外照射療法
    　　　　1）外照射療法の進歩
    　　　　2）寡分割照射の有用性
    　　　　3）放射線療法の合併症とその対策
    　　　　4）再発の定義と問題点
    　　　　5）再発に対する治療戦略
    　　（3）小線源療法
    　　　　1）密封小線源永久挿入療法
    　　　　2）高線量率小線源治療
    　　　　3）高リスク前立腺癌に対するトリモダリティ―治療
    　　（4）粒子線治療
    　　　　1）陽子線治療
    　　　　2）重粒子線治療
    　3．Focal therapy
    　　（1）高密度焦点式超音波療法（HIFU）
    　　（2）癌病巣標的化凍結治療
    　　（3）低線量率小線源療法を用いたfocal therapy
    　4．薬物療法
    　　（1）薬物療法概論：現況と将来展望
    　　（2）古典的薬物療法
    　　　　1）LH-RHアゴニストによるアンドロゲン除去療法
    　　　　2）LH-RHアンタゴニストによるアンドロゲン除去療法
    　　　　3）その他の古典的薬物療法
    　　　　4）ホルモン療法に伴う有害事象
    　　　　5）去勢抵抗性の診断と問題点
    　　（3）新規薬物療法
    　　　　1）転移性去勢感受性癌に対する治療の進歩
    　　　　2）非転移性去勢抵抗性癌に対する治療の進歩
    　　　　3）mCRPCに対する治療の進歩
    　　　　4）アビラテロン
    　　　　5）エンザルタミド
    　　　　6）アパルタミド
    　　　　7）ダロルタミド
    　　　　8）ドセタキセル
    　　　　9）カバジタキセル
    　　　 10）進行性前立腺癌に対するオラパリブの役割
    11）去勢抵抗性前立腺癌に対するラジウム-223治療
    12）新規薬物併用療法の有用性と問題点
    13）開発中の新規薬物療法
    　5．その他の治療
    　　（1）監視療法
    　　（2）骨関連事象に対する薬物療法
    　　（3）緩和治療～疼痛に対する薬物療法～
    　　（4）局所進行・オリゴ転移性前立腺癌に対する原発巣治療
    　　（5）日本人去勢抵抗性前立腺癌患者に対するPSMAリガンドによる核医学治療の経験

    V．特　論
    　1．前立腺癌の疫学的動向
    　2．病理診断update
    　3．臨床解剖学的研究の進歩―前立腺全摘除術への応用―
    　4．ガイドラインの意義

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I 総論

P.11 掲載の参考文献
1) Gutman AB, Gutman EB:An "Acid" Phosphatase Occurring in the Serum of Patients with Metastasizing Carcinoma of the Prostate Gland. J Clin Invest 17:473-478, 1938.
 
2) Huggins C, Hodges CV:Studies on Prostatic Cancer. I. The Effect of Castration, of Estrogen and of Androgen Injection on Serum Phosphatases in Metastatic Carcinoma of the Prostate. Cancer res 1:293-297, 1941.
 
3) Huggins C, Stevens RE Jr, Hodges CV:Studies on Prostatic Cancer:II. the Effects of Castration on Advanced Carcinoma of the Prostate Gland. Arch of Surg 43:209-223, 1941.
 
4) Huggins C, Scott WW, Hodges CV:Studies on Prostatic Cancer. III. The Effects of Fever, of Desoxycorticosterone and of Estrogen on Clinical Patients with Metastatic Carcinoma of the Prostate. Urol 46:997-1006, 1941.
 
5) Davies AH, Zoubeidi A:Targeting androgen receptor signaling:a historical perspective. Endocr Relat Cancer 28:T11-T18, 2021.
PubMed
6) White JW:I. The Results of Double Castration in Hypertrophy of the Prostate. Ann Surg 22:1-80, 1895.
PubMed
7) Huggins C, Stevens RA:The Effect of Castration on Benign Hypertrophy of the Prostate in Men. Urol 43:705-714, 1940.
 
8) Huggins C, Dao TL:Adrenalectomy and oophorectomy in treatment of advanced carcinoma of the breast. J Am Med Assoc 151:1388-1394, 1953.
PubMed
9) Huggins C, Scott WW:Bilateral Adrenalectomy in Prostatic Cancer:Clinical Features and Urinary Excretion of 17-Ketosteroids and Estrogen. Ann Surg 122:1031-1041, 1945.
PubMed
10) Byar DP:Treatment of prostatic cancer:studies by the Veterans Administration cooperative urological research group. Bull N Y Acad Med 48:751-766, 1972.
PubMed
11) Schally AV, Arimura A, Bowers CY, et al:Purification of hypothalamic releasing hormones of human origin. J Clin Endocrinol Metab 31:291-300, 1970.
PubMed
12) 松尾寿之:ストックホルムへの道-内分泌学におけるGuillemin, Schallyの先陣争い. 科学 48:537-547, 1978.
 
13) Schally AV, Arimura A, Kastin AJ, et al:Gonadotropin-releasing hormone:one polypeptide regulates secretion of luteinizing and follicle-stimulating hormones. Science 173:1036-1038, 1971.
PubMed
14) Guillemin R, Burgus R:The hormones of the hypothalamus. Sci Am 227:24-33, 1972.
PubMed
15) Sandow J, Von Rechenberg W, Jerzabek G, et al:Pituitary gonadotropin inhibition by a highly active analog of luteinizing hormone-releasing hormone. Fertil Steril 30:205-209, 1978.
PubMed
16) Klotz L, Boccon-Gibod L, Shore ND, et al:The efficacy and safety of degarelix:a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int 102:1531-1538, 2008.
PubMed
17) Toft D, Gorski J:A receptor molecule for estrogens:isolation from the rat uterus and preliminary characterization. Proc Natl Acad Sci U S A 55:1574-1581, 1966.
 
18) Mainwaring WI:A soluble androgen receptor in the cytoplasm of rat prostate. J Endocrinol 45:531-541, 1969.
PubMed
19) Fang S, Anderson KM, Liao S:Receptor proteins for androgens. On the role of specific proteins in selective retention of 17-beta-hydroxy-5-alpha-androstan-3-one by rat ventral prostate in vivo and in vitro. J Biol Chem 244:6584-6595, 1969.
PubMed
20) Baulieu EE, Jung I:A prostatic cytosol receptor. Biochem Biophys Res Commun 38:599-606, 1970.
 
21) Bruchovsky N, Wilson JD:The intranuclear binding of testosterone and 5-alpha-androstan-17-beta-ol-3-one by rat prostate. J Biol Chem 243:5953-5960, 1968.
PubMed
22) Baulieu EE, Lasnizki I, Robel P:Metabolism of testosterone and action of metabolites on prostate glands grown in organ culture. Nature 219:1155-1156, 1968.
PubMed
23) Shimazaki J, Kurihara H, Ito Y, et al:Testosterone metabolism in prostate; formation of androstan-17-beta-ol-3-one and androst-4-ene-3, 17-dione, and inhibitory effect of natural and synthetic estrogens. Gunma J Med Sci 14:313-325, 1965.
PubMed
24) 鈴木和浩, 新井誠二:前立腺癌に対する内分泌療法:歴史と概論. 臨床泌尿器科 69:330-333, 2015.
 
25) Pavone-Macaluso M, de Voogt HJ, Viggiano G, et al:Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer:final analysis of a randomized phase III trial of the European Organization for Research on Treatment of Cancer Urological Group. J Urol 136:624-631, 1986.
 
26) 志田圭三, 島崎 淳, 浦野悦郎, ほか:アンドロゲンの前立腺に対する作用機序に関する研究(第III編)合成ゲスターゲン剤の抗アンドロゲン効果(附)Chlormadinone acetateによる前立腺肥大症治験. 日本泌尿器科学会雑誌 63:109-128, 1972.
 
27) 志田圭三, 辻 一郎, 島崎 淳, ほか:前立腺癌に対する酢酸クロルマジノンの臨床効果. 泌尿器科紀要 26:1553-1574, 1980.
 
28) Tran C, Ouk S, Clegg NJ, et al:Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324:787-790, 2009.
PubMed
29) Potter GA, Barrie SE, Jarman M, et al:Novel steroidal inhibitors of human cytochrome P45017 alpha(17 alpha-hydroxylase-C17,20-lyase):potential agents for the treatment of prostatic cancer. J Med Chem 38:2463-2471, 1995.
PubMed
30) Aggarwal R, Huang J, Alumkal JJ, et al:Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer:A Multi-institutional Prospective Study. J Clin Oncol 36:2492-2503, 2018.
PubMed

II 基礎研究

P.21 掲載の参考文献
1) Huggins C:Effect of Orchiectomy and Irradiation on Cancer of the Prostate. Ann Surg 115:1192-1200, 1942.
PubMed
2) Locke JA, Guns ES, Lubik AA, et al:Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 68:6407-6415, 2008.
PubMed
3) Obinata D, Takayama K, Takahashi S, et al:Crosstalk of the Androgen Receptor with Transcriptional Collaborators:Potential Therapeutic Targets for Castration-Resistant Prostate Cancer. Cancers (Basel) 9:22, 2017.
PubMed
4) Tagawa ST, Antonarakis ES, Gjyrezi A, et al:Expression of AR-V7 and ARv567es in Circulating Tumor Cells Correlates with Outcomes to Taxane Therapy in Men with Metastatic Prostate Cancer Treated in TAXYNERGY. Clin Cancer Res 25:1880-1888, 2019.
PubMed
5) Wang Q, Li W, Liu XS, et al:A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell 27:380-392, 2007.
 
6) Quigley DA, Dang HX, Zhao SG, et al:Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell 174:758-769. e9, 2018.
 
7) Takeda DY, Spisak S, Seo JH, et al:A Somatically Acquired Enhancer of the Androgen Receptor Is a Noncoding Driver in Advanced Prostate Cancer. Cell 174:422-432. e13, 2018.
 
8) Lawrence MG, Obinata D, Sandhu S, et al:Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy. Eur Urol 74:562-572, 2018.
PubMed
9) Borgmann H, Lallous N, Ozistanbullu D, et al:Moving Towards Precision Urologic Oncology:Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201). Eur Urol 73:4-8, 2018.
PubMed
10) Rathkopf DE, Smith MR, Ryan CJ, et al:Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide. Ann Oncol 28:2264-2271, 2017.
PubMed
11) Takayama KI, Suzuki T, Fujimura T, et al:Dysregulation of spliceosome gene expression in advanced prostate cancer by RNA-binding protein PSF. Proc Natl Acad Sci U S A 114:10461-10466, 2017.
PubMed
12) Cai L, Tsai YH, Wang P, et al:ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer. Mol Cell 72:341-354. e6, 2018.
 
13) Sharma NL, Massie CE, Ramos-Montoya A, et al:The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man. Cancer Cell 23:35-47, 2013.
PubMed
14) Obinata D, Funakoshi D, Takayama K, et al:OCT1-target neural gene PFN2 promotes tumor growth in androgen receptor-negative prostate cancer. Sci Rep 12:6094, 2022.
PubMed
15) Herberts C, Annala M, Sipola J, et al:Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer. Nature 608:199-208, 2022.
PubMed
P.28 掲載の参考文献
1) Siegel RL, Miller KD, Fuchs HE, et al:Cancer statistics, 2022. CA Cancer J Clin 72:7-33, 2022.
PubMed
2) Labrie F, Dupont A, Belanger A:Complete androgen blockade for the treatment of prostate cancer. Important Adv Oncol:193-217, 1985.
PubMed
3) Mizokami A, Koh E, Fujita H, et al:The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor. Cancer Res 64:765-771, 2004.
PubMed
4) Akaza H:Global update on defining and treating high-risk localized prostate cancer with leuprorelin:a Japanese perspective-the effect of primary androgen deprivation therapy on stage C prostate cancer. BJU Int 99 (Suppl 1):10-18, 2007.
 
5) Labrie F:Multiple intracrine hormonal targets in the prostate:opportunities and challenges. BJU Int 100 (Suppl 2):48-51, 2007.
 
6) Mizokami A, Koh E, Izumi K, et al:Prostate cancer stromal cells and LNCaP cells coordinately activate the androgen receptor through synthesis of testosterone and dihydrotestosterone from dehydroepiandrosterone. Endocr Relat Cancer 16:1139-1155, 2009.
PubMed
7) Fujimoto N, Miyamoto H, Mizokami A, et al:Prostate cancer cells increase androgen sensitivity by increase in nuclear androgen receptor and androgen receptor coactivators; a possible mechanism of hormone-resistance of prostate cancer cells. Cancer Invest 25:32-37, 2007.
PubMed
8) Pinto-Bazurco Mendieta MA, Negri M, Jagusch C, et al:Synthesis, biological evaluation, and molecular modeling of abiraterone analogues:novel CYP17 inhibitors for the treatment of prostate cancer. J Med Chem 51:5009-5018, 2008.
PubMed
9) Shen HC, Balk SP:Development of androgen receptor antagonists with promising activity in castration-resistant prostate cancer. Cancer Cell 15:461-463, 2009.
PubMed
10) Efstathiou E, Titus M, Tsavachidou D, et al:Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. J Clin Oncol 30:637-643, 2012.
 
11) Hoffman-Censits J, Kelly WK:Enzalutamide:a novel antiandrogen for patients with castrate-resistant prostate cancer. Clin Cancer Res 19:1335-1339, 2013.
 
12) Izumi K, Shima T, Mita K, et al:Enzalutamide Versus Abiraterone plus Prednisolone Before Chemotherapy for Castration-resistant Prostate Cancer:A Multicenter Randomized Controlled Trial. Eur Urol Open Sci 41:16-23, 2022.
PubMed
13) Mizokami A, Gotoh A, Yamada H, et al:Tumor necrosis factor-alpha represses androgen sensitivity in the LNCaP prostate cancer cell line. J Urol 164:800-805, 2000.
PubMed
P.34 掲載の参考文献
1) 国立がん研究センターホームページ. [https://www.ncc.go.jp/jp/information/pr_release/2014/1103/index.html]
 
2) Momozawa Y, Iwasaki Y, Hirata M, et al:Germline Pathogenic Variants in 7636 Japanese Patients With Prostate Cancer and 12 366 Controls. J Natl Cancer Inst 112:369-376, 2020.
PubMed
3) Conti DV, Darst BF, Moss LC, et al:Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nat Genet 53:65-75, 2021.
PubMed
4) Takata R, Takahashi A, Fujita M, et al:12 new susceptibility loci for prostate cancer identified by genome-wide association study in Japanese population. Nat Commun 10:4422, 2019.
PubMed
5) Akamatsu S, Takata R, Ashikawa K, et al:A functional variant in NKX3.1 associated with prostate cancer susceptibility down-regulates NKX3.1 expression. Hum Mol Genet 19:4265-4272, 2010.
 
6) Nguyen HH, Takata R, Akamatsu S, et al:IRX4 at 5p15 suppresses prostate cancer growth through the interaction with vitamin D receptor, conferring prostate cancer susceptibility. Hum Mol Genet 21:2076-2085, 2012.
PubMed
7) Pomerantz MM, Ahmadiyeh N, Jia L, et al:The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer. Nat Genet 41:882-884, 2009.
PubMed
8) Cancer Genome Atlas Research Network:The Molecular Taxonomy of Primary Prostate Cancer. Cell 163:1011-1025, 2015.
 
9) Tomlins SA, Rhodes DR, Perner S, et al:Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310:644-648, 2005.
PubMed
10) Cotter K, Rubin MA:The evolving landscape of prostate cancer somatic mutations. Prostate 82 (Suppl 1):S13-S24, 2022.
 
11) Wang Q, Li W, Zhang Y, et al:Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 138:245-256, 2009.
 
12) Deek MP, Van der Eecken K, Phillips R, et al:The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer:The Spectrum Theory Revisited. Eur Urol 80:632-640, 2021.
PubMed
13) Robinson D, Van Allen EM, Wu YM, et al:Integrative clinical genomics of advanced prostate cancer. Cell 161:1215-1228, 2015.
PubMed
P.40 掲載の参考文献
1) Epstein JI, Amin MB, Beltran H, et al:Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am J Surg Pathol 38:756-767, 2014.
PubMed
2) Beltran H, Prandi D, Mosquera JM, et al:Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med 22:298-305, 2016.
PubMed
3) Netto GJ, Amin MB, Berney DM, et al:The 2022 World Health Organization Classification of Tumors of the Urinary System and Male Genital Organs-Part B:Prostate and Urinary Tract Tumors. Eur Urol 82:469-482, 2022.
PubMed
4) Beltran H, Rickman DS, Park K, et al:Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov 1:487-495, 2011.
PubMed
5) Fine SW:Neuroendocrine tumors of the prostate. Mod Pathol 31:S122-S132, 2018.
PubMed
6) Aggarwal R, Huang J, Alumkal JJ, et al:Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer:A Multi-institutional Prospective Study. J Clin Oncol 36:2492-2503, 2018.
PubMed
7) Bluemn EG, Coleman IM, Lucas JM, et al:Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling. Cancer Cell 32:474-489. e6, 2017.
 
8) Patel GK, Chugh N, Tripathi M:Neuroendocrine Differentiation of Prostate Cancer-An Intriguing Example of Tumor Evolution at Play. Cancers (Basel) 11:1405 2019.
PubMed
9) Chen R, Dong X, Gleave M:Molecular model for neuroendocrine prostate cancer progression. BJU Int 122:560-570, 2018.
 
10) Chedgy EC, Vandekerkhove G, Herberts C, et al:Biallelic tumour suppressor loss and DNA repair defects in de novo small-cell prostate carcinoma. J Pathol 246:244-253, 2018.
PubMed
11) Kosaka T, Hongo H, Aimono E, et al:A first Japanese case of neuroendocrine prostate cancer accompanied by lung and brain metastasis with somatic and germline BRCA2 mutation. Pathol Int 69:715-720, 2019.
PubMed
12) Abida W, Cyrta J, Heller G, et al:Genomic correlates of clinical outcome in advanced prostate cancer. Proc Natl Acad Sci U S A 116:11428-11436, 2019.
PubMed
13) Conteduca V, Oromendia C, Eng KW, et al:Clinical features of neuroendocrine prostate cancer. Eur J Cancer 121:7-18, 2019.
PubMed
14) Wang HT, Yao YH, Li BG, et al:Neuroendocrine Prostate Cancer (NEPC) progressing from conventional prostatic adenocarcinoma:factors associated with time to development of NEPC and survival from NEPC diagnosis-a systematic review and pooled analysis. J Clin Oncol 32:3383-3390, 2014.
PubMed
15) Aparicio AM, Harzstark AL, Corn PG, et al:Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res 19:3621-3630, 2013.
 
16) Beltran H, Oromendia C, Danila DC, et al:A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer:Efficacy and Biomarkers. Clin Cancer Res 25:43-51, 2019.
PubMed
17) Corn PG, Heath EI, Zurita A, et al:Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers:a randomised, open-label, phase 1-2 trial. Lancet Oncol 20:1432-1443, 2019.
PubMed
18) Puca L, Gavyert K, Sailer V, et al:Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer. Sci Transl Med 11:eaav0891, 2019.
 
19) Baba Y, Kosaka T, Kobayashi H, et al:Castration-resistant prostate cancer patient presenting with whole genome doubling with CDK-12 mutation. BMC Med Genomics 15:32, 2022.
PubMed
20) Daimon T, Kosaka T, Hongo H, et al:Prominent response to platinum-based chemotherapy in a patient with BRCA2 mutant-neuroendocrine prostate cancer and MDM2 amplification. IJU Case Rep 4:216-219, 2021.
 
21) Hongo H, Kosaka T, Aimono E, et al:Aggressive prostate cancer with somatic loss of the homologous recombination repair gene FANCA:a case report. Diagn Pathol 15:5, 2020.
PubMed
22) Hongo H, Kosaka T, Hayashi H, et al:Germline BRCA2 mutation in a case of aggressive prostate cancer accompanied by spinal bulbar muscular atrophy. Asian J Androl 24:116-118, 2022.
 
23) Iwasawa T, Kosaka T, Morita S, et al:A Japanese case of castration-resistant prostate cancer with BRCA2 and RB1 co-loss and TP53 mutation:a case report. BMC Med Genomics 15:138, 2022.
PubMed
24) Izawa M, Kosaka T, Nakamura K, et al:Pulmonary metastasis secondary to abiraterone-resistant prostate cancer with homozygous deletions of BRCA2:First Japanese case. IJU Case Rep 4:14-17, 2021.
PubMed
25) Kobayashi H, Kosaka T, Nakamura K, et al:A first case of ductal adenocarcinoma of the prostate having characteristics of neuroendocrine phenotype with PTEN, RB1 and TP53 alterations. BMC Med Genomics 14:245, 2021.
PubMed
26) Masuda T, Kosaka T, Nakamura K, et al:Multiple metastases of androgen indifferent prostate cancer in the urinary tract:two case reports and a literature review. BMC Med Genomics 15:118, 2022.
 
27) Omura M, Kosaka T, Aimono E, et al:First successful case of platinum-based chemotherapy for neuroendocrine prostate cancer with BRCA2 and PTEN alterations. IJU Case Rep 5:41-44, 2022.
PubMed
28) Watanabe K, Kosaka T, Aimono E, et al:Japanese Case of Enzalutamide-Resistant Prostate Cancer Harboring a SPOP Mutation With Scattered Allelic Imbalance:Response to Platinum-Based Therapy. Clin Genitourin Cancer 17:e897-e902, 2019.
PubMed
29) Ku SY, Rosario S, Wang Y, et al:Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science 355:78-83, 2017.
PubMed
30) Park JW, Lee JK, Sheu KM, et al:Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage. Science 362:91-95, 2018.
PubMed
31) Lee JK, Lee J, Kim S, et al:Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas. J Clin Oncol 35:3065-3074, 2017.
 
32) Konukiewitz B, Schlitter AM, Jesinghaus M, et al:Somatostatin receptor expression related to TP53 and RB1 alterations in pancreatic and extrapancreatic neuroendocrine neoplasms with a Ki67-index above 20. Mod Pathol 30:587-598, 2017.
PubMed
33) Mu P, Zhang Z, Benelli M, et al:SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. Science 355:84-88, 2017.
PubMed
34) Yasumizu Y, Rajabi H, Jin C, et al:MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer. Nat Commun 11:338, 2020.
PubMed
35) Carver BS, Chapinski C, Wongvipat J, et al:Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 19:575-586, 2011.
 
36) Dardenne E, Beltran H, Benelli M, et al:N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer. Cancer Cell 30:563-577, 2016.
PubMed
37) Liu B, Li L, Yang G, et al:PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer. Clin Cancer Res 25:6839-6851, 2019.
 
38) Li Y, Donmez N, Sahinalp C, et al:SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway Inhibition. Eur Urol 71:68-78, 2017.
PubMed
39) Rotinen M, You S, Yang J, et al:ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis. Nat Med 24:1887-1898, 2018.
PubMed
40) Li Y, Xie N, Chen R, et al:RNA Splicing of the BHC80 Gene Contributes to Neuroendocrine Prostate Cancer Progression. Eur Urol 76:157-166, 2019.
PubMed
41) Kim J, Jin H, Zhao JC, et al:FOXA1 inhibits prostate cancer neuroendocrine differentiation. Oncogene 36:4072-4080, 2017.
 
42) Adams EJ, Karthaus WR, Hoover E, et al:FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes. Nature 571:408-412, 2019.
PubMed
43) Park JW, Lee JK, Witte ON, et al:FOXA2 is a sensitive and specific marker for small cell neuroendocrine carcinoma of the prostate. Mod Pathol 30:1262-1272, 2017.
PubMed
44) Qi J, Nakayama K, Cardiff RD, et al:Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors. Cancer Cell 18:23-38, 2010.
PubMed
45) Guo H, Ci X, Ahmed M, et al:ONECUT2 is a driver of neuroendocrine prostate cancer. Nat Commun 10:278, 2019.
PubMed
46) Lee GT, Kwon SJ, Lee JH, et al:Macrophages induce neuroendocrine differentiation of prostate cancer cells via BMP6-IL6 Loop. Prostate 71:1525-1537, 2011.
PubMed
47) Wang C, Peng G, Huang H, et al:Blocking the Feedback Loop between Neuroendocrine Differentiation and Macrophages Improves the Therapeutic Effects of Enzalutamide (MDV3100) on Prostate Cancer. Clin Cancer Res 24:708-723, 2018.
PubMed
48) Tang F, Xu D, Wang S, et al:Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets. Science 376(6596);DOI:10.1126/science.abe150, 2022.
 
P.47 掲載の参考文献
1) Coleman RE:Skeletal complications of malignancy. Cancer 80:1588-1594, 1997.
PubMed
2) Yokomizo A, Koga H, Shinohara N, et al:Skeletal-related events in urological cancer patients with bone metastasis:a multicenter study in Japan. Int J Urol 17:332-336, 2010.
PubMed
3) Ganguly SS, Li X, Miranti CK:The host microenvironment influences prostate cancer invasion, systemic spread, bone colonization, and osteoblastic metastasis. Front Oncol 4:364, 2014.
PubMed
4) Kang J, La Manna F, Bonollo F, et al:Tumor microenvironment mechanisms and bone metastatic disease progression of prostate cancer. Cancer Lett 530:156-169, 2022.
PubMed
5) Yoneda T, Hiraga T:Crosstalk between cancer cells and bone microenvironment in bone metastasis. Biochem Biophys Res Commun 328:679-687, 2005.
PubMed
6) Nakanishi M, Hata K, Yoneda T:[Encounter of cancer cells with bone. Molecular mechanism of cancer-induced bone pain]. Clin Calcium 21:357-363, 2011.
PubMed
7) Roodman GD, Dougall WC:RANK ligand as a therapeutic target for bone metastases and multiple myeloma. Cancer Treat Rev 34:92-101, 2008.
PubMed
8) Yonou H, Aoyagi Y, Kanomata N, et al:Prostate-specific antigen induces osteoplastic changes by an autonomous mechanism. Biochem Biophys Res Commun 289:1082-1087, 2001.
PubMed
9) Lipton A, Costa L, Ali S, et al:Use of markers of bone turnover for monitoring bone metastases and the response to therapy. Semin Oncol 28(4 Suppl 11):54-59, 2001.
 
10) Coleman RE, Major P, Lipton A, et al:Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 23:4925-4935, 2005.
PubMed
11) 米納浩幸, 斎藤誠一:前立腺癌造骨性骨転移の成立・進展のメカニズム. 臨床泌尿器科 63:759-769, 2009.
 
12) Gundem G, Van Loo P, Kremeyer B, et al:The evolutionary history of lethal metastatic prostate cancer. Nature 520:353-357, 2015
PubMed
P.51 掲載の参考文献
1) Stein R, Gruenbaum Y, Pollack Y, et al:Clonal inheritance of the pattern of DNA methylation in mouse cells. Proc Natl Acad Sci U S A 79:61-65, 1982.
PubMed
2) Bastian PJ, Yegnasubramanian S, Palapattu GS, et al:Molecular biomarker in prostate cancer:the role of CpG island hypermethylation. Eur Urol 46:698-708, 2004.
PubMed
3) Mahon KL, Qu W, Lin HM, et al:Serum Free Methylated Glutathione S-transferase 1 DNA Levels, Survival, and Response to Docetaxel in Metastatic, Castration-resistant Prostate Cancer:Post Hoc Analyses of Data from a Phase 3 Trial. Eur Urol 76:306-312, 2019.
PubMed
4) Takayama K, Misawa A, Suzuki T, et al:TET2 repression by androgen hormone regulates global hydroxymethylation status and prostate cancer progression. Nat Commun 6:8219, 2015.
PubMed
5) Cancer Genome Atlas Research Network:The Molecular Taxonomy of Primary Prostate Cancer. Cell 163:1011-1025, 2015.
 
6) Zhao SG, Chen WS, Li H, et al:The DNA methylation landscape of advanced prostate cancer. Nat Genet 52:778-789, 2020.
PubMed
7) Ellinger J, Kahl P, von der Gathen J, et al:Global levels of histone modifications predict prostate cancer recurrence. Prostate 70:61-69, 2010.
PubMed
8) Pomerantz MM, Qiu X, Zhu Y, et al:Prostate cancer reactivates developmental epigenomic programs during metastatic progression. Nat Genet 52:790-799, 2020.
PubMed
9) Gao S, Chen S, Han D, et al:Chromatin binding of FOXA1 is promoted by LSD1-mediated demethylation in prostate cancer. Nat Genet 52:1011-1017, 2020.
 
10) Asangani IA, Dommeti VL, Wang X, et al:Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature 510:278-282, 2014.
PubMed
11) Welti J, Sharp A, Yuan W, et al:Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC). Clin Cancer Res 24:3149-3162, 2018.
PubMed
12) Lasko LM, Jakob CG, Edalji RP, et al:Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours. Nature 550:128-132, 2017.
PubMed
13) Dardenne E, Beltran H, Benelli M, et al:N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer. Cancer Cell 30:563-577, 2016.
PubMed
P.57 掲載の参考文献
1) Valadi H, Ekstrom K, Bossios A, et al:Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 9:654-659, 2007.
PubMed
2) Thery C, Witwer KW, Aikawa E, et al:Minimal information for studies of extracellular vesicles 2018 (MISEV2018):a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles 7:1535750, 2018.
PubMed
3) Kosaka N, Iguchi H, Yoshioka Y, et al:Competitive interactions of cancer cells and normal cells via secretory microRNAs. J Biol Chem 287:1397-1405, 2012.
PubMed
4) Krishn SR, Salem I, Quaglia F, et al:The αvβ6 integrin in cancer cell-derived small extracellular vesicles enhances angiogenesis. J Extracell Vesicles 9:1763594, 2020.
 
5) Corcoran C, Rani S, O'Brien K, et al:Docetaxel-resistance in prostate cancer:evaluating associated phenotypic changes and potential for resistance transfer via exosomes. PLoS One 7:e50999, 2012.
PubMed
6) Webber JP, Spary LK, Sanders AJ, et al:Differentiation of tumour-promoting stromal myofibroblasts by cancer exosomes. Oncogene 34:290-302, 2015.
PubMed
7) Poggio M, Hu T, Pai CC, et al:Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory. Cell 177:414-427. e13, 2019.
 
8) Martens-Uzunova ES, Kusuma GD, Crucitta S, et al:Androgens alter the heterogeneity of small extracellular vesicles and the small RNA cargo in prostate cancer. J Extracell Vesicles 10:e12136, 2021.
PubMed
9) Hashimoto K, Ochi H, Sunamura S, et al:Cancer-secreted hsa-miR-940 induces an osteoblastic phenotype in the bone metastatic microenvironment via targeting ARHGAP1 and FAM134A. Proc Natl Acad Sci U S A 115:2204-2209, 2018.
PubMed
10) Ma Q, Liang M, Wu Y, et al:Small extracellular vesicles deliver osteolytic effectors and mediate cancer-induced osteolysis in bone metastatic niche. J Extracell Vesicles 10:e12068, 2021.
PubMed
11) Urabe F, Kosaka N, Yamamoto Y, et al:Metastatic prostate cancer-derived extracellular vesicles facilitate osteoclastogenesis by transferring the CDCP1 protein. J Extracell Vesicles 12:e12312, 2023.
 
12) Wang CB, Chen SH, Zhao L, et al:Urine-derived exosomal PSMA is a promising diagnostic biomarker for the detection of prostate cancer on initial biopsy. Clin Transl Oncol 25:758-767, 2023.
PubMed
13) Mugoni V, Ciani Y, Nardella C, et al:Circulating RNAs in prostate cancer patients. Cancer Lett 524:57-69, 2022.
PubMed
14) Nishida-Aoki N, Tominaga N, Takeshita F, et al:Disruption of Circulating Extracellular Vesicles as a Novel Therapeutic Strategy against Cancer Metastasis. Mol Ther 25:181-191, 2017.
PubMed
15) Urabe F, Kosaka N, Sawa Y, et al:miR-26a regulates extracellular vesicle secretion from prostate cancer cells via targeting SHC4, PFDN4, and CHORDC1. Sci Adv 6:eaay3051, 2020.
PubMed
P.63 掲載の参考文献
1) Watt KW, Lee PJ, M'Timkulu T, et al:Human prostate-specific antigen:structural and functional similarity with serine proteases. Proc Natl Acad Sci U S A 83:3166-3170, 1986.
 
2) Ohyama C, Hosono M, Nitta K, et al:Carbohydrate structure and differential binding of prostate specific antigen to Maackia amurensis lectin between prostate cancer and benign prostate hypertrophy. Glycobiology 14:671-679, 2004.
PubMed
3) Tajiri M, Ohyama C, Wada Y:Oligosaccharide profiles of the prostate specific antigen in free and complexed forms from the prostate cancer patient serum and in seminal plasma:a glycopeptide approach. Glycobiology 18:2-8, 2008.
PubMed
4) Ishikawa T, Yoneyama T, Tobisawa Y, et al:An Automated Micro-Total Immunoassay System for Measuring Cancer-Associated α2,3-linked Sialyl N-Glycan-Carrying Prostate-Specific Antigen May Improve the Accuracy of Prostate Cancer Diagnosis. Int J Mol Sci 18:470, 2017.
 
5) Yoneyama T, Yamamoto H, Sutoh Yoneyama M, et al:Characteristics of α2,3-sialyl N-glycosylated PSA as a biomarker for clinically significant prostate cancer in men with elevated PSA level. Prostate 81:1411-1427, 2021.
 
P.69 掲載の参考文献
1) Robinson D, Van Allen EM, Wu YM, et al:Integrative clinical genomics of advanced prostate cancer. Cell 161:1215-1228, 2015.
PubMed
2) Zhao SG, Chang SL, Erho N, et al:Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy. JAMA Oncol 3:1663-1672, 2017.
PubMed
3) Wyatt AW, Annala M, Aggarwal R, et al:Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer [Internet]. J Natl Cancer Inst 109:djx118, 2017. [http://dx.doi.org/10.1093/jnci/djx118]
 
4) Annala M, Vandekerkhove G, Khalaf D, et al:Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer. Cancer Discov 8:444-457, 2018.
PubMed
5) Scher HI, Jia X, de Bono JS, et al:Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer:a reanalysis of IMMC38 trial data. Lancet Oncol 10:233-239, 2009.
PubMed
6) Heller G, McCormack R, Kheoh T, et al:Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer:A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials. J Clin Oncol 36:572-580, 2018.
PubMed
7) Annala M, Fu S, Bacon JVW, et al:Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer:a multicentre, randomised, open-label, phase II trial. Ann Oncol 32:896-905, 2021.
PubMed
8) Wyatt AW, Azad AA, Volik SV, et al:Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer. JAMA Oncol 2:1598-1606, 2016.
PubMed
9) Sumiyoshi T, Mizuno K, Yamasaki T, et al:Clinical utility of androgen receptor gene aberrations in circulating cell-free DNA as a biomarker for treatment of castration-resistant prostate cancer. Sci Rep 9:4030, 2019.
PubMed
10) Antonarakis ES, Lu C, Wang H, et al:AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 371:1028-1038, 2014.
PubMed
11) Warner E, Herberts C, Fu S, et al:BRCA2, ATM, and CDK12 Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical Aggression. Clin Cancer Res 27:1650-1662, 2021.
PubMed
12) Kimura H, Mizuno K, Shiota M, et al:Prognostic significance of pathogenic variants in BRCA1, BRCA2, ATM and PALB2 genes in men undergoing hormonal therapy for advanced prostate cancer. Br J Cancer 127:1680-1690, 2022.
PubMed
13) Mizuno K, Sumiyoshi T, Okegawa T, et al:Clinical Impact of Detecting Low-Frequency Variants in Cell-Free DNA on Treatment of Castration-Resistant Prostate Cancer. Clin Cancer Res 27:6164-6173, 2021.
PubMed
14) de Bono J, Mateo J, Fizazi K, et al:Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med 382:2091-2102, 2020.
PubMed
15) Chi KN, Barnicle A, Sibilla C, et al:Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound. Clin Cancer Res 29:81-91, 2023.
PubMed
16) Hussain M, Corcoran C, Sibilla C, et al:Tumor Genomic Testing for > 4000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib). Clin Cancer Res 28:1518-1530, 2022.
 
17) Abida W, Cheng ML, Armenia J, et al:Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade. JAMA Oncol 5:471-478, 2019.
PubMed
18) Ritch E, Fu SYF, Herberts C, et al:Identification of Hypermutation and Defective Mismatch Repair in ctDNA from Metastatic Prostate Cancer. Clin Cancer Res 26:1114-1125, 2020.
PubMed
19) Kwan EM, Dai C, Fettke H, et al:Plasma Cell-Free DNA Profiling of PTEN-PI3K-AKT Pathway Aberrations in Metastatic Castration-Resistant Prostate Cancer. JCO Precis Oncol 5:622-637, 2021.
 
20) Hussain M, Lin D, Saad F, et al:Newly Diagnosed High-Risk Prostate Cancer in an Era of Rapidly Evolving New Imaging:How Do We Treat? J Clin Oncol 39:13-16, 2021.
 
21) Herberts C, Murtha AJ, Fu S, et al:Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer [Internet]. Eur Urol 78:834-844, 2020.
PubMed
22) Lorente D, Olmos D, Mateo J, et al:Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer. Eur Urol 70:985-992, 2016.
PubMed
23) Herberts C, Annala M, Sipola J, et al:Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer. Nature 608:199-208, 2022.
PubMed
P.74 掲載の参考文献
1) Blas L, Shiota M, Eto M:Current status and future perspective on the management of metastatic castration-sensitive prostate cancer. Cancer Treat Res Commun 32:100606, 2022.
PubMed
2) 塩田真己, 藤本直浩, 江藤正俊:遺伝子多型と前立腺癌薬物療法. 日本臨牀 78:918-923, 2020.
Medical*Online
3) Shiota M, Akamatsu S, Narita S, et al:Genetic Polymorphisms and Pharmacotherapy for Prostate Cancer. JMA J 4:99-111, 2021.
PubMed
4) 塩田真己:前立腺癌におけるステロイド代謝関連遺伝子多型と治療感受性. Prostate Journal 9:41-44, 2022.
Medical*Online
5) Shiota M, Yokomizo A, Naito S:Pro-survival and anti-apoptotic properties of androgen receptor signaling by oxidative stress promote treatment resistance in prostate cancer. Endocr Relat Cancer 19:R243-R253, 2012.
 
6) 塩田真己, 鑪野秀一, 賀本敏行, ほか:ゲノムワイド関連解析により同定した進行性前立腺癌の予後と関連する遺伝子多型;KYUCOG-1401-A試験. 第110回日本泌尿器科学会総会, 2023.
 
7) Shiota M, Narita S, Akamatsu S, et al:Association of missense polymorphism in HSD3B1 with outcomes among men with prostate cancer treated with androgen-deprivation therapy or abiraterone. JAMA Netw Open 2:e190115, 2019.
PubMed
8) Shiota M, Akamatsu S, Narita S, et al:The association between missense polymorphisms in SRD5A2 and HSD3B1 and treatment failure with abiraterone for castration-resistant prostate cancer. Pharmacogenomics J 21:440-445, 2021.
PubMed
9) Shiota M, Inoue R, Tashiro K, et al:A phase II trial of abiraterone with dutasteride for second-generation antiandrogen-and chemotherapy-naive patients with castration-resistant prostate cancer. J Clin Pharmacol 63:445-454, 2023.
PubMed
10) Shiota M, Takeuchi A, Song Y, et al:Y-box binding protein-1 promotes castration-resistant prostate cancer growth via androgen receptor expression. Endocr Relat Cancer 18:505-517, 2011.
 
11) Shiota M, Fujimoto N, Imada K, et al:Potential role for YB-1 in castration-resistant prostate cancer and resistance to enzalutamide through the androgen receptor V7. J Natl Cancer Inst 108:djw005, 2016.
PubMed
12) Shiota M, Narita S, Habuchi T, et al:Validated prognostic significance of YB-1 genetic variation in metastatic prostate cancer. Pharmacogenomics J 21:102-105, 2021.
PubMed
13) Afonso A, Silva J, Lopes AR, et al:YB-1 variant and androgen receptor axis-targeted agents in metastatic castration-resistant prostate cancer patients. Pharmacogenomics 21:919-928, 2020.
 
14) Herrero Rivera D, Vacas CG, Kovandzic LM, et al:Single-nucleotide polymorphism associations with efficacy and toxicity in metastatic castration-resistant prostate cancer treated with cabazitaxel. Pharmacogenomics 23:627-638, 2022.
PubMed
15) Shiota M, Akamatsu S, Sekine Y, et al:Genetic variations predicting progression with docetaxel and novel androgen-receptor pathway inhibitors. Cancer Sci 114:1625-1634, 2023.
PubMed
P.79 掲載の参考文献
1) Kantoff PW, Higano CS, Shore ND, et al:Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411-422, 2010.
PubMed
2) Kurooka M, Kaneda Y:Inactivated Sendai virus particles eradicate tumors by inducing immune responses through blocking regulatory T cells. Cancer Res 67:227-236, 2007.
PubMed
3) Hatano K, Miyamoto Y, Nonomura N, et al:Expression of gangliosides, GD1a, and sialyl paragloboside is regulated by NF-κB-dependent transcriptional control of α2,3-sialyltransferase I, II, and VI in human castration-resistant prostate cancer cells. Int J Cancer 129:1838-1847, 2011.
 
4) Fujita K, Nakai Y, Kawashima A, et al:Phase I/II clinical trial to assess safety and efficacy of intratumoral and subcutaneous injection of HVJ-E in castration-resistant prostate cancer patients. Cancer Gene Ther 24:277-281, 2017.
PubMed
5) Fujita K, Kato T, Hatano K, et al:Intratumoral and s.c. injection of inactivated hemagglutinating virus of Japan envelope (GEN0101) in metastatic castration-resistant prostate cancer. Cancer Sci 111:1692-1698, 2020.
 
6) Koga N, Noguchi M:[Peptide vaccination for castration-resistant prostate cancer]. Nihon Rinsho 72:2147-2151, 2014.
PubMed
7) Yoshimura K, Minami T, Nozawa M, et al:A Phase 2 Randomized Controlled Trial of Personalized Peptide Vaccine Immunotherapy with Low-dose Dexamethasone Versus Dexamethasone Alone in Chemotherapy-naive Castration-resistant Prostate Cancer. Eur Urol 70:35-41, 2016.
PubMed
8) Noguchi M, Fujimoto K, Arai G, et al:A randomized phase III trial of personalized peptide vaccination for castration-resistant prostate cancer progressing after docetaxel. Oncol Rep 45:159-168, 2021.
PubMed
9) 第3相 KEYNOTE-921 試験の最新情報(日本語訳)に関するプレスリリース. [https://www.msd.co.jp/news/chq-20220819/]
 
10) Abida W, Cheng ML, Armenia J, et al:Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade. JAMA Oncol 5:471-478, 2019.
PubMed
11) Graf RP, Fisher V, Weberpals J, et al:Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer. JAMA Netw Open 5:e225394, 2022.
PubMed
P.91 掲載の参考文献
1) Todo T, Ito H, Ino Y, et al:Intratumoral oncolytic herpes virus G47△ for residual or recurrent glioblastoma:a phase 2 trial. Nat Med 28:1630-1639, 2022.
 
2) Guild BC, Finer MH, Housman DE, et al:Development of retrovirus vectors useful for expressing genes in cultured murine embryonal cells and hematopoietic cells in vivo. J Virol 62:3795-3801, 1988.
PubMed
3) Isaacs WB, Carter BS, Ewing CM:Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res 51:4716-4720, 1991.
PubMed
4) Fukuhara H, Ino Y, Kuroda T, et al:Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system. Cancer Res 65:10663-10668, 2005.
PubMed
5) Chesney JA, Ribas A, Long GV, et al:Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma. J Clin Oncol 41:528-540, 2023.
PubMed
6) Dock G:The influence of complicating diseases upon leukemia. Am J Med Sci 127:563-592, 1904.
 
7) De Pace N:Sulla scomparsa di un enorme cancro vegetante del collo dell'utero senza cura chirurgica. Ginecologia 9:82-89, 1912.
 
8) Kelly E, Russell SJ:History of oncolytic viruses:genesis to genetic engineering. Mol Ther 15:651-659, 2007.
PubMed
9) Martuza RL, Malick A, Markert JM, et al:Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252:854-856, 1991.
PubMed
10) Wang G, Liu Y, Liu S, et al:Oncolyic Virotherapy for Prostate Cancer:Lighting a Fire in Winter. Int J Mol Sci 23:12647, 2022.
PubMed
11) Yew PR, Berk AJ:Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein. Nature 357:82-85, 1992.
PubMed
12) Ganly I, Kirn D, Eckhardt G, et al:A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res 6:798-806, 2000.
PubMed
13) Xia ZJ, Chang JH, Zhang L, et al:[Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus]. Ai Zheng 23:1666-1670, 2004.
PubMed
14) Andtbacka RH, Kaufman HL, Collichio F, et al:Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin Oncol 33:2780-2788, 2015.
PubMed
15) Fukuhara H, Todo T:New generation, conditionally replicating herpes simplex virus G47Δ as a potential backbone vector for expressing foreign proteins. Drugs of the Future 28:43-49, 2003.
 
16) Mineta T, Rabkin SD, Yazaki T, et al:Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1:938-943, 1995.
PubMed
17) Markert JM, Medlock MD, Rabkin SD, et al:Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma:results of a phase I trial. Gene Ther 7:867-874, 2000.
PubMed
18) Todo T, Martuza RL, Rabkin SD, et al:Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci U S A 98:6396-6401, 2001.
PubMed
19) Taguchi S, Fukuhara H, Homma Y, et al:Current status of clinical trials assessing oncolytic virus therapy for urological cancers. Int J Urol 24:342-351, 2017.
PubMed
20) DeWeese TL, van der Poel H, Li S, et al:A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res 61:7464-7472, 2001.
 
21) Small EJ, Carducci MA, Burke JM, et al:A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol Ther 14:107-117, 2006.
PubMed
22) Freytag SO, Khil M, Stricker H, et al:Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res 62:4968-4976, 2002.
PubMed
23) Freytag SO, Stricker H, Pegg J, et al:Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer. Cancer Res 63:7497-7506, 2003.
PubMed
24) Freytag SO, Stricker H, Peabody J, et al:Five-year follow-up of trial of replication-competent adenovirus-mediated suicide gene therapy for treatment of prostate cancer. Mol Ther 15:636-642, 2007.
PubMed
25) Freytag SO, Movsas B, Aref I, et al:Phase I trial of replication-competent adenovirus-mediated suicide gene therapy combined with IMRT for prostate cancer. Mol Ther 15:1016-1023, 2007.
PubMed
26) Freytag SO, Stricker H, Lu M, et al:Prospective randomized phase 2 trial of intensity modulated radiation therapy with or without oncolytic adenovirus-mediated cytotoxic gene therapy in intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 89:268-276, 2014.
PubMed
27) Barton KN, Stricker H, Brown SL, et al:Phase I study of noninvasive imaging of adenovirus-mediated gene expression in the human prostate. Mol Ther 16:1761-1769, 2008.
PubMed
28) Barton KN, Stricker H, Elshaikh MA, et al:Feasibility of adenovirus-mediated hNIS gene transfer and 131I radioiodine therapy as a definitive treatment for localized prostate cancer. Mol Ther 19:1353-1359, 2011.
 
29) Dong W, van Ginkel JWH, Au KY, et al:ORCA-010, a novel potency-enhanced oncolytic adenovirus, exerts strong antitumor activity in preclinical models. Hum Gene Ther 25:897-904, 2014.
PubMed
30) Vidal L, Pandha HS, Yap TA, et al:A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clin Cancer Res 14:7127-7137, 2008.
PubMed
31) Comins C, Spicer J, Protheroe A, et al:REO-10:a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer. Clin Cancer Res 16:5564-5572, 2010.
PubMed
32) Eigl BJ, Chi K, Tu D, et al:A randomized phase II study of pelareorep and docetaxel or docetaxel alone in men with metastatic castration resistant prostate cancer:CCTG study IND 209. Oncotarget 9:8155-8164, 2018.
PubMed
33) Rudin CM, Pandha HS, Zibelman M, et al:Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors. J Immunother Cancer 11:e005007, 2023.
PubMed
34) Schirrmacher V, Bihari AS, Stucker W, et al:Long-term remission of prostate cancer with extensive bone metastases upon immuno- and virotherapy:A case report. Oncol Lett 8:2403-2406, 2014.
PubMed
35) Pisters LL, Pettaway CA, Troncoso P, et al:Evidence that transfer of functional p53 protein results in increased apoptosis in prostate cancer. Clin Cancer Res 10:2587-2593, 2004.
PubMed
36) Sonpavde G, Thompson TC, Jain RK, et al:GLIPR1 tumor suppressor gene expressed by adenoviral vector as neoadjuvant intraprostatic injection for localized intermediate or high-risk prostate cancer preceding radical prostatectomy. Clin Cancer Res 17:7174-7182, 2011.
PubMed
37) Herman JR, Adler HL, Aguilar-Cordova E, et al:In situ gene therapy for adenocarcinoma of the prostate:a phase I clinical trial. Hum Gene Ther 10:1239-1249, 1999.
PubMed
38) Miles BJ, Shalev M, Aguilar-Cordova E, et al:Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy. Hum Gene Ther 12:1955-1967, 2001.
PubMed
39) Teh BS, Ayala G, Aguilar L, et al:Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data. Int J Radiat Oncol Biol Phys 58:1520-1529, 2004.
PubMed
40) van der Linden RR, Haagmans BL, Mongiat-Artus P, et al:Virus specific immune responses after human neoadjuvant adenovirus-mediated suicide gene therapy for prostate cancer. Eur Urol 48:153-161, 2005.
PubMed
41) Nasu Y, Saika T, Ebara S, et al:Suicide gene therapy with adenoviral delivery of HSV-tK gene for patients with local recurrence of prostate cancer after hormonal therapy. Mol Ther 15:834-840, 2007.
PubMed
42) Rojas-Martinez A, Manzanera AG, Sukin SW, et al:Intraprostatic distribution and long-term follow-up after AdV-tk immunotherapy as neoadjuvant to surgery in patients with prostate cancer. Cancer Gene Ther 20:642-649, 2013.
PubMed
43) Fujita T, Teh BS, Timme TL, et al:Sustained long-term immune responses after in situ gene therapy combined with radiotherapy and hormonal therapy in prostate cancer patients. Int J Radiat Oncol Biol Phys 65:84-90, 2006.
PubMed
44) Kumon H, Ariyoshi Y, Sasaki K, et al:Adenovirus vector carrying REIC/DKK-3 gene:neoadjuvant intraprostatic injection for high-risk localized prostate cancer undergoing radical prostatectomy. Cancer Gene Ther 23:400-409, 2016.
PubMed
45) Trudel S, Trachtenberg J, Toi A, et al:A phase I trial of adenovector-mediated delivery of interleukin-2 (AdIL-2) in high-risk localized prostate cancer. Cancer Gene Ther 10:755-763, 2003.
PubMed
46) Sasaki K, Nasu Y, Kaku H, et al:A phase I/II study of adenovirus-mediated interleukin-12 gene therapy for hormone-refractory prostate cancer:An interim report. J Clin Oncol 29 (7 Suppl):Abstract 148, 2011.
 
47) Patel P, Young JG, Mautner V, et al:A phase I/II clinical trial in localized prostate cancer of an adenovirus expressing nitroreductase with CB1954 [correction of CB1984]. Mol Ther 17:1292-1299, 2009.
PubMed
48) Kubo H, Gardner TA, Wada Y, et al:Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer. Hum Gene Ther 14:227-241, 2003.
PubMed
49) Hinata N, Shirakawa T, Terao S, et al:Progress report on phase I/II clinical trial of Ad-OC-TK plus VAL therapy for metastatic or locally recurrent prostate cancer:Initial experience at Kobe University. Int J Urol 13:834-837, 2006.
PubMed
50) Fujita K, Nakai Y, Kawashima A, et al:Phase I/II clinical trial to assess safety and efficacy of intratumoral and subcutaneous injection of HVJ-E in castration-resistant prostate cancer patients. Cancer Gene Ther 24:277-281, 2017.
PubMed
51) Fujita K, Kato T, Hatano K, et al:Intratumoral and s.c. injection of inactivated hemagglutinating virus of Japan envelope (GEN0101) in metastatic castration-resistant prostate cancer. Cancer Sci 111:1692-1698, 2020.
 

III 診断

P.101 掲載の参考文献
1) Hugosson J, Roobol MJ, Mansson M, et al:A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer. Eur Urol 76:43-51, 2019.
PubMed
2) Hugosson J, Carlsson S, Aus G, et al:Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 11:725-732, 2010.
PubMed
3) Oberaigner W, Siebert U, Horninger W, et al:Prostate-specific antigen testing in Tyrol, Austria:prostate cancer mortality reduction was supported by an update with mortality data up to 2008. Int J Public Health 57:57-62, 2012.
PubMed
4) 前立腺がん検診市町村別実施状況-2015年6月調査-(前立腺研究財団 編), 前立腺研究財団, 2016.
 
5) 有効性評価に基づく前立腺がん検診ガイドライン(平成19年度 厚生労働省がん研究助成金「がん検診の適切な方法とその評価法の確立に関する研究」班(主任研究者:濱島ちさと)編), 2008.
 
6) 有効性評価に基づく前立腺がん検診ガイドライン:ERSPC・PLCOに関する更新ステートメント(平成22年度がん研究開発費「がん検診の評価とあり方に関する研究」班(主任研究者:垣添忠生)編), 2011.
 
7) 前立腺がん検診ガイドライン[2018年版](日本泌尿器科学会 編), メディカルレビュー社, 2018.
 
8) European Commission:Proposal for a Council Recommendation (CR) on Strengthening prevention through early detection:A new approach on cancer screening replacing CR 2003/878/EC. [homepage on internet]. [https://health.ec.europa.eu/publications/proposal-council-recommendation-cr-strengthening-prevention-through-early-detection-new-approach_en]
 
9) 前立腺がん撲滅推進委員会, 前立腺研究財団:広域研究「日本における前立腺がん検診の広域研究」. 対照研究「前立腺がん検診の死亡率減少効果に関する検証研究」総括報告書(平成13～17年度), 前立腺がん撲滅推進委員会, 2011.
 
10) 山中英壽, 島崎 淳, 伊藤一人, ほか:人間ドックにおける前立腺がん検診実施状況調査(平成17年度). 泌尿器外科 20:1113-1115, 2007.
Medical*Online
11) 伊藤一人, 加瀬嘉明, 平尾佳彦, ほか:人間ドック施設における前立腺がん検診アンケート集計報告(第17回調査)-2021年度-. 泌尿器外科, 2023. [印刷中]
 
12) Van Poppel H, Hogenhout R, Albers P, et al:Early Detection of Prostate Cancer in 2020 and Beyond:Facts and Recommendations for the European Union and the European Commission. Eur Urol 79:327-329, 2021.
 
13) Ito K, Oki R, Sekine Y, et al:Screening for prostate cancer:History, evidence, controversies and future perspectives toward individualized screening. Int J Urol 26:956-970, 2019.
PubMed
14) Heijnsdijk EA, Wever EM, Auvinen A, et al:Quality-of-life effects of prostate-specific antigen screening. N Engl J Med 367:595-605, 2012.
PubMed
P.107 掲載の参考文献
1) Andriole GL, Crawford ED, Grubb RL 3rd, et al:Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360:1310-1319, 2009.
 
2) Schroder FH, Hugosson J, Roobol MJ, et al:Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360:1320-1328, 2009.
 
3) Harris R, Lohr KN:Screening for prostate cancer:an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 137:917-929, 2002
 
4) U.S. Preventive Services Task Force:Screening for prostate cancer:U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 149:185-191, 2008.
PubMed
5) Moyer VA; U.S. Preventive Services Task Force:Screening for prostate cancer:U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 157:120-134, 2012.
PubMed
6) US Preventive Services Task Force; Grossman DC, Curry SJ, Owens DK, et al:Screening for Prostate Cancer:US Preventive Services Task Force Recommendation Statement. JAMA 319:1901-1913, 2018.
PubMed
7) Shoag JE, Mittal S, Hu JC:Reevaluating PSA Testing Rates in the PLCO Trial. N Engl J Med 374:1795-1796, 2016.
 
8) Howard DH:Declines in prostate cancer incidence after changes in screening recommendations. Arch Intern Med 172:1267-1268, 2012.
PubMed
9) Weiner AB, Matulewicz RS, Eggener SE, et al:Increasing incidence of metastatic prostate cancer in the United States (2004-2013). Prostate Cancer Prostatic Dis 19:395-397, 2016.
 
10) Prostate-specific antigen (PSA) best practice policy. American Urological Association (AUA). Oncology (Williston Park) 14:267-272, 277-278, 280 passim, 2000.
 
11) Carter HB, Albertsen PC, Barry MJ, et al:Early detection of prostate cancer:AUA Guideline. J Urol 190:419-426, 2013.
PubMed
12) European Association of Urology (EAU):EAU Guideline, Prostate Cancer, 2022. [https://uroweb.org/guidelines/prostate-cancer/chapter/diagnostic-evaluation]
 
13) Ilic D, Djulbegovic M, Jung JH, et al:Prostate cancer screening with prostate-specific antigen (PSA) test:a systematic review and meta-analysis. BMJ 362:k3519, 2018.
 
14) Hugosson J, Roobol MJ, Mansson M, et al:A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer. Eur Urol 76:43-51, 2019.
PubMed
15) Eklund M, Jaderling F, Discacciati A, et al:MRI-Targeted or Standard Biopsy in Prostate Cancer Screening. N Engl J Med 385:908-920, 2021.
 
P.112 掲載の参考文献
1) Ito K, Yamamoto T, Kubota Y, et al:Usefulness of age-specific reference range of prostate-specific antigen for Japanese men older than 60 years in mass screening for prostate cancer. Urology 56:278-282, 2000.
PubMed
2) Benson MC, McMahon DJ, Cooner WH, et al:An algorithm for prostate cancer detection in a patient population using prostate-specific antigen and prostate-specific antigen density. World J Urol 11:206-213, 1993.
 
3) Arai Y, Maeda H, Ishitoya S, et al:Prospective evaluation of prostate specific antigen density and systematic biopsy for detecting prostate cancer in Japanese patients with normal rectal examinations and intermediate prostate specific antigen levels. J Urol 158:861-864, 1997.
 
4) Djavan B, Zlotta AR, Byttebier G, et al:Prostate specific antigen density of the transition zone for early detection of prostate cancer. J Urol 160:411-419, 1998.
PubMed
5) Carter HB, Pearson JD, Waclawiw Z, et al:Prostate-specific antigen variability in men without prostate cancer:effect of sampling interval on prostate-specific antigen velocity. Urology 45:591-596, 1995.
PubMed
6) Bangma CH, van Schaik RH, Blijenberg BG et al:On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate Cancer. Eur J Cancer 46:3109-3119, 2010.
PubMed
7) Partin AW, Brawer MK, Subong EN, et al:Prospective evaluation of percent free-PSA and complexed-PSA for early detection of prostate cancer. Prostate Cancer Prostatic Dis 1:197-203, 1998.
PubMed
8) Ito K, Fujizuka Y, Ishikura K, et al:Next-generation prostate-specific antigen test:precursor form of prostate-specific antigen. Int J Clin Oncol 19:782-792, 2014.
 
9) Jansen FH, van Schaik RH, Kurstjens J, et al:Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol 57:921-927, 2010.
PubMed
10) Ito K, Miyakubo M, Sekine Y, et al:Diagnostic significance of [-2]pro-PSA and prostate dimension-adjusted PSA-related indices in men with total PSA in the 2.0-10.0 ng/mL range. World J Urol 31:305-311, 2013.
 
11) BECKMAN COULTER:アクセス ハイブリテック p2PSA 添付文書[(第2版)]. 2021年11月改訂.
 
12) 前立腺がん検診ガイドライン[2018年版](日本泌尿器科学会編), p72-74, メディカルレビュー社, 2018.
 
13) Kikuchi E, Nakashima J, Ishibashi M, et al:Prostate specific antigen adjusted for transition zone volume:the most powerful method for detecting prostate carcinoma. Cancer 89:842-849, 2000.
PubMed
14) Kadmon D, Weinberg AD, Williams RH et al:Pitfalls in interpreting prostate specific antigen velocity. J Urol 155:1655-1657, 1996.
PubMed
15) Bul M, Zhu X, Valdagni R, et al:Active surveillance for low-risk prostate cancer worldwide:the PRIAS study. Eur Urol 63:597-603, 2013.
PubMed
16) Hirama H, Sugimoto M, Ito K, et al:The impact of baseline [-2]proPSA-related indices on the prediction of pathological reclassification at 1 year during active surveillance for low-risk prostate cancer:the Japanese multicenter study cohort. J Cancer Res Clin Oncol 140:257-263, 2014.
PubMed
17) Ito K, Yokomizo A, Tokunaga S, et al:Diagnostic Impacts of Clinical Laboratory Based p2PSA Indexes on any Grade, Gleason Grade Group 2 or Greater, or 3 or Greater Prostate Cancer and Prostate Specific Antigen below 10 ng/mL. J Urol 203:83-91, 2020
 
P.117 掲載の参考文献
1) Hodge KK, McNeal JE, Terris MK, et al:Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 142:71-75, 1989.
PubMed
2) Eichler K, Hempel S, Wilby J, et al:Diagnostic value of systematic biopsy methods in the investigation of prostate cancer:a systematic review. J Urol 175:1605-1612, 2006.
PubMed
3) Scattoni V, Maccagnano C, Zanni G, et al:Is extended and saturation biopsy necessary? Int J Urol 17:432-447, 2010.
PubMed
4) Ploussard G, Nicolaiew N, Marchand C, et al:Prospective evaluation of an extended 21-core biopsy scheme as initial prostate cancer diagnostic strategy. Eur Urol 65:154-161, 2014.
PubMed
5) Futterer JJ, Briganti A, De Visschere P, et al:Can Clinically Significant Prostate Cancer Be Detected with Multiparametric Magnetic Resonance Imaging? A Systematic Review of the Literature. Eur Urol 68:1045-1053, 2015.
PubMed
6) Abdollah F, Novara G, Briganti A, et al:Trans-rectal versus trans-perineal saturation rebiopsy of the prostate:is there a difference in cancer detection rate? Urology 77:921-925, 2011.
 
7) Shen PF, Zhu YC, Wei WR, et al:The results of transperineal versus transrectal prostate biopsy:a systematic review and meta-analysis. Asian J Androl 14:310-315, 2012.
PubMed
8) McNeal JE, Redwine EA, Freiha FS, et al:Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol 12:897-906, 1988.
PubMed
9) Miyake H, Harada K, Inoue TA, et al:Additional sampling of dorsal apex on systematic prostate biopsy:impact on early detection of prostate cancer. Urology 69:738-742, 2007.
PubMed
10) Takeshita H, Kawakami S, Numao N, et al:Diagnostic performance and safety of a three-dimensional 14-core systematic biopsy method. BJU Int 115:412-418, 2015.
PubMed
11) Nam RK, Saskin R, Lee Y, et al:Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol 183:963-968, 2010.
PubMed
12) Kakehi Y, Naito S; Japanese Urological Association:Complication rates of ultrasound-guided prostate biopsy:a nation-wide survey in Japan. Int J Urol 15:319-321, 2008.
PubMed
13) Pinkhasov GI, Lin YK, Palmerola R, et al:Complications following prostate needle biopsy requiring hospital admission or emergency department visits - experience from 1000 consecutive cases. BJU Int 110:369-374, 2012.
PubMed
14) Togo Y, Kubo T, Taoka R, et al:Occurrence of infection following prostate biopsy procedures in Japan:Japanese Research Group for Urinary Tract Infection (JRGU) - a multi-center retrospective study. J Infect Chemother 20:232-237, 2014.
 
15) Elshal AM, Atwa AM, El-Nahas AR, et al:Chemoprophylaxis during transrectal prostate needle biopsy:critical analysis through randomized clinical trial. World J Urol 36:1845-1852, 2018.
PubMed
16) Shigemura K, Matsumoto M, Tanaka K, et al:Efficacy of combination use of Beta-lactamase inhibitor with penicillin and fluoroquinolones for antibiotic prophylaxis in transrectal prostate biopsy. Korean J Urol 52:289-292, 2011.
PubMed
17) 泌尿器科領域における周術期感染予防ガイドライン 2015(日本泌尿器科学会 編), メディカルレビュー社, 2016.
 
18) Pradere B, Veeratterapillay R, Dimitropoulos K, et al:Nonantibiotic Strategies for the Prevention of Infectious Complications following Prostate Biopsy:A Systematic Review and Meta-Analysis. J Urol 205:653-663, 2021.
PubMed
19) Sigle A, Suarez-Ibarrola R, Pudimat M, et al:Safety and side effects of transperineal prostate biopsy without antibiotic prophylaxis. Urol Oncol 39:782. e1-e5, 2021.
 
P.121 掲載の参考文献
1) 国立がん研究センター:がん情報サービス「がん統計」(厚生労働省人口動態統計). 全国がん罹患データ(2016年～2019年). [https://ganjoho.jp/reg_stat/statistics/data/dl/index.html#a14]
 
2) Tu X, Liu Z, Chang T, et al:Transperineal magnetic resonance imaging-targeted biopsy may perform better than transrectal route in the detection of clinically significant prostate cancer:Systematic review and meta-analysis. Clin Genitourin Cancer 17:e860-e870, 2019.
 
3) 泌尿器科・病理・放射線科 前立腺癌取扱い規約[第5版](日本泌尿器科学会, 日本病理学会, 日本医学放射線学会 編), メディカルレビュー社, 2022.
 
4) Aggarwal R, Huang J, Alumkal JJ, et al:Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer:A Multi-institutional Prospective Study. J Clin Oncol 36:2492-2503, 2018.
PubMed
5) Kawakami S, Okuno T, Yonese J, et al:Optimal sampling sites for repeat prostate biopsy:a recursive partitioning analysis of three-dimensional 26-core systematic biopsy. Eur Urol 51:675-683, 2007.
PubMed
6) Kawakami S, Numao N, Okubo Y, et al:Development, validation, and head-to-head comparison of logistic regression-based nomograms and artificial neural network models predicting prostate cancer on initial extended biopsy. Eur Urol 54:601-611, 2008.
PubMed
7) Numao N, Yoshida S, Komai Y, et al:Usefulness of pre-biopsy multiparametric magnetic resonance imaging and clinical variables to reduce initial prostate biopsy in men with suspected clinically localized prostate cancer. J Urol 190:502-508, 2013.
PubMed
8) Drost FH, Osses DF, Nieboer D, et al:Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer. Cochrane Database Syst Rev 4:CD012663, 2019.
PubMed
9) Oerther B, Engel H, Bamberg F, et al:Cancer detection rates of the PI-RADSv2.1 assessment categories:systematic review and meta-analysis on lesion level and patient level. Prostate Cancer Prostatic Dis 25:256-263, 2022.
PubMed
10) Mottet N, Cornford P, van den Bergh RCN, et al:EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer, European Association of Urology, Arnhem, 2022.
 
11) National Comprehensive Cancer Network(NCCN):NCCN Guidelines Insights:Prostate Cancer Early Detection, Version 1.2023.
PubMed
12) Wegelin O, Exterkate L, van der Leest M, et al:The FUTURE Trial:A Multicenter Randomised Controlled Trial on Target Biopsy Techniques Based on Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer in Patients with Prior Negative Biopsies. Eur Urol 75:582-590, 2019.
 
13) Andriole GL, Bostwick D, Brawley OW, et al:The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy:results from the REDUCE study. J Urol 185:126-131, 2011.
PubMed
14) Takeshita H, Kawakami S, Yano A, et al:Percent decrease of serum prostate-specific antigen after dutasteride administration is equivalent in men with clinical benign prostatic hyperplasia having baseline prostate-specific antigen > 10 ng/mL and those having baseline prostate-specific antigen 2.5-10 ng/mL. Int J Urol 24:238-239, 2017.
 
15) Marberger M, Freedland SJ, Andriole GL, et al:Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride:lessons from the REDUCE study. BJU Int 109:1162-1169, 2012.
PubMed
P.126 掲載の参考文献
1) Logan JK, Rais-Bahrami S, Turkbey B, et al:Current status of magnetic resonance imaging (MRI) and ultrasonography fusion software platforms for guidance of prostate biopsies. BJU Int 114:641-652, 2014.
PubMed
2) Kasivisvanathan V, Rannikko AS, Borghi M, et al:MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. N Engl J Med 378:1767-1777, 2018.
 
3) Feuer Z, Meng X, Rosenkrantz AB, et al:Application of the PRECISION Trial Biopsy Strategy to a Contemporary Magnetic Resonance Imaging-Targeted Biopsy Cohort-How Many Clinically Significant Prostate Cancers are Missed? J Urol 205:740-747, 2021.
PubMed
4) Ahdoot M, Wilbur AR, Reese SE, et al:MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis. N Engl J Med 382:917-928, 2020.
PubMed
5) Xie J, Jin C, Liu M, et al:MRI/Transrectal Ultrasound Fusion-Guided Targeted Biopsy and Transrectal Ultrasound-Guided Systematic Biopsy for Diagnosis of Prostate Cancer:A Systematic Review and Meta-analysis. Front Oncol 12:880336, 2022.
 
6) 藤井慎介, 林 哲太郎, 韓 向鋭, ほか:MRI/transrectal ultrasonography 融合前立腺標的生検と従来の系統的生検の比較. 西日本泌尿器科 82:234-241, 2020.
Medical*Online
7) Yamada Y, Fujihara A, Shiraishi T, et al:Magnetic resonance imaging/transrectal ultrasound fusion-targeted prostate biopsy using three-dimensional ultrasound-based organ-tracking technol-ogy:Initial experience in Japan. Int J Urol 26:544-549, 2019.
 
8) Woo S, Suh CH, Kim SY, et al:Diagnostic Performance of Prostate Imaging Reporting and Data System Version 2 for Detection of Prostate Cancer:A Systematic Review and Diagnostic Meta-analysis. Eur Urol 72:177-188, 2017.
 
9) Tamada T, Kido A, Yamamoto A, et al:Comparison of Biparametric and Multiparametric MRI for Clinically Significant Prostate cancer Detection With PI-RADS Version 2.1. J Magn Reson Imaging 53:283-291, 2021.
PubMed
10) Liu W, Laitinen S, Khan S, et al:Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med 15:559-565, 2009.
PubMed
11) Hayashi T, Fujii S, Miyamoto S, et al:Magnetic resonance imaging-transrectal ultrasound image-fusion biopsies improved accurate identification of the index tumor at radical prostatectomy specimens. J Urol, 203(Suppl 4):e1062, 2020.
 
12) Baco E, Ukimura O, Rud E, et al:Magnetic resonance imaging-transectal ultrasound image-fusion biopsies accurately characterize the index tumor:correlation with step-sectioned radical prostatectomy specimens in 135 patients. Eur Urol 67:787-794, 2015.
PubMed
P.133 掲載の参考文献
1) Ahmed HU, El-Shater Bosaily A, Brown LC, et al:Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS):a paired validating confirmatory study. Lancet 389:815-822, 2017.
 
2) Kasivisvanathan V, Rannikko AS, Borghi M, et al:MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. N Engl J Med 378:1767-1777, 2018.
 
3) Brennan DL, Lazarakis S, Lee A, et al:Do antispasmodics or rectal enemas improve image quality on multiparametric prostate MRI? An 'Evidence-Based Practice' review of the literature. Abdom Radiol (NY) 46:2770-2778, 2021.
PubMed
4) 画像診断ガイドライン[2021年版](日本医学放射線学会 編). 金原出版, 2021.
 
5) Weinreb JC, Barentsz JO, Choyke PL, et al:PI-RADS Prostate Imaging - Reporting and Data System:2015, Version 2. Eur Urol 69:16-40, 2016.
 
6) Turkbey B, Rosenkrantz AB, Haider MA, et al:Prostate Imaging Reporting and Data System Version 2.1:2019 Update of Prostate Imaging Reporting and Data System Version 2. Eur Urol 76:340-351, 2019.
PubMed
7) 玉田 勉:PI-RADS v2.1 とは. 泌尿器領域 画像診断の勘ドコロ NEO(編集代表:玉田 勉), p133-137, メジカルビュー社, . 2021.
 
8) Tamada T, Kido A, Takeuchi M, et al:Comparison of PI-RADS version 2 and PI-RADS version 2.1 for the detection of transition zone prostate cancer. Eur J Radiol 121:108704, 2019.
PubMed
9) Byun J, Park KJ, Kim MH, et al:Direct Comparison of PI-RADS Version 2 and 2.1 in Transition Zone Lesions for Detection of Prostate Cancer:Preliminary Experience. J Magn Reson Imaging 52:577-586, 2020.
PubMed
10) Tamada T, Kido A, Yamamoto A, et al:Comparison of Biparametric and Multiparametric MRI for Clinically Significant Prostate Cancer Detection With PI-RADS Version 2.1. J Magn Reson Imaging 53:283-291, 2021.
PubMed
11) Tavakoli AA, Hielscher T, Badura P, et al:Contribution of Dynamic Contrast-enhanced and Diffusion MRI to PI-RADS for Detecting Clinically Significant Prostate Cancer. Radiology 306:186-199, 2023.
PubMed
12) Kido A, Tamada T, Kanomata N, et al:Multidimensional analysis of clinicopathological characteristics of false-negative clinically significant prostate cancers on multiparametric MRI of the prostate in Japanese men. Jpn J Radiol 37:154-164, 2019.
PubMed
13) Mikoshi A, Miyai K, Hamabe F, et al:MRI-detectability and histological factors of prostate cancer including intraductal carcinoma and cribriform pattern. Prostate 82:452-463, 2022.
PubMed
14) Mottet N, van den Bergh RCN, Briers E, et al:EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1:Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol 79:243-262, 2021.
PubMed
15) Tamada T, Ueda Y, Ueno Y, et al:Diffusion-weighted imaging in prostate cancer. MAGMA 35:533-547, 2022.
PubMed
P.140 掲載の参考文献
1) Committee on PI-RADS(R):Prostate Imaging Reporting and Data System (PI-RADS(R)) version 2.1, 2019. [https://www.acr.org/-/media/ACR/Files/RADS/PI-RADS/PIRADS-V2-1]
 
2) Vargas HA, Akin O, Afaq A, et al:Magnetic resonance imaging for predicting prostate biopsy findings in patients considered for active surveillance of clinically low risk prostate cancer. J Urol 188:1732-1738, 2012.
PubMed
3) Martini A, Gupta A, Cumarasamy S, et al:Novel nomogram for the prediction of seminal vesicle invasion including multiparametric magnetic resonance imaging. Int J Urol 26:458-464, 2019.
PubMed
4) Tay KJ, Gupta RT, Brown AF, et al:Defining the Incremental Utility of Prostate Multiparametric Magnetic Resonance Imaging at Standard and Specialized Read in Predicting Extracapsular Extension of Prostate Cancer. Eur Urol 70:211-213, 2016.
PubMed
5) Ayala AG, Ro JY, Babaian R, et al:The prostatic capsule:does it exist? Its importance in the staging and treatment of prostatic carcinoma. Am J Surg Pathol 13:21-27, 1989.
PubMed
6) Walz J, Epstein JI, Ganzer R, et al:A Critical Analysis of the Current Knowledge of Surgical Anatomy of the Prostate Related to Optimisation of Cancer Control and Preservation of Continence and Erection in Candidates for Radical Prostatectomy:An Update. Eur Urol 70:301-311, 2016.
PubMed
7) Walker SM, Choyke PL, Turkbey B:What you need to know before reading multiparametric MRI for prostate cancer. AJR Am J Roentgenol 214:1211-1219, 2020.
PubMed
8) Mygatt J, Sesterhenn I, Rosner I, et al:Anterior tumors of the prostate:clinicopathological features and outcomes. Prostate Cancer Prostatic Dis 17:75-80, 2014.
PubMed
9) Woo S, Cho JY, Kim SY, et al:Extracapsular extension in prostate cancer:added value of diffusion-weighted MRI in patients with equivocal findings on T2-weighted imaging. AJR Am J Roentgenol 204:W168-175, 2015.
PubMed
10) Futterer JJ, Engelbrecht MR, Huisman HJ, et al:Staging prostate cancer with dynamic contrast-enhanced endorectal MR imaging prior to radical prostatectomy:experienced versus less experienced readers. Radiology 237:541-549, 2005.
PubMed
11) Sapre N, Pedersen J, Hong MK, et al:Re-evaluating the biological significance of seminal vesicle invasion (SVI) in locally advanced prostate cancer. BJU Int 110 (Suppl 4):58-63, 2012.
 
12) Bastide C, Rossi D, Lechevallier E, et al:Seminal vesicle invasion:what is the best adjuvant treatment after radical prostatectomy? BJU Int 109:525-532, 2012.
PubMed
13) Roethke M, Kaufmann S, Kniess M, et al:Seminal vesicle invasion:accuracy and analysis of infiltration patterns with high-spatial resolution T2-weighted sequences on endorectal magnetic resonance imaging. Urol Int 92:294-299, 2014.
PubMed
P.146 掲載の参考文献
1) 泌尿器科・病理・放射線科 前立腺癌取扱い規約[第5版](日本泌尿器科学会, 日本病理学会, 日本医学放射線学会 編), p94-95, メディカルレビュー社, 2022.
 
2) Leventis AK, Shariat SF, Slawin KM:Local recurrence after radical prostatectomy:correlation of US features with prostatic fossa biopsy findings. Radiology 219:432-439, 2001.
PubMed
3) Wu LM, Xu JR, Gu HY, et al:Role of magnetic resonance imaging in the detection of local prostate cancer recurrence after external beam radiotherapy and radical prostatectomy. Clin Oncol (R Coll Radiol) 25:252-264, 2013.
PubMed
4) Kitajima K, Hartman RP, Froemming AT, et al:Detection of Local Recurrence of Prostate Cancer After Radical Prostatectomy Using Endorectal Coil MRI at 3 T:Addition of DWI and Dynamic Contrast Enhancement to T2-Weighted MRI. AJR Am J Roentgenol 205:807-816, 2015.
PubMed
5) Liauw SL, Pitroda SP, Eggener SE, et al:Evaluation of the prostate bed for local recurrence after radical prostatectomy using endorectal magnetic resonance imaging. Int J Radiat Oncol Biol Phys 85:378-384, 2013.
PubMed
6) Panebianco V, Barchetti F, Sciarra A, et al:Prostate cancer recurrence after radical prostatectomy:the role of 3-T diffusion imaging in multi-parametric magnetic resonance imaging. Eur Radiol 23:1745-1752, 2013.
PubMed
7) Pucar D, Hricak H, Shukla-Dave A, et al:Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumor:magnetic resonance imaging and step-section pathology evidence. Int J Radiat Oncol Biol Phys 69:62-69, 2007.
PubMed
8) Tamada T, Sone T, Jo Y, et al:Locally recurrent prostate cancer after high-dose-rate brachytherapy:the value of diffusion-weighted imaging, dynamic contrast-enhanced MRI, and T2-weighted imaging in localizing tumors. AJR Am J Roentgenol 197:408-414, 2011.
PubMed
9) Panebianco V, Villeirs G, Weinreb JC, et al:Prostate Magnetic Resonance Imaging for Local Recurrence Reporting (PI-RR):International Consensus-based Guidelines on Multiparametric Magnetic Resonance Imaging for Prostate Cancer Recurrence after Radiation Therapy and Radical Prostatectomy. Eur Urol Oncol 4:868-876, 2021.
PubMed
10) Pecoraro M, Turkbey B, Purysko AS, et al:Diagnostic Accuracy and Observer Agreement of the MRI Prostate Imaging for Recurrence Reporting Assessment Score. Radiology 304:342-350, 2022.
PubMed
11) Jager GJ, Barentsz JO, Oosterhof GO, et al:Pelvic adenopathy in prostatic and urinary bladder carcinoma:MR imaging with a three-dimensional TI-weighted magnetization-prepared-rapid gradient-echo sequence. AJR Am J Roentgenol 167:1503-1507, 1996.
PubMed
12) Hovels AM, Heesakkers RA, Adang EM, et al:The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer:a meta-analysis. Clin Radiol 63:387-395, 2008.
PubMed
13) Ghanem N, Uhl M, Brink I, et al:Diagnostic value of MRI in comparison to scintigraphy, PET, MS-CT and PET/CT for the detection of metastases of bone. Eur J Radiol 55:41-55, 2005.
 
14) Padhani AR, Lecouvet FE, Tunariu N, et al:METastasis Reporting and Data System for Prostate Cancer:Practical Guidelines for Acquisition, Interpretation, and Reporting of Whole-body Magnetic Resonance Imaging-based Evaluations of Multiorgan Involvement in Advanced Prostate Cancer. Eur Urol 71:81-92, 2017.
PubMed
15) Eiber M, Maurer T, Souvatzoglou M, et al:Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy. J Nucl Med 56:668-674, 2015.
PubMed
P.154 掲載の参考文献
1) Soloway MS, Hardeman SW, Hickey D, et al:Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 61:195-202, 1988.
PubMed
2) Scher HI, Morris MJ, Stadler WM, et al:Trial Design and Objectives for Castration-Resistant Prostate Cancer:Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol 34:1402-1418, 2016.
 
3) Kaboteh R, Gjertsson P, Leek H, et al:Progression of bone metastases in patients with prostate cancer - automated detection of new lesions and calculation of bone scan index. EJNMMI Res 3:64, 2013.
PubMed
4) Erdi YE, Humm JL, Imbriaco M, et al:Quantitative bone metastases analysis based on image segmentation. J Nucl Med 38:1401-1406, 1997.
PubMed
5) Sadik M, Hamadeh I, Nordblom P, et al:Computer-assisted interpretation of planar whole-body bone scans. J Nucl Med 49:1958-1965, 2008.
PubMed
6) Ulmert D, Kaboteh R, Fox JJ, et al:A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index. Eur Urol 62:78-84, 2012.
PubMed
7) Reza M, Bjartell A, Ohlsson M, et al:Bone Scan Index as a prognostic imaging biomarker during androgen deprivation therapy. EJNMMI Res 4:58, 2014.
PubMed
8) Reza M, Ohlsson M, Kaboteh R, et al:Bone Scan Index as an Imaging Biomarker in Metastatic Castration-resistant Prostate Cancer:A Multicentre Study Based on Patients Treated with Abiraterone Acetate (Zytiga) in Clinical Practice. Eur Urol Focus 2:540-546, 2016.
PubMed
9) Mitsui Y, Shiina H, Yamamoto Y, et al:Prediction of survival benefit using an automated bone scan index in patients with castration-resistant prostate cancer. BJU Int 110:E628-E634, 2012.
PubMed
10) Dennis ER, Jia X, Mezheritskiy IS, et al:Bone scan index:a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer. J Clin Oncol 30:519-524, 2012.
PubMed
11) Van den Wyngaert T, Strobel K, Kampen WU, et al:The EANM practice guidelines for bone scintigraphy. Eur J Nucl Med Mol Imaging 43:1723-1738, 2016.
PubMed
12) Armstrong AJ, Anand A, Edenbrandt L, et al:Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer:A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol 4:944-951, 2018.
PubMed
13) Nakajima K, Mizokami A, Matsuyama H, et al:Prognosis of patients with prostate cancer and bone metastasis from the Japanese Prostatic Cancer Registry of Standard Hormonal and Chemotherapy Using Bone Scan Index cohort study. Int J Urol 28:955-963, 2021.
PubMed
14) Ali A, Hoyle AP, Parker CC, et al:The Automated Bone Scan Index as a Predictor of Response to Prostate Radiotherapy in Men with Newly Diagnosed Metastatic Prostate Cancer:An Exploratory Analysis of STAMPEDE's "M1|RT Comparison", Eur Urol Oncol 3:412-419, 2020.
PubMed
15) Kitajima K, Igeta M, Kuyama J, et al:Novel nomogram developed for determining suitability of metastatic castration resistant prostate cancer patients to receive maximum benefit from radium-223 dichloride treatment - Japanese Ra-223 Therapy in Prostate Cancer using Bone Scan Index (J-RAP-BSI) Trial. Eur J Nucl Med Mol Imaging 50:1487-1498, 2023.
PubMed
P.159 掲載の参考文献
1) Muehlematter UJ, Burger IA, Becker AS, et al:Diagnostic Accuracy of Multiparametric MRI versus 68Ga-PSMA-11 PET/MRI for Extracapsular Extension and Seminal Vesicle Invasion in Patients with Prostate Cancer. Radiology 293:350-358, 2019.
PubMed
2) Giesel FL, Knorr K, Spohn F, et al:Detection Efficacy of 18F-PSMA-1007 PET/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy. J Nucl Med 60:362-368, 2019.
PubMed
3) Sprute K, Kramer V, Koerber SA, et al:Diagnostic Accuracy of 18F-PSMA-1007 PET/CT Imaging for Lymph Node Staging of Prostate Carcinoma in Primary and Biochemical Recurrence. J Nucl Med 62:208-213, 2021.
PubMed
4) Watabe T, Uemura M, Soeda F, et al:High detection rate in [18F]PSMA-1007 PET:interim results focusing on biochemical recurrence in prostate cancer patients. Ann Nucl Med 35:523-528, 2021.
PubMed
5) Rogowski P, Roach M 3rd, Schmidt-Hegemann NS, et al:Radiotherapy of oligometastatic prostate cancer:a systematic review. Radiat Oncol 16:50, 2021.
 
6) Mori S, Kato T, Watabe T, et al:Oligometastatic Lymph Node Recurrence Detected Using 18F-PSMA-1007 PET/CT in a Patient With Castration-resistant Prostate Cancer After Radiation Therapy. Cancer Diagn Progn 2:598-602, 2022.
 
7) Zhou J, Gou Z, Wu R, et al:Comparison of PSMA-PET/CT, choline-PET/CT, NaF-PET/CT, MRI, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer:a systematic review and meta-analysis. Skeletal Radiol 48:1915-1924, 2019.
PubMed
8) Zhao G, Ji B:Head-To-Head Comparison of 68Ga-PSMA-11 PET/CT and 99mTc-MDP Bone Scintigraphy for the Detection of Bone Metastases in Patients With Prostate Cancer:A Meta-Analysis. AJR Am J Roentgenol 219:386-395, 2022. [Erratum in:AJR Am J Roentgenol 219:529, 2022.]
 
9) Malaspina S, Anttinen M, Taimen P, et al:Prospective comparison of 18F-PSMA-1007 PET/CT, whole-body MRI and CT in primary nodal staging of unfavourable intermediate- and high-risk prostate cancer. Eur J Nucl Med Mol Imaging 48:2951-2959, 2021.
PubMed
10) Anttinen M, Ettala O, Malaspina S, et al:A Prospective Comparison of 18F-prostate-specific Membrane Antigen-1007 Positron Emission Tomography Computed Tomography, Whole-body 1.5 T Magnetic Resonance Imaging with Diffusion-weighted Imaging, and Single-photon Emission Computed Tomography/Computed Tomography with Traditional Imaging in Primary Distant Metastasis Staging of Prostate Cancer (PROSTAGE). Eur Urol Oncol 4:635-644, 2021.
 

IV 治療

P.168 掲載の参考文献
1) Reiner WG, Walsh PC:An anatomical approach to the surgical management of the dorsal vein and Santorini's plexus during radical retropubic surgery. J Urol 121:198-200, 1979.
 
2) Walsh PC, Donker PJ:Impotence following radical prostatectomy:insight into etiology and prevention. J Urol 128:492-497, 1982.
PubMed
3) Hatano K, Tanaka J, Nakai Y, et al:Utility of index lesion volume assessed by multiparametric MRI combined with Gleason grade for assessment of lymph node involvement in patients with high-risk prostate cancer. Jpn J Clin Oncol 50:333-337, 2020.
PubMed
4) Gandaglia G, Ploussard G, Valerio M, et al:A Novel Nomogram to Identify Candidates for Extended Pelvic Lymph Node Dissection Among Patients with Clinically Localized Prostate Cancer Diagnosed with Magnetic Resonance Imaging-targeted and Systematic Biopsies. Eur Urol 75:506-514, 2019.
 
5) Hatano K, Okusa T, Ishizuya Y, et al:Postoperative early ultrasensitive prostate-specific antigen identifies patients at risk for biochemical recurrence in margin positive prostate cancers:a single-center study. Jpn J Clin Oncol 47:74-79, 2017.
PubMed
6) Schuessler WW, Schulam PG, Clayman RV, et al:Laparoscopic radical prostatectomy:initial short-term experience. Urology 50:854-857, 1997.
PubMed
7) Touijer K, Eastham JA, Secin FP, et al:Comprehensive prospective comparative analysis of outcomes between open and laparoscopic radical prostatectomy conducted in 2003 to 2005. J Urol 179:1811-1817, 2008.
PubMed
8) Binder J, Kramer W:Robotically-assisted laparoscopic radical prostatectomy. BJU Int 87:408-410, 2001.
PubMed
9) Menon M, Tewari A, Baize B, et al:Prospective comparison of radical retropubic prostatectomy and robot-assisted anatomic prostatectomy:the Vattikuti Urology Institute experience. Urology 60:864-868, 2002.
PubMed
10) Haglind E, Carlsson S, Stranne J, et al:Urinary Incontinence and Erectile Dysfunction After Robotic Versus Open Radical Prostatectomy:A Prospective, Controlled, Nonrandomised Trial. Eur Urol 68:216-225, 2015.
 
11) Coughlin GD, Yaxley JW, Chambers SK, et al:Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy:24-month outcomes from a randomised controlled study. Lancet Oncol 19:1051-1060, 2018.
 
12) Wilt TJ, Brawer MK, Jones KM, et al:Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 367:203-213, 2012.
PubMed
13) Hamdy FC, Donovan JL, Lane JA, et al:10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. N Engl J Med 375:1415-1424, 2016.
 
14) Bill-Axelson A, Holmberg L, Garmo H, et al:Radical Prostatectomy or Watchful Waiting in Prostate Cancer-29-Year Follow-up. N Engl J Med 379:2319-2329, 2018.
 
15) Watabe T, Uemura M, Soeda F, et al:High detection rate in [18F]PSMA-1007 PET:interim results focusing on biochemical recurrence in prostate cancer patients. Ann Nucl Med 35:523-528, 2021.
PubMed
P.175 掲載の参考文献
1) 川島清隆, 市川寛樹:根治性と低侵襲性の追求によるミニマム創/開腹 拡大前立腺全摘術+拡大リンパ節郭清の確立-解剖の探求, 手技の変遷と治療成績の変化-. 日本ミニマム創泌尿器内視鏡外科学会雑誌 12:51-64, 2020.
 
2) Coughlin GD, Yaxley JW, Chambers SK, et al:Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy:24-month outcomes from a randomised controlled study. Lancet Oncol 19:1051-1060, 2018.
 
3) ロボット支援前立腺全摘除術 A to Z-解剖から理解する(鳥取大学医学部附属病院低侵襲外科センター 編), メジカルビュー社, 2016.
 
4) ガスレス・シングルポート泌尿器手術 基盤・上級編-非気腹手技を修める先端型ミニマム創内視鏡下手術(木原和徳 編著), 医学図書出版, 2018.
 
5) 佐藤達夫:臓側筋膜の局所解剖 層構成の基本と各部位における分化. 日本臨床外科医学会雑誌 56:2253-2272, 1995.
 
6) 川島清隆, 市川寛樹, 後藤健太郎:骨盤内筋膜概念のパラダイムシフト-筋膜からfascia(ファシア)へ, さらに細胞外マトリックスへ-. 泌尿器外科 32:1119-1126, 2019.
Medical*Online
7) Guimberteau JC, Armstrong C:Architecture of Human Living Fascia:The Extracellular Matrix and Cells Revealed Through Endoscopy, Handspring Publishing, Edinburgh, 2015.
 
8) Fasciaの評価と治療 解剖・動作・エコーで導く Fascia リリースの基本と臨床[第2版]-ハイドロリリースのすべて(木村裕明, 小林 只, 並木宏文 編), 文光堂, 2021.
 
9) Myers TW:Anatomy Trains:Myofascial Meridians for Manual & Movement Therapists, 3rd ed, Churchill Livingstone, Edinburgh, 2014.
 
10) 林 利彦:細胞外マトリックスとその生物学的機能. 蛋白質 核酸 酵素 37:2269-2278, 1992.
 
11) 鳶巣賢一:安全で確実な術式のために 膜と層を意識した術式〈ミニマム創内視鏡下前立腺全摘術の場合〉(アストラゼネカ作成 DVD), 2015.
 
12) 新 癌の外科-手術手技シリーズ 2 泌尿器癌(藤元博行 編), メジカルビュー社, 2001.
 
13) 川島清隆:新しい膜の解剖と前立腺全摘術-Fascia の理解に基づく手術手技-メジカルビュー社, 2023. (出版準備中)
 
P.180 掲載の参考文献
1) Schuessler WW, Schulam PG, Clayman RV, et al:Laparoscopic radical prostatectomy:initial short-term experience. Urology 50:854-857, 1997.
PubMed
2) Guillonneau B, Vallancien G:Laparoscopic radical prostatectomy:the Montsouris technique. J Urol 163:1643-1649, 2000.
PubMed
3) 日本内視鏡外科学会学術委員会:内視鏡外科手術に関するアンケート調査-第16回集計結果報告-. 日本内視鏡外科学会, 2022.
 
4) 繁田正信:腹腔鏡下前立腺全摘除術. Prostate Journal 8:83-87, 2021.
Medical*Online
P.186 掲載の参考文献
1) Murphy DG, Bjartell A, Ficarra V, et al:Downsides of robot-assisted laparoscopic radical prostatectomy:limitations and complications. Eur Urol 57:735-746, 2010.
PubMed
2) Okhawere KE, Shih IF, Lee SH, et al:Comparison of 1-Year Health Care Costs and Use Associated With Open vs Robotic-Assisted Radical Prostatectomy. JAMA Netw Open 4:e212265, 2021.
PubMed
3) Chang P, Wagner AA, Regan MM, et al:Prospective Multicenter Comparison of Open and Robotic Radical Prostatectomy:The PROST-QA/RP2 Consortium. J Urol 207:127-136, 2022.
PubMed
4) Takahara K, Yoshizawa A, Nishino M, et al:Clinical Outcomes Associated with Robot-Assisted Radical Prostatectomy(RARP) Using the Extraperitoneal Approach in Japanese Men. Clinics in Surgery 3:1952, 2018.
 
5) Diaz M, Peabody JO, Kapoor V, et al:Oncologic outcomes at 10 years following robotic radical prostatectomy. Eur Urol 67:1168-1176, 2015.
PubMed
6) Sooriakumaran P, Srivastava A, Shariat SF, et al:A multinational, multi-institutional study comparing positive surgical margin rates among 22393 open, laparoscopic, and robot-assisted radical prostatectomy patients. Eur Urol 66:450-456, 2014.
PubMed
7) Okegawa T, Omura S, Samejima M, et al:Laparoscopic radical prostatectomy versus robot-assisted radical prostatectomy:comparison of oncological outcomes at a single center. Prostate Int 8:16-21, 2020.
 
8) Lantz A, Bock D, Akre O, et al:Functional and Oncological Outcomes After Open Versus Robot-assisted Laparoscopic Radical Prostatectomy for Localised Prostate Cancer:8-Year Follow-up. Eur Urol 80:650-660, 2021.
 
9) Wang Y, Gieschen H, Greenberger M, et al:Survival After Robotic-assisted Prostatectomy for Localized Prostate Cancer:An Epidemiologic Study. Ann Surg 274:e507-e514, 2021.
PubMed
10) Walsh PC, Mostwin JL:Radical prostatectomy and cystoprostatectomy with preservation of potency. Results using a new nerve-sparing technique. Br J Urol 56:694-697, 1984.
PubMed
11) Sridhar AN, Abozaid M, Rajan P, et al:Surgical Techniques to Optimize Early Urinary Continence Recovery Post Robot Assisted Radical Prostatectomy for Prostate Cancer. Curr Urol Rep 18:71, 2017.
PubMed
12) Haglind E, Carlsson S, Stranne J, et al:Urinary Incontinence and Erectile Dysfunction After Robotic Versus Open Radical Prostatectomy:A Prospective, Controlled, Nonrandomised Trial. Eur Urol 68:216-225, 2015.
 
13) Sooriakumaran P, Pini G, Nyberg T, et al:Erectile Function and Oncologic Outcomes Following Open Retropubic and Robot-assisted Radical Prostatectomy:Results from the LAParoscopic Prostatectomy Robot Open Trial. Eur Urol 73:618-627, 2018.
PubMed
14) 白木良一, 深谷孝介, 深見直彦, ほか:ロボット支援救済前立腺全摘術(salvage RARP). 泌尿器外科 29(臨時増刊):849-850, 2016.
Medical*Online
15) Sooriakumaran P, Wilson C, Rombach I, et al:Feasibility and safety of radical prostatectomy for oligo-metastatic prostate cancer:the Testing Radical prostatectomy in men with prostate cancer and oligo-Metastases to the bone (TRoMbone) trial. BJU Int 130:43-53, 2022.
 
P.190 掲載の参考文献
1) 泌尿器科・病理・放射線科 前立腺癌取扱い規約[第5版](日本泌尿器科学会, 日本病理学会, 日本医学放射線学会 編), p31, メディカルレビュー社, 2022.
 
2) Moore KL, Dalley AF, Agur AMR:臨床のための解剖学[第2版](佐藤達夫, 坂井建雄 監訳), p344-345, メディカル・サイエンス・インターナショナル, 2016.
 
3) Miki J, Yanagisawa T, Tsuzuki S, et al:Anatomical localization and clinical impact of sentinel lymph nodes based on patterns of pelvic lymphatic drainage in clinically localized prostate cancer. Prostate 78:419-425, 2018.
PubMed
4) Schiavina R, Manferrari F, Garofalo M, et al:The extent of pelvic lymph node dissection correlates with the biochemical recurrence rate in patients with intermediate- and high-risk prostate cancer. BJU Int 108:1262-1268, 2011.
PubMed
5) 前立腺癌診療ガイドライン[2016年版](日本泌尿器科学会 編), p118, メディカルレビュー社, 2016.
 
6) Fossati N, Willemse PM, Van den Broeck T, et al:The Benefits and Harms of Different Extents of Lymph Node Dissection During Radical Prostatectomy for Prostate Cancer:A Systematic Review. Eur Urol 72:84-109, 2017.
PubMed
7) Lestingi JFP, Guglielmetti GB, Trinh QD, et al:Extended Versus Limited Pelvic Lymph Node Dissection During Radical Prostatectomy for Intermediate- and High-risk Prostate Cancer:Early Oncological Outcomes from a Randomized Phase 3 Trial. Eur Urol 79:595-604, 2021.
PubMed
8) Touijer KA, Sjoberg DD, Benfante N, et al:Limited versus Extended Pelvic Lymph Node Dissection for Prostate Cancer:A Randomized Clinical Trial. Eur Urol Oncol 4:532-539, 2021.
PubMed
9) Namiki S, Kawase M, Ebara S, et al:Pelvic Lymphadenectomy May Not Improve Biochemical Recurrence-Free Survival in Patients with Prostate Cancer Treated with Robot-Assisted Radical Prostatectomy in Japan (The MSUG94 Group). Cancers (Basel) 14:5803, 2022.
PubMed
10) Mottet N, Cornford P, van den Bergh RCN, et al:EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer, p56-57, European Association of Urology, Arnhem, 2022.
 
11) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines(R)):Prostate Cancer, PROS-H1-2, National Comprehensive Cancer Network, Plymouth Meeting, 2022.
 
12) Preisser F, Bandini M, Marchioni M, et al:Extent of lymph node dissection improves survival in prostate cancer patients treated with radical prostatectomy without lymph node invasion. Prostate 78:469-475, 2018.
PubMed
13) Shimbo M, Endo F, Matsushita K, et al:Impact of indocyanine green-guided extended pelvic lymph node dissection during robot-assisted radical prostatectomy. Int J Urol 27:845-850, 2020.
PubMed
14) Mattei A, Fuechsel FG, Bhatta Dhar N, et al:The template of the primary lymphatic landing sites of the prostate should be revisited:results of a multimodality mapping study. Eur Urol 53:118-125, 2008.
PubMed
15) Cacciamani GE, Maas M, Nassiri N, et al:Impact of Pelvic Lymph Node Dissection and Its Extent on Perioperative Morbidity in Patients Undergoing Radical Prostatectomy for Prostate Cancer:A Comprehensive Systematic Review and Meta-analysis. Eur Urol Oncol 4:134-149, 2021.
PubMed
16) Choo MS, Kim M, Ku JH, et al:Extended versus Standard Pelvic Lymph Node Dissection in Radical Prostatectomy on Oncological and Functional Outcomes:A Systematic Review and Meta-Analysis. Ann Surg Oncol 24:2047-2054, 2017.
 
17) 佐野雅之, 藤崎章子, 新保正貴, ほか:ロボット支援下前立腺全摘除術において拡大リンパ節郭清は術後機能に影響を与えるか. Japanese Journal of Endourology 33:330-334, 2020.
Medical*Online
18) Hofman MS, Lawrentschuk N, Francis RJ, et al:Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA):a prospective, randomised, multicentre study. Lancet 395:1208-1216, 2020.
 
P.197 掲載の参考文献
1) 日本内視鏡外科学会学術委員会:内視鏡外科手術に関するアンケート調査-第16回集計結果報告-, p115-140, 日本内視鏡外科学会, 2022.
 
2) 鈴木康友, 近藤幸尋:周術期合併症とその対策;臨床. 前立腺癌の治療. 術後合併症とその対策. 日本臨牀 69(増刊:前立腺癌(第2版)):369-373, 2011.
 
3) 古家琢也, 畠山真吾, 米山高弘, ほか:周術期合併症とその対策;前立腺癌の治療. 外科治療. 術後合併症とその対策. 日本臨牀 74(増刊:新前立腺癌学):456-460, 2016.
 
4) Sotelo RJ, Haese A, Machuca V, et al:Safer Surgery by Learning from Complications:A Focus on Robotic Prostate Surgery. Eur Urol 69:334-344, 2016.
PubMed
5) Schaeffer EM, Partin AW, Lepor H:Open Radical Prostatectomy. In:Campbell-Walsh-Wein Urology, 12th ed(ed by Partin AW, Dmochowski RR, Kavoussi LR, et al), p3548-3565, Elsevier, Philadelphia, 2020.
 
6) Moretti TBC, Magna LA, Reis LO:Surgical Results and Complications for Open, Laparoscopic, and Robot-assisted Radical Prostatectomy:A Reverse Systematic Review. Eur Urol Open Sci 44:150-161, 2022.
PubMed
7) Tang K, Jiang K, Chen H, et al:Robotic vs. Retropubic radical prostatectomy in prostate cancer:A systematic review and an meta-analysis update. Oncotarget 8:32237-32257, 2017.
 
8) Carlsson S, Nilsson AE, Schumacher MC, et al:Surgery-related complications in 1253 robot-assisted and 485 open retropubic radical prostatectomies at the Karolinska University Hospital, Sweden. Urology 75:1092-1097, 2010.
PubMed
9) Tewari A, Sooriakumaran P, Bloch DA, et al:Positive surgical margin and perioperative complication rates of primary surgical treatments for prostate cancer:a systematic review and meta-analysis comparing retropubic, laparoscopic, and robotic prostatectomy. Eur Urol 62:1-15, 2012.
PubMed
10) Hedican SP, Walsh PC:Postoperative bleeding following radical retropubic prostatectomy. J Urol 152:1181-1183, 1994.
PubMed
11) Browne BM, Vanni AJ:Management of Urethral Stricture and Bladder Neck Contracture Following Primary and Salvage Treatment of Prostate Cancer. Curr Urol Rep 18:76, 2017.
PubMed
12) Uy M, Cassim R, Kim J, et al:Extraperitoneal versus transperitoneal approach for robot-assisted radical prostatectomy:a contemporary systematic review and meta-analysis. J Robot Surg 16:257-264, 2022.
PubMed
13) Rohloff M, Cicic A, Christensen C, et al:Reduction in postoperative ileus rates utilizing lower pressure pneumoperitoneum in robotic-assisted radical prostatectomy. J Robot Surg 13:671-674, 2019.
PubMed
14) Su LM, Otto BJ, Costello AJ:Laparoscopic and Robotic-Assisted Laparoscopic Radical Prostatectomy and Pelvic Lymphadenectomy. In:Campbell-Walsh-Wein Urology, 12th ed(ed by Partin AW, Dmochowski RR, Kavoussi LR, et al), p3566-3586, Elsevier, Philadelphia, 2020.
 
15) Awad H, Santilli S, Ohr M, et al:The effects of steep trendelenburg positioning on intraocular pressure during robotic radical prostatectomy. Anesth Analg 109:473-478, 2009.
PubMed
P.202 掲載の参考文献
1) Kojima Y, Takahashi N, Haga N, et al:Urinary incontinence after robot-assisted radical prostatectomy:pathophysiology and intraoperative techniques to improve surgical outcome. Int J Urol 20:1052-1063, 2013.
PubMed
2) Galfano A, Ascione A, Grimaldi S, et al:A new anatomic approach for robot-assisted laparoscopic prostatectomy:a feasibility study for completely intrafascial surgery. Eur Urol 58:457-461, 2010.
 
3) Xu JN, Xu ZY, Yin HM:Comparison of Retzius-Sparing Robot-Assisted Radical Prostatectomy vs. Conventional Robot-Assisted Radical Prostatectomy:An Up-to-Date Meta-Analysis. Front Surg 8:738421, 2021.
PubMed
4) Nguyen LN, Head L, Witiuk K, et al:The Risks and Benefits of Cavernous Neurovascular Bundle Sparing during Radical Prostatectomy:A Systematic Review and Meta-Analysis. J Urol 198:760-769, 2017.
PubMed
5) Reeves F, Preece P, Kapoor J, et al:Preservation of the neurovascular bundles is associated with improved time to continence after radical prostatectomy but not long-term continence rates:results of a systematic review and meta-analysis. Eur Urol 68:692-704, 2015.
 
6) Kim JW, Kim DK, Ahn HK, et al:Effect of Bladder Neck Preservation on Long-Term Urinary Continence after Robot-Assisted Laparoscopic Prostatectomy:A Systematic Review and Meta-Analysis. J Clin Med 8:2068, 2019.
 
7) Lei Y, Alemozaffar M, Williams SB, et al:Athermal division and selective suture ligation of the dorsal vein complex during robot-assisted laparoscopic radical prostatectomy:description of technique and outcomes. Eur Urol 59:235-243, 2011.
PubMed
8) Haga N, Ogawa S, Yabe M, et al:Factors Contributing to Early Recovery of Urinary Continence Analyzed by Pre- and Postoperative Pelvic Anatomical Features at Robot-Assisted Laparoscopic Radical Prostatectomy. J Endourol 29:683-690, 2015.
PubMed
9) Ogawa S, Hoshi S, Koguchi T, et al:Three-Layer Two-Step Posterior Reconstruction Using Peritoneum During Robot-Assisted Radical Prostatectomy to Improve Recovery of Urinary Continence:A Prospective Comparative Study. J Endourol 31:1251-1257, 2017.
PubMed
10) Student V Jr, Vidlar A, Grepl M, et al:Advanced Reconstruction of Vesicourethral Support (ARVUS) during Robot-assisted Radical Prostatectomy:One-year Functional Outcomes in a Two-group Randomised Controlled Trial. Eur Urol 71:822-830, 2017.
 
11) Patel VR, Coelho RF, Palmer KJ, et al:Periurethral suspension stitch during robot-assisted laparoscopic radical prostatectomy:description of the technique and continence outcomes. Eur Urol 56:472-478, 2009.
PubMed
12) Tewari A, Jhaveri J, Rao S, et al:Total reconstruction of the vesico-urethral junction. BJU Int 101:871-877, 2008.
PubMed
13) Kojima Y, Hamakawa T, Kubota Y, et al:Bladder neck sling suspension during robot-assisted radical prostatectomy to improve early return of urinary continence:a comparative analysis. Urology 83:632-639, 2014.
PubMed
14) Walsh PC, Marschke PL:Intussusception of the reconstructed bladder neck leads to earlier continence after radical prostatectomy. Urology 59:934-938, 2002.
PubMed
15) Haga N, Kurita N, Yanagida T, et al:Effects of barbed suture during robot-assisted radical prostatectomy on postoperative tissue damage and longitudinal changes in lower urinary tract outcome. Surg Endosc 32:145-153, 2018.
PubMed
P.208 掲載の参考文献
1) Hongo F, Okihara K, Kitamura K, et al:Prostate cancer meeting the Japanese active surveillance criteria and diagnosed by community-based prostate-specific antigen screening:A 21-year follow-up study, Int J Urol 26:827-832, 2019.
PubMed
2) Galfano A, Ascione A, Grimaldi S, et al:A new anatomic approach for robot-assisted laparoscopic prostatectomy:a feasibility study for completely intrafascial surgery. Eur Urol 58:457-461, 2010.
 
3) Wagaskar VG, Mittal A, Sobotka S, et al:Hood Technique for Robotic Radical Prostatectomy-Preserving Periurethral Anatomical Structures in the Space of Retzius and Sparing the Pouch of Douglas, Enabling Early Return of Continence Without Compromising Surgical Margin Rates 80:213-221, 2021.
PubMed
4) Takenaka A, Soga H, Hinata N, et al:Classification of the distribution of cavernous nerve fibers around the prostate by intraoperative electrical stimulation during laparoscopic radical prostatec-tomy. Int J Impot Res 23:56-61, 2011.
 
5) Tewari AK, Srivastava A, Huang MW, et al:Anatomical grades of nerve sparing:a risk-stratified approach to neural-hammock sparing during robot-assisted radical prostatectomy (RARP). BJU Int 108:984-992, 2011.
PubMed
6) Yao A, Iwamoto H, Masago T, et al:The role of staging MRI in predicting apical margin positivity for robot-assisted laparoscopic radical prostatectomy. Urol Int 93:182-188, 2014.
PubMed
7) Muraoka K, Hinata N, Morizane S, et al:Site-dependent and interindividual variations in Denonvilliers' fascia:a histological study using donated elderly male cadavers. BMC Urol 15:42, 2015.
PubMed
8) Costello AJ, Brooks M, Cole OJ:Anatomical studies of the neurovascular bundle and cavernosal nerves. BJU Int 94:1071-1076, 2004.
PubMed
9) Hinata N, Murakami G, Miyake H, et al:Histological study of the cavernous nerve mesh outside the periprostatic region:anatomical basis for erectile function after nonnerve sparing radical prostatectomy. J Urol 193:1052-1059, 2015.
PubMed
10) Tewari AK, Ali A, Metgud S, et al:Functional outcomes following robotic prostatectomy using athermal, traction free risk-stratified grades of nerve sparing. World J Urol 31:471-480, 2013.
PubMed
11) Yumioka T, Honda M, Kimura Y, et al:Influence of multinerve-sparing, robot-assisted radical prostatectomy on the recovery of erection in Japanese patients. Reprod Med Biol 17:36-43, 2018.
PubMed
12) Suardi N, Moschini M, Gallina A, et al:Nerve-sparing approach during radical prostatectomy is strongly associated with the rate of postoperative urinary continence recovery. BJU Int 111:717-722, 2013.
PubMed
13) Ngoo KS, Honda M, Kimura Y, et al:Longitudinal study on the impact of urinary continence and sexual function on health-related quality of life among Japanese men after robot-assisted radical prostatectomy. Int J Med Robot 15:e2018, 2019.
PubMed
14) Hikita K, Honda M, Shimizu R, et al:Longitudinal, 5-year long-term outcomes for urinary continence and quality of life after robot-assisted radical prostatectomy in Japanese patients. Low Urin Tract Symptoms 14:178-185, 2022.
PubMed
P.214 掲載の参考文献
1) Arai Y, Kaiho Y, Takei M, et al:Burden of male stress urinary incontinence:a survey among urologists in Japan. Int J Urol 16:915-917, 2009.
PubMed
2) Bates AS, Martin RM, Terry TR:Complications following artificial urinary sphincter placement after radical prostatectomy and radiotherapy:a meta-analysis. BJU Int 116:623-633, 2015.
PubMed
3) Boswell TC, Elliott DS, Rangel LJ, et al:Long-term device survival and quality of life outcomes following artificial urinary sphincter placement. Transl Androl Urol 9:56-61, 2020.
PubMed
4) 海法康裕:人工尿道括約筋植込手術. 泌尿器外科 34:147-153, 2021.
Medical*Online
5) 海法康裕:人工尿道括約筋植込術. Urologic Surgery Next. 8, 陰茎・陰嚢・アンドロロジーの手術(高橋 悟 編), p34-44, 株式会社メジカルビュー社, 2021.
 
6) Arai Y, Takei M, Nonomura K, et al:Current use of the artificial urinary sphincter and its long-term durability:a nationwide survey in Japan. Int J Urol 16:101-104, 2009.
PubMed
7) 海法康裕, 伊藤 淳:AMS-800(R)人工尿道括約筋の作動休止と作動開始の方法(動画), 2017. [https://www.youtube.com/watch?v=zqszdHwnlD8]
 
8) Chung E, Liao L, Kim JH, et al:The Asia-Pacific AMS800 artificial urinary sphincter consensus statement. Int J Urol. 30:128-138, 2023.
 
9) Kaiho Y, Masuda H, Takei M, et al:Surgical and Patient Reported Outcomes of Artificial Urinary Sphincter Implantation:A Multicenter, Prospective, Observational Study. J Urol 199:245-250, 2018.
PubMed
P.220 掲載の参考文献
1) Fujii Y, Yamamoto S, Yonese J, et al:A novel technique to prevent postradical retropubic prostatectomy inguinal hernia:the processus vaginalis transection method. Urology 75:713-717, 2010.
PubMed
2) Fernando H, Garcia C, Hossack T, et al:Incidence, Predictive Factors and Preventive Measures for Inguinal Hernia following Robotic and Laparoscopic Radical Prostatectomy:A Systematic Review. J Urol 201:1072-1079, 2019.
PubMed
3) Shimbo M, Endo F, Matsushita K, et al:Incidence, Risk Factors and a Novel Prevention Technique for Inguinal Hernia after Robot-Assisted Radical Prostatectomy. Urol Int 98:54-60, 2017.
 
4) Fujii Y, Yamamoto S, Yonese J, et al:The processus vaginalis transection method to prevent postradical prostatectomy inguinal hernia:long-term results. Urology 83:247-252, 2014.
PubMed
5) Chang KD, Abdel Raheem A, Santok GDR, et al:Anatomical Retzius-space preservation is associated with lower incidence of postoperative inguinal hernia development after robot-assisted radical prostatectomy. Hernia 21:555-561, 2017.
PubMed
6) Uy M, Cassim R, Kim J, et al:Extraperitoneal versus transperitoneal approach for robot-assisted radical prostatectomy:a contemporary systematic review and meta-analysis. J Robot Surg 16:257-264, 2022.
PubMed
7) 藤井靖久, 木原和徳, 酒井康之, ほか:前立腺全摘術後の鼠径ヘルニア発症を防止する腹膜鞘状突起切断法:ミニマム創内視鏡下手術への導入. 日本ミニマム創泌尿器内視鏡外科学会雑誌 3:77-80, 2011.
Medical*Online
8) 影山幸雄:前立腺全摘術における術後鼠径ヘルニア予防:ミニマム創(小切開)手術からロボット支援手術へ. 日本ミニマム創泌尿器内視鏡外科学会雑誌 10:103-105, 2018.
 
9) 早川哲史:de novo 型I型ヘルニアの概念と分類. 臨床外科 74:1288-1297, 2019.
 
10) Shimbo M, Endo F, Matsubara T, et al:Long-term results after robot-assisted radical prostatectomy of a simplified inguinal hernia prevention technique without artificial substance use. Int J Urol 29:1315-1321, 2022.
PubMed
11) Lee DH, Koo KC, Lee SH, et al:A simple procedure to prevent postoperative inguinal hernia after robot-assisted laparoscopic radical prostatectomy:a plugging method of the internal inguinal floor for patients with patent processus vaginalis. J Urol 191:468-472, 2014.
 
12) Callahan ZM, Donovan K, Su BS, et al:Laparoscopic inguinal hernia repair after prostatectomy:Evaluating safety, efficacy, and efficiency. Surgery 166:607-614, 2019.
PubMed
13) 鼠径部ヘルニア診療ガイドライン 2015(日本ヘルニア学会 ガイドライン委員会 編), p77-78, 金原出版, 2015.
 
14) Angus A, DeMare A, Iacco A:Evaluating outcomes for robotic-assisted inguinal hernia repair in males with prior urologic surgery:a propensity-matched analysis from a national database. Surg Endosc 35:5310-5314, 2021.
PubMed
15) Melhem M, Burki J, Algurabi O, et al:The safety and feasibility of simultaneous robotic repair of an inguinal hernia during robotic-assisted laparoscopic prostatectomy:a systematic review and meta-analysis. Scand J Urol 56:197-205, 2022.
PubMed
P.225 掲載の参考文献
1) Binder J, Kramer W:Robotically-assisted laparoscopic radical prostatectomy. BJU Int 87:408-410, 2001.
PubMed
2) 「泌尿器科領域におけるロボット支援手術を行うに当たってのガイドライン」日本泌尿器内視鏡・ロボティクス学会, 2022年12月23日改定. [https://www.jsee.jp/davinci/guideline/]
 
3) Hinata N, Yamaguchi R, Kusuhara Y, et al:Hinotori Surgical Robot System, a novel robot-assisted surgical platform:Preclinical and clinical evaluation. Int J Urol 29:1213-1220, 2022.
PubMed
4) Dobbs RW, Halgrimson WR, Madueke I, et al:Single-port robot-assisted laparoscopic radical prostatectomy:initial experience and technique with the da Vinci SP platform. BJU Int 124:1022-1027, 2019.
 
5) Sarchi L, Mottaran A, Bravi CA, et al:Robot-assisted radical prostatectomy feasibility and setting with the Hugo(TM) robot-assisted surgery system. BJU Int 130:671-675, 2022.
 
6) Bravi CA, Paciotti M, Sarchi L, et al:Robot-assisted Radical Prostatectomy with the Novel Hugo Robotic System:Initial Experience and Optimal Surgical Set-up at a Tertiary Referral Robotic Center. Eur Urol 82:233-237, 2022.
 
P.232 掲載の参考文献
1) Galfano A, Ascione A, Grimaldi S, et al:A new anatomic approach for robot-assisted laparoscopic prostatectomy:a feasibility study for completely intrafascial surgery. Eur Urol 58:457-461, 2010.
 
2) Phukan C, Mclean A, Nambiar A, et al:Retzius sparing robotic assisted radical prostatectomy vs. conventional robotic assisted radical prostatectomy:a systematic review and meta-analysis. World J Urol 38:1123-1134, 2020.
PubMed
3) Menon M, Dalela D, Jamil M, et al:Functional Recovery, Oncologic Outcomes and Postoperative Complications after Robot-Assisted Radical Prostatectomy:An Evidence-Based Analysis Comparing the Retzius Sparing and Standard Approaches. J Urol 199:1210-1217, 2018.
PubMed
4) Dalela D, Jeong W, Prasad MA, et al:A Pragmatic Randomized Controlled Trial Examining the Impact of the Retzius-sparing Approach on Early Urinary Continence Recovery After Robot-assisted Radical Prostatectomy. Eur Urol 72:677-685, 2017.
PubMed
5) Lim SK, Kim KH, Shin TY, et al:Retzius-sparing robot-assisted laparoscopic radical prostatectomy:combining the best of retropubic and perineal approaches. BJU Int 114:236-244, 2014.
PubMed
6) Lee J, Kim HY, Goh HJ, et al:Retzius Sparing Robot-Assisted Radical Prostatectomy Conveys Early Regain of Continence over Conventional Robot-Assisted Radical Prostatectomy:A Propensity Score Matched Analysis of 1,863 Patients. J Urol 203:137-144, 2020.
 
7) Egan J, Marhamati S, Carvalho FLF, et al:Retzius-sparing Robot-assisted Radical Prostatectomy Leads to Durable Improvement in Urinary Function and Quality of Life Versus Standard Robot-assisted Radical Prostatectomy Without Compromise on Oncologic Efficacy:Single-surgeon Series and Step-by-step Guide. Eur Urol 79:839-857, 2021.
PubMed
8) Checcucci E, Veccia A, Fiori C, et al:Retzius-sparing robot-assisted radical prostatectomy vs the standard approach:a systematic review and analysis of comparative outcomes. BJU Int 125:8-16, 2020.
PubMed
9) Galfano A, Di Trapani D, Sozzi F, et al:Beyond the learning curve of the Retzius-sparing approach for robot-assisted laparoscopic radical prostatectomy:oncologic and functional results of the first 200 patients with >=1 year of follow-up. Eur Urol 64:974-980, 2013.
PubMed
10) Chang LW, Hung SC, Hu JC, et al:Retzius-sparing Robotic-assisted Radical Prostatectomy Associated with Less Bladder Neck Descent and Better Early Continence Outcome. Anticancer Res 38:345-351, 2018.
PubMed
P.238 掲載の参考文献
1) Mottet N, Cornford P, van den Bergh RCN, et al:EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer, European Association of Urology, Arnhem, 2022. [EAU-EANM-ESTRO-ESUR-ISUP_SIOG-Guidelines-on-Prostate-Cancer-2022_2022-04-25-063938_yfos.pdf]
 
2) National Comprehensive Cancer Network(NCCN):NCCN Guidelines Prostate Cancer, Ver 1, 2023. [https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf]
 
3) Pompe RS, Karakiewicz PI, Tian Z, et al:Oncologic and Functional Outcomes after Radical Prostatectomy for High or Very High Risk Prostate Cancer:European Validation of the Current NCCN Guideline. J Urol 198:354-361, 2017.
PubMed
4) Sundi D, Wang VM, Pierorazio PM, et al:Very-high-risk localized prostate cancer:definition and outcomes. Prostate Cancer Prostatic Dis 17:57-63, 2014.
PubMed
5) Ham WS, Park SY, Rha KH, et al:Robotic radical prostatectomy for patients with locally advanced prostate cancer is feasible:results of a single-institution study. J Laparoendosc Adv Surg Tech A 19:329-332, 2009.
 
6) Vora AA, Marchalik D, Kowalczyk KJ, et al:Robotic-assisted prostatectomy and open radical retropubic prostatectomy for locally-advanced prostate cancer:multi-institution comparison of oncologic outcomes. Prostate Int 1:31-36, 2013.
PubMed
7) Koo KC, Jung DC, Lee SH, et al:Feasibility of robot-assisted radical prostatectomy for very-high risk prostate cancer:surgical and oncological outcomes in men aged >=70 years. Prostate Int 2:127-132, 2014.
PubMed
8) Casey JT, Meeks JJ, Greco KA, et al:Outcomes of locally advanced (T3 or greater) prostate cancer in men undergoing robot-assisted laparoscopic prostatectomy. J Endourol 23:1519-1522, 2009.
PubMed
9) Gandaglia G, De Lorenzis E, Novara G, et al:Robot-assisted Radical Prostatectomy and Extended Pelvic Lymph Node Dissection in Patients with Locally-advanced Prostate Cancer. Eur Urol 71:249-256, 2017.
PubMed
10) Mazzone E, Dell'Oglio P, Rosiello G, et al:Technical Refinements in Superextended Robot-assisted Radical Prostatectomy for Locally Advanced Prostate Cancer Patients at Multiparametric Magnetic Resonance Imaging. Eur Urol 80:104-112, 2021.
PubMed
11) Miura N, Sugihara N, Funaki K, et al:Extended robot-assisted laparoscopic prostatectomy and extended pelvic lymph node dissection as a monotherapy in patients with very high-risk prostate cancer Patients. Cancer Med 10:7968-7976, 2021.
PubMed
12) Bandini M, Marchioni M, Preisser F, et al:Survival after radical prostatectomy or radiotherapy for locally advanced (cT3) prostate cancer. World J Urol 36:1399-1407, 2018.
 
13) Sussman R, Carvalho FLF, Harbin A, et al:Survival and secondary interventions following treatment for locally-advanced prostate cancer. Can J Urol 25:9516-9524, 2018.
PubMed
14) Jang TL, Patel N, Faiena I, et al:Comparative effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer. Cancer 124:4010-4022, 2018.
PubMed
15) Moris L, Cumberbatch MG, Van den Broeck T, et al:Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer:An International Multidisciplinary Systematic Review. Eur Urol 77:614-627, 2020.
PubMed
16) ClinicalTrials.gov:Surgery Versus Radiotherapy for Locally Advanced Prostate Cancer (SPCG-15), 2014(Last Update Posted:March 31, 2022). [https://clinicaltrials.gov/ct2/show/NCT02102477]
 
17) Chao KK, Goldstein NS, Yan D, et al:Clinicopathologic analysis of extracapsular extension in prostate cancer:should the clinical target volume be expanded posterolaterally to account for microscopic extension? Int J Radiat Oncol Biol Phys 65:999-1007, 2006.
PubMed
18) Wenzel M, Wurnschimmel C, Chierigo F, et al:Non-cancer mortality in elderly prostate cancer patients treated with combination of radical prostatectomy and external beam radiation therapy. Prostate 81:728-735, 2021
PubMed
P.244 掲載の参考文献
1) Cary KC, Paciorek A, Fuldeore MJ, et al:Temporal trends and predictors of salvage cancer treatment after failure following radical prostatectomy or radiation therapy:an analysis from the CaPSURE registry. Cancer 120:507-512, 2014.
PubMed
2) Mottet N, Cornford P, van den Bergh RCN, et al:Guidelines on prostate cancer. European Association of Urology Web site, 2022. [https://uroweb.org/guidelines/prostate-cancer]
 
3) Pfister D, Kokx R, Hartmann F, et al:Salvage radical prostatectomy after local radiotherapy in prostate cancer. Curr Opin Urol 31:194-198, 2021.
PubMed
4) NCCN Clinical Practice Guidelines in Oncology(NCCN Guidelines) Prostate Cancer, Version 1. 2023. [https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf]
 
5) Chade DC, Eastham J, Graefen M, et al:Cancer Control and Functional Outcomes of Salvage Radical Prostatectomy for Radiation-recurrent Prostate Cancer:A Systematic Review of the Literature. Eur Urol 61:961-971, 2012.
PubMed
6) Valle LF, Lehrer EJ, Markovic D, et al:A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER). Eur Urol 80:280-292, 2021.
 
7) Chade DC, Shariat SF, Cronin AM, et al:Salvage radical prostatectomy for radiation-recurrent prostate cancer:a multi-institutional collaboration. Eur Urol 60:205-210, 2011.
PubMed
8) Marra G, Karnes RJ, Calleris G, et al:Oncological outcomes of salvage radical prostatectomy for recurrent prostate cancer in the contemporary era:A multicenter retrospective study. Urol Oncol 39:296.e21-296.e29, 2021.
 
9) Bates AS, Samavedi S, Kumar A, et al:Salvage robot assisted radical prostatectomy:A propensity matched study of perioperative, oncological and functional outcomes. Eur J Surg Oncol 41:1540-1546, 2015.
PubMed
10) Chen BT, Wood DP Jr:Salvage prostatectomy in patients who have failed radiation therapy or cryotherapy as primary treatment for prostate cancer. Urology 62 Suppl 1:69-78, 2003.
PubMed
11) Calleris G, Marra G, Dalmasso E, et al:Is it worth to perform salvage radical prostatectomy for radio-recurrent prostate cancer? A literature review. World J Urol 37:1469-1483, 2019.
PubMed
12) Branche B, Crocerossa F, Carbonara U, et al:Management of Bladder Neck Contracture in the Age of Robotic Prostatectomy:An Evidence-based Guide. Eur Urol Focus 8:297-301, 2022.
PubMed
13) Borboroglu PG, Sands JP, Roberts JL, et al:Risk factors for vesicourethral anastomotic stricture after radical prostatectomy. Urology 56:96-100, 2000.
PubMed
14) LaBossiere JR, Cheung D, Rourke K:Endoscopic Treatment of Vesicourethral Stenosis after Radical Prostatectomy:Outcomes and Predictors of Success. J Urol 195:1495-1500, 2016.
PubMed
15) Davis BJ, Horwitz EM, Lee WR, et al:American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. Brachytherapy 11:6-19, 2012.
PubMed
P.249 掲載の参考文献
1) Stephenson AJ, Kattan MW, Eastham JA, et al:Defining biochemical recurrence of prostate cancer after radical prostatectomy:a proposal for a standardized definition. J Clin Oncol 24:3973-3978, 2006.
PubMed
2) 前立腺癌診療ガイドライン[2016年版](日本泌尿器科学会 編), メディカルレビュー社, 2016.
 
3) Pound CR, Partin AW, Eisenberger MA, et al:Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281:1591-1597, 1999.
PubMed
4) Rouviere O, Vitry T, Lyonnet D:Imaging of prostate cancer local recurrences:why and how? Eur Radiol 20:1254-1266, 2010.
PubMed
5) Beresford MJ, Gillatt D, Benson RJ, et al:A systematic review of the role of imaging before salvage radiotherapy for post-prostatectomy biochemical recurrence. Clin Oncol (R Coll Radiol) 22:46-55, 2010.
PubMed
6) Gomez P, Manoharan M, Kim SS, et al:Radionuclide bone scintigraphy in patients with biochemical recurrence after radical prostatectomy:when is it indicated? BJU Int 94:299-302, 2004.
PubMed
7) Kane CJ, Amling CL, Johnstone PAS, et al:Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urology 61:607-611, 2003.
PubMed
8) Eiber M, Herrmann K, Fendler WP, et al:68Ga-labeled Prostate-specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Imaging:The New Kid on the Block-Early or Too Early to Draw Conclusions? Eur Urol 70:938-940, 2016.
PubMed
9) Ceci F, Uprimny C, Nilica B, et al:68Ga-PSMA PET/CT for restaging recurrent prostate cancer:which factors are associated with PET/CT detection rate? Eur J Nucl Med Mol Imaging 42:1284-1294, 2015.
PubMed
10) van Leeuwen PJ, Stricker P, Hruby G, et al:68Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment. BJU Int 117:732-739, 2016.
 
11) Roach PJ, Francis R, Emmett L, et al:The Impact of 68Ga-PSMA PET/CT on management intent in prostate cancer:results of an Australian prospective multicenter study. J Nucl Med 59:82-88, 2018.
 
12) Emmett L, van Leeuwen PJ, Nandurkar R, et al:Treatment outcomes from 68Ga-PSMA PET/CT-informed salvage radiation treatment in men with rising PSA after radical prostatectomy:Prognostic value of a negative PSMA PET. J Nucl Med 58:1972-1976, 2017.
 
13) Eiber M, Holzapfel K, Ganter C, et al:Whole-body MRI including diffusion-weighted imaging (DWI) for patients with recurring prostate cancer:technical feasibility and assessment of lesion conspicuity in DWI. J Magn Reson Imaging 33:1160-1170, 2011.
PubMed
14) Naito S:Evaluation and management of prostate-specific antigen recurrence after radical prostatectomy for localized prostate cancer. Jpn J Clin Oncol 35:365-374, 2005.
PubMed
15) King CR:The timing of salvage radiotherapy after radical prostatectomy:a systematic review. Int J Radiat Oncol Biol Phys 84:104-111, 2012.
PubMed
P.253 掲載の参考文献
1) Parker CC, Clarke NW, Cook AD, et al:Timing of radiotherapy after radical prostatectomy (RADICALS-RT):a randomised, controlled phase 3 trial. Lancet 396:1413-1421, 2020.
PubMed
2) Vale CL, Fisher D, Kneebone A, et al:Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer:a prospectively planned systematic review and meta-analysis of aggregate data. Lancet 396:1422-1431, 2020.
PubMed
3) Cornford P, Bellmunt J, Bolla M, et al:EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II:Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. Eur Urol 71:630-642, 2017.
PubMed
4) Valicenti RK, Thompson I Jr, Albertsen P, et al:Adjuvant and salvage radiation therapy after prostatectomy:American Society for Radiation Oncology/American Urological Association guidelines. Int J Radiat Oncol Biol Phys 86:822-828, 2013.
 
5) Tilki D, Preisser F, Graefen M, et al:External Validation of the European Association of Urology Biochemical Recurrence Risk Groups to Predict Metastasis and Mortality After Radical Prostatectomy in a European Cohort. Eur Urol 75:896-900, 2019.
 
6) Tendulkar RD, Agrawal S, Gao T, et al:Contemporary Update of a Multi-Institutional Predictive Nomogram for Salvage Radiotherapy After Radical Prostatectomy. J Clin Oncol 34:3648-3654, 2016.
PubMed
7) Zaorsky NG, Calais J, Fanti S, et al:Salvage therapy for prostate cancer after radical prostatectomy. Nat Rev Urol 18:643-668, 2021.
PubMed
8) Yokomizo A, Wakabayashi M, Satoh T, et al:Salvage Radiotherapy Versus Hormone Therapy for Prostate-specific Antigen Failure After Radical Prostatectomy:A Randomised, Multicentre, Open-label, Phase 3 Trial (JCOG0401). Eur Urol 77:689-698, 2020.
PubMed
9) Nabid A, Carrier N, Martin AG, et al:Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer:A Randomized Phase III Trial. Eur Urol 74:432-441, 2018.
PubMed
10) Crook JM, O'Callaghan CJ, Duncan G, et al:Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med 367:895-903, 2012.
PubMed
11) Dess RT, Sun Y, Jackson WC, et al:Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer. JAMA Oncol 6:735-743, 2020.
PubMed
12) Van den Broeck T, van den Bergh RCN, Arfi N, et al:Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer:A Systematic Review. Eur Urol 75:967-987, 2019.
PubMed
13) Greenberger BA, Zaorsky NG, Den RB:Comparison of Radical Prostatectomy Versus Radiation and Androgen Deprivation Therapy Strategies as Primary Treatment for High-risk Localized Prostate Cancer:A Systematic Review and Meta-analysis. Eur Urol Focus 6:404-418, 2020.
PubMed
14) Fossati N, Karnes RJ, Colicchia M, et al:Impact of Early Salvage Radiation Therapy in Patients with Persistently Elevated or Rising Prostate-specific Antigen After Radical Prostatectomy. Eur Urol 73:436-444, 2018.
PubMed
15) Shipley WU, Seiferheld W, Lukka HR, et al:Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer. N Engl J Med 376:417-428, 2017.
 
P.258 掲載の参考文献
1) Hummel S, Simpson EL, Hemingway P, et al:Intensity-modulated radiotherapy for the treatment of prostate cancer:a systematic review and economic evaluation. Health Technol Assess 14:1-108, iii-iv, 2010.
 
2) Wang S, Tang W, Luo H, et al:The role of image-guided radiotherapy in prostate cancer:A systematic review and meta-analysis. Clin Transl Radiat Oncol 38:81-89, 2023.
PubMed
3) Lehrer EJ, Kishan AU, Yu JB, et al:Ultrahypofractionated versus hypofractionated and conventionally fractionated radiation therapy for localized prostate cancer:A systematic review and meta-analysis of phase III randomized trials. Radiother Oncol 148:235-242, 2020.
PubMed
4) Ishikawa H, Tsuji H, Murayama S, et al:Particle therapy for prostate cancer:The past, present and future. Int J U 26:971-979, 2019.
 
5) Luo W, Li J, Fourkal E, et al:Dosimetric advantages of IMPT over IMRT for laser-accelerated proton beams. Phys Med Biol 53:7151-7166, 2008.
PubMed
6) Sheets NC, Goldin GH, Meyer AM, et al:Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA 307:1611-1620, 2012.
PubMed
7) 平山亮一:重粒子線における酸素効果とそのメカニズム. 医学物理 34:65-69, 2014.
 
8) Zaorsky NG, Palmer JD, Hurwitz MD, et al:What is the ideal radiotherapy dose to treat prostate cancer? A meta-analysis of biologically equivalent dose escalation. Radiother Oncol 115:295-300, 2015.
PubMed
9) Hoskin PJ, Rojas AM, Ostler PJ, et al:Randomised trial of external-beam radiotherapy alone or with high-dose-rate brachytherapy for prostate cancer:Mature 12-year results. Radiother Oncol 154:214-219, 2021.
 
10) Oh J, Tyldesley S, Pai H, et al:An Updated Analysis of the Survival Endpoints of ASCENDE-RT. Int J Radiat Oncol Biol Phys 115:1061-1070, 2023.
PubMed
11) Ghadjar P, Hayoz S, Bernhard J, et al:Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy:The SAKK 09/10 Randomized Phase 3 Trial. Eur Urol 80:306-315, 2021.
PubMed
12) Ghadjar P, Aebersold DM, Albrecht C, et al:Use of androgen deprivation and salvage radiation therapy for patients with prostate cancer and biochemical recurrence after prostatectomy. Strahlenther Onkol 194:619-626, 2018.
PubMed
13) Pollack A, Karrison TG, Balogh AG, et al:The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT):an international, multicentre, randomised phase 3 trial. Lancet 399:1886-1901, 2022.
PubMed
14) Kneebone A, Fraser-Browne C, Duchesne GM, et al:Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES):a randomised, controlled, phase 3, non-inferiority trial. Lancet Oncol 21:1331-1340, 2020.
PubMed
15) Parker CC, Clarke NW, Cook AD, et al:Timing of radiotherapy after radical prostatectomy (RADICALS-RT):a randomised, controlled phase 3 trial. Lancet 396:1413-1421, 2020.
PubMed
P.263 掲載の参考文献
1) Dearnaley DP, Jovic G, Syndikus I, et al:Escalated-dose versus control-dose conformal radiotherapy for prostate cancer:long-term results from the MRC RT01 randomised controlled trial. Lancet Oncol 15:464-473, 2014.
PubMed
2) Sheets NC, Goldin GH, Meyer AM, et al:Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA 307:1611-1620, 2012.
PubMed
3) Aizawa R, Takayama K, Nakamura K, et al:Ten-year outcomes of high-dose intensity-modulated radiation therapy for nonmetastatic prostate cancer with unfavorable risk:early initiation of salvage therapy may replace long-term adjuvant androgen deprivation. Int J Clin Oncol 24:1247-1255, 2019.
PubMed
4) Sasamura K, Soyano T, Kozuka T, et al:Outcomes of intensity-modulated radiation therapy for intermediate- or high-risk prostate cancer:a single-institutional study. Jpn J Clin Oncol 52:170-178, 2022.
PubMed
5) de Crevoisier R, Bayar MA, Pommier P, et al:Daily Versus Weekly Prostate Cancer Image Guided Radiation Therapy:Phase 3 Multicenter Randomized Trial. Int J Radiat Oncol Biol Phys 102:1420-1429, 2018.
PubMed
6) Murray J, Griffin C, Gulliford S, et al:A randomised assessment of image guided radiotherapy within a phase 3 trial of conventional or hypofractionated high dose intensity modulated radiotherapy forprostate cancer. Radiother Oncol 142:62-71, 2020.
PubMed
7) Kerkmeijer LGW, Groen VH, Pos FJ, et al:Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer:Results From the FLAME Randomized Phase III Trial. J Clin Oncol 39:787-796, 2021.
 
8) Hamstra DA, Mariados N, Sylvester J, et al:Continued Benefit to Rectal Separation for Prostate Radiation Therapy:Final Results of a Phase III Trial. Int J Radiat Oncol Biol Phys 97:976-985, 2017.
PubMed
9) Bolla M, Van Tienhoven G, Warde P, et al:External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk:10-year results of an EORTC randomised study. Lancet Oncol 11:1066-1073, 2010.
 
10) Jones CU, Hunt D, McGowan DG, et al:Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med 365:107-118, 2011.
PubMed
P.268 掲載の参考文献
1) Lee WR, Dignam JJ, Amin MB, et al:Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer. J Clin Oncol 34:2325-2332, 2016.
PubMed
2) Dearnaley D, Syndikus I, Mossop H, et al:Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer:5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol 17:1047-1060, 2016.
PubMed
3) Catton CN, Lukka H, Gu CS, et al:Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer. J Clin Oncol 35:1884-1890, 2017.
PubMed
4) Incrocci L, Wortel RC, Alemayehu WG, et al:Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO):final efficacy results from a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 17:1061-1069, 2016.
PubMed
5) Hickey BE, James ML, Daly T, et al:Hypofractionation for clinically localized prostate cancer. Cochrane Database Syst Rev 9:CD011462, 2019.
PubMed
6) NCCN Clinical Practice Guidelines in Oncology, Prostate Cancer version 3:2022. [https://www.nccn.org/]
 
7) Nihei K, Nakamura K, Karasawa K, et al:A Japanese multi-institutional phase ii study of moderate hypofractionated intensity-modulated radiotherapy with image-guided technique for prostate cancer. Int J Radiat Onco. Biol Phys 111(Suppl), E288, 2021.
 
8) Widmark A, Gunnlaugsson A, Beckman L, et al:Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer:5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet 394:385-395, 2019.
PubMed
9) Tree AC, Ostler P, van der Voet H, et al:Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B):2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol 23:1308-1320, 2022.
 
10) Ishiyama H, Tsumura H, Nagano H, et al:Multi-institutional retrospective analysis of ultrahypofrac-tionated radiotherapy for Japanese prostate cancer patients. Sci Rep 11:13194, 2021.
PubMed
11) Murthy V, Maitre P, Kannan S, et al:Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT):Outcomes From Phase III Randomized Controlled Trial. J Clin Oncol 39:1234-1242, 2021.
 
12) Correa RJM, Loblaw A:Stereotactic Body Radiotherapy:Hitting Harder, Faster, and Smarter in High-Risk Prostate Cancer. Front Oncol 12:889132, 2022.
PubMed
13) Musunuru HB, Cheung P, Vesprini D, et al:Gantry-based 5-fraction elective nodal irradiation in unfavorable-risk prostate cancer:outcomes from 2 prospective studies comparing SABR boost with MR dose-painted HDR brachytherapy boost. Int J Radiat Oncol Biol Phys 112:735-743, 2022.
PubMed
14) Bauman G, Ferguson M, Lock M, et al:A Phase 1/2 Trial of Brief Androgen Suppression and Stereotactic Radiation Therapy (FASTR) for High-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys 92:856-862, 2015.
 
15) Kerkmeijer LGW, Groen VH, Pos FJ, et al:Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer:Results From the FLAME Randomized Phase III Trial. J Clin Oncol 39:787-796, 2021.
 
P.276 掲載の参考文献
1) Michaelson MD, Cotter SE, Gargollo PC, et al:Management of complications of prostate cancer treatment. CA Cancer J Clin 58:196-213, 2008.
PubMed
2) Zaorsky NG, Davis BJ, Nguyen PL, et al:The evolution of brachytherapy for prostate cancer. Nat Rev Urol 14:415-439, 2017.
PubMed
3) Matta R, Chapple CR, Fisch M, et al:Pelvic Complications After Prostate Cancer Radiation Therapy and Their Management:An International Collaborative Narrative Review. Eur Urol 75:464-476, 2019.
PubMed
4) King MT, Keyes M, Frank SJ, et al:Low dose rate brachytherapy for primary treatment of localized prostate cancer:A systemic review and executive summary of an evidence-based consensus statement. Brachytherapy 20:1114-1129, 2021.
PubMed
5) Dohm A, Sanchez J, Stotsky-Himelfarb E, et al:Strategies to Minimize Late Effects From Pelvic Radiotherapy. Am Soc Clin Oncol Educ Book 41:158-168, 2021.
PubMed
6) Dearnaley D, Syndikus I, Mossop H, et al:Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer:5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol 17:1047-1060, 2016.
PubMed
7) Brand DH, Tree AC, Ostler P, et al:Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B):acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. Lancet Oncol 20:1531-1543, 2019.
 
8) Morgan SC, Hoffman K, Loblaw DA, et al:Hypofractionated Radiation Therapy for Localized Prostate Cancer:Executive Summary of an ASTRO, ASCO, and AUA Evidence-Based Guideline. Pract Radiat Oncol 8:354-360, 2018.
PubMed
9) Lehrer EJ, Kishan AU, Yu JB, et al:Ultrahypofractionated versus hypofractionated and conventionally fractionated radiation therapy for localized prostate cancer:A systematic review and meta-analysis of phase III randomized trials. Radiother Oncol 148:235-242, 2020.
PubMed
10) Tree AC, Ostler P, van der Voet H, et al:Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B):2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol 23:1308-1320, 2022.
 
11) がん治療に伴う粘膜障害マネジメントの手引き[2020年版](日本がんサポーティブケア学会, 日本がん口腔支持療法学会 編), 金原出版, 2020.
 
12) Nguyen DD, Berlin A, Matthew AG, et al:Sexual function and rehabilitation after radiation therapy for prostate cancer:a review. Int J Impot Res 33:410-417, 2021.
PubMed
13) Dang A, Kupelian PA, Cao M, et al:Image-guided radiotherapy for prostate cancer. Transl Androl Urol 7:308-320, 2018.
PubMed
14) Hall WA, Tree AC, Dearnaley D, et al:Considering benefit and risk before routinely recommending SpaceOAR. Lancet Oncol 22:11-13, 2021.
PubMed
15) Kord E, Flores JP, Posielski N, et al:Patient reported outcomes and health related quality of life in localized prostate cancer:A review of current evidence. Urol Oncol 40:304-314, 2022.
PubMed
P.279 掲載の参考文献
1) Pound CR, Partin AW, Eisenberger MA, et al:Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281:1591-1597, 1999.
PubMed
2) Zagars GK, Pollack A:Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer. Radiother Oncol 44:213-221, 1997.
PubMed
3) Consensus statement:guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys 37:1035-1041, 1997.
 
4) Thames H, Kuban D, Levy L, et al:Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. Int J Radiat Oncol Biol Phys 57:929-943, 2003.
PubMed
5) Horwitz EM, Thames HD, Kuban DA, et al:Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone:a multi-institutional pooled analysis. J Urol 173:797-802, 2005.
 
6) Pickles T, Kim-Sing C, Morris WJ, et al:Evaluation of the Houston biochemical relapse definition in men treated with prolonged neoadjuvant and adjuvant androgen ablation and assessment of follow-up lead-time bias. Int J Radiat Oncol Biol Phys 57:11-18, 2003.
PubMed
7) Roach M 3rd, Hanks G, Thames H Jr, et al:Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer:recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65:965-974, 2006.
 
8) Zumsteg ZS, Spratt DE, Romesser PB, et al:The natural history and predictors of outcome following biochemical relapse in the dose escalation era for prostate cancer patients undergoing definitive external beam radiotherapy. Eur Urol 67:1009-1016, 2015.
PubMed
9) Buyyounouski MK, Pickles T, Kestin LL, et al:Validating the interval to biochemical failure for the identification of potentially lethal prostate cancer. J Clin Oncol 30:1857-1863, 2012.
PubMed
10) Moul JW:Prostate specific antigen only progression of prostate cancer. J Urol 163:1632-1642, 2000.
PubMed
11) 泌尿器科・病理・放射線科 前立腺癌取扱い規約[第4版](日本泌尿器科学会, 日本病理学会, 日本医学放射線学会 編), 金原出版, 2010.
 
12) Abramowitz MC, Li T, Buyyounouski MK, et al:The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer. Cancer 112:55-60, 2008.
PubMed
13) Xie W, Regan MM, Buyse M, et al:Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation. J Clin Oncol 38:3032-3041, 2020.
 
14) Xie W, Regan MM, Buyse M, et al:Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer. J Clin Oncol 35:3097-3104, 2017.
 
15) Thompson A, Keyes M, Pickles T, et al:Evaluating the Phoenix definition of biochemical failure after 125I prostate brachytherapy:Can PSA kinetics distinguish PSA failures from PSA bounces? Int J Radiat Oncol Biol Phys 78:415-421, 2010.
PubMed
16) Mydin AR, Dunne MT, Finn MA, et al:Early salvage hormonal therapy for biochemical failure improved survival in prostate cancer patients after neoadjuvant hormonal therapy plus radiation therapy-a secondary analysis of irish clinical oncology research group 97-01. Int J Radiat Oncol Biol Phys 85:101-108, 2013.
PubMed
P.283 掲載の参考文献
1) National Comprehensive Cancer Network(NCCN):NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines(R)):Prostate Cancer, Version 1. 2023.
 
2) Roach M 3rd, Hanks G, Thames H Jr, et al:Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer:recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65:965-974, 2006.
 
3) Zumsteg ZS, Spratt DE, Romesser PB, et al:The natural history and predictors of outcome following biochemical relapse in the dose escalation era for prostate cancer patients undergoing definitive external beam radiotherapy. Eur Urol 67:1009-1016, 2015.
PubMed
4) Pinover WH, Horwitz EM, Hanlon AL, et al:Validation of a treatment policy for patients with prostate specific antigen failure after three-dimensional conformal prostate radiation therapy. Cancer 97:1127-1133, 2003.
PubMed
5) Zumsteg ZS, Spratt DE, Romesser PB, et al:Anatomical Patterns of Recurrence Following Biochemical Relapse in the Dose Escalation Era of External Beam Radiotherapy for Prostate Cancer. J Urol 194:1624-1630, 2015.
PubMed
6) Natarajan A, Agrawal A, Murthy V, et al:Initial experience of Ga-68 prostate-specific membrane antigen positron emission tomography/computed tomography imaging in evaluation of biochemical recurrence in prostate cancer patients. World J Nucl Med 18:244-250, 2019.
PubMed
7) Jansen BHE, van Leeuwen PJ, Wondergem M, et al:Detection of Recurrent Prostate Cancer Using Prostate-specific Membrane Antigen Positron Emission Tomography in Patients not Meeting the Phoenix Criteria for Biochemical Recurrence After Curative Radiotherapy. Eur Urol Oncol 4:821-825, 2021.
 
8) Vargas HA, Wassberg C, Akin O, et al:MR imaging of treated prostate cancer. Radiology 262:26-42, 2012.
PubMed
9) Chade DC, Eastham J, Graefen M, et al:Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer:a systematic review of the literature. Eur Urol 61:961-971, 2012.
PubMed
10) Valle LF, Lehrer EJ, Markovic D, et al:A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER). Eur Urol 80:280-292, 2021.
 
11) Phillips R, Shi WY, Deek M, et al:Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer:The ORIOLE Phase 2 Randomized Clinical Trial. JAMA Oncol 6:650-659, 2020.
PubMed
12) Ost P, Reynders D, Decaestecker K, et al:Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence:A Prospective, Randomized, Multicenter Phase II Trial. J Clin Oncol 36:446-453, 2018.
PubMed
13) Glicksman RM, Metser U, Vines D, et al:Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer:A Prospective Phase II Trial Testing the Oligometastasis Hypothesis. Eur Urol 80:374-382, 2021.
PubMed
14) Cary KC, Paciorek A, Fuldeore MJ, et al:Temporal trends and predictors of salvage cancer treatment after failure following radical prostatectomy or radiation therapy:an analysis from the CaPSURE registry. Cancer 120:507-512, 2014.
PubMed
15) Tran H, Kwok J, Pickles T, et al:Underutilization of local salvage therapy after radiation therapy for prostate cancer. Urol Oncol 32:701-706, 2014.
PubMed
16) Crook JM, O'Callaghan CJ, Duncan G, et al:Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med 367:895-903, 2012
PubMed
P.290 掲載の参考文献
1) Holm HH, Juul N, Pedersen JF, et al:Transperineal 125iodine seed implantation in prostatic cancer guided by transrectal ultrasonography. J Urol 130:283-286, 1983.
PubMed
2) Stone NN, Stock RG, Cesaretti JA, et al:Local control following permanent prostate brachytherapy:effect of high biologically effective dose on biopsy results and oncologic outcomes. Int J Radiat Oncol Biol Phys 76:355-360, 2010.
PubMed
3) Taira AV, Merrick GS, Butler WM, et al:Long-term outcome for clinically localized prostate cancer treated with permanent interstitial brachytherapy. Int J Radiat Oncol Biol Phys 79:1336-1342, 2011.
PubMed
4) Yorozu A, Kuroiwa N, Takahashi A, et al:Permanent prostate brachytherapy with or without supplemental external beam radiotherapy as practiced in Japan:outcomes of 1300 patients. Brachytherapy 14:111-117, 2015.
PubMed
5) Tanaka N, Nakai Y, Asakawa I, et al:Local dose (biologically effective dose >=180 Gy2) is an important predictor of biochemical recurrence in patients undergoing low-dose-rate brachytherapy. Int J Urol 29:1560-1568, 2022.
PubMed
6) Zelefsky MJ, Yamada Y, Pei X, et al:Comparison of tumor control and toxicity outcomes of high-dose intensity-modulated radiotherapy and brachytherapy for patients with favorable risk prostate cancer. Urology 77:986-990, 2011.
PubMed
7) Spratt DE, Zumsteg ZS, Ghadjar P, et al:Comparison of high-dose (86.4 Gy) IMRT vs combined brachytherapy plus IMRT for intermediate-risk prostate cancer. BJU Int 114:360-367, 2014.
PubMed
8) Morris WJ, Tyldesley S, Rodda S, et al:Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial):An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer. Int J Radiat Oncol Biol Phys 98:275-285, 2017.
PubMed
9) Tanaka N, Asakawa I, Nakai Y, et al:Comparison of PSA value at last follow-up of patients who underwent low-dose rate brachytherapy and intensity-modulated radiation therapy for prostate cancer. BMC Cancer 17:573, 2017.
PubMed
10) Morris WJ, Pickles T, Keyes M:Using a surgical prostate-specific antigen threshold of > 0.2 ng/mL to define biochemical failure for intermediate- and high-risk prostate cancer patients treated with definitive radiation therapy in the ASCENDE-RT randomized control trial. Brachytherapy 17:837-844, 2018.
 
11) Tsumura H, Tanaka N, Oguchi T, et al:Direct comparison of low-dose-rate brachytherapy versus radical prostatectomy using the surgical definition of biochemical recurrence for patients with intermediate-risk prostate cancer. Radiat Oncol 17:71, 2022.
PubMed
12) Lawton CA, Hunt D, Lee WR, et al:Long-term results of a phase II trial of ultrasound-guided radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (RTOG 98-05). Int J Radiat Oncol Biol Phys 81:1-7, 2011.
PubMed
13) Lawton CA, Yan Y, Lee WR, et al:Long-term results of an RTOG Phase II trial (00-19) of external-beam radiation therapy combined with permanent source brachytherapy for intermediate-risk clinically localized adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys 82:e795-801, 2012.
 
14) Ohashi T, Yorozu A, Saito S, et al:Urinary and Rectal Toxicity Profiles After Permanent Iodine-125 Implant Brachytherapy in Japanese Men:Nationwide J-POPS Multi-institutional Prospective Cohort Study. Int J Radiat Oncol Biol Phys 93:141-149, 2015.
PubMed
15) Katayama N, Yorozu A, Maruo S, et al:Predictive factors of rectal toxicity after permanent iodine-125 seed implantation:Prospective cohort study in 2339 patients. Brachytherapy 15:736-745, 2016.
PubMed
16) Tanaka N, Yorozu A, Kikuchi T, et al:Genitourinary toxicity after permanent iodine-125 seed implantation:The nationwide Japanese prostate cancer outcome study of permanent iodine-125 seed implantation (J-POPS). Brachytherapy 18:484-492, 2019.
PubMed
17) Nakai Y, Tanaka N, Asakawa I, et al:Quality of life in patients who underwent 125I brachytherapy, 125I brachytherapy combined with three-dimensional conformal radiation therapy, or intensity-modulated radiation therapy, for prostate cancer. J Radiat Res 60:270-280, 2019.
PubMed
18) Prestidge BR, Winter K, Sanda MG, et al:Initial Report of NRG Oncology/RTOG 0232:A Phase 3 Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy with Brachytherapy Alone for Selected Patients with Intermediate Risk Prostatic Carcinoma. Int J Radiat Oncol Biol Phys 96(Suppl):S4, 2016.
 
19) Tsumura H, Tanaka N, Oguchi T, et al:Comparative effectiveness of low-dose-rate brachytherapy with or without external beam radiotherapy in favorable and unfavorable intermediate-risk prostate cancer. Sci Rep 12:11023, 2022.
 
P.298 掲載の参考文献
1) Holm HH:The history of interstitial brachytherapy of prostatic cancer. Semin Surg Oncol 13:431-437, 1997.
PubMed
2) Hoskin PJ, Rojas AM, Ostler PJ, et al:Randomised trial of external-beam radiotherapy alone or with high-dose-rate brachytherapy for prostate cancer:Mature 12-year results. Radiother Oncol 154:214-219, 2021.
 
3) Oh J, Tyldesley S, Pai H, et al:An Updated Analysis of the Survival Endpoints of ASCENDE-RT. Int J Radiat Oncol Biol Phys, 115:1061-1070, 2023.
PubMed
4) Chin J, Rumble RB, Kollmeier M, et al:Brachytherapy for Patients With Prostate Cancer:American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline Update. J Clin Oncol 35:1737-1743, 2017.
 
5) Hoskin P, Rojas A, Ostler P, et al:Single-dose high-dose-rate brachytherapy compared to two and three fractions for locally advanced prostate cancer. Radiother Oncol 124:56-60, 2017.
PubMed
6) Yoshioka Y, Kotsuma T, Komiya A, et al:Nationwide, Multicenter, Retrospective Study on High-Dose-Rate Brachytherapy as Monotherapy for Prostate Cancer. Int J Radiat Oncol Biol Phys 97:952-961, 2017.
PubMed
7) Joseph D, Denham JW, Steigler A, et al:Radiation Dose Escalation or Longer Androgen Suppression to Prevent Distant Progression in Men With Locally Advanced Prostate Cancer:10-Year Data From the TROG 03. 04 RADAR Trial. Int J Radiat Oncol Biol Phys 106:693-702, 2020.
 
8) Mukherjee K, Small W Jr, Duszak R Jr:Trends and variations in utilization and costs of radiotherapy for prostate cancer:A SEER medicare analysis from 2007 through 2016. Brachytherapy 21:12-21, 2022
PubMed
P.304 掲載の参考文献
1) Bittner NH, Orio PF 3rd, Merrick GS, et al:The American College of Radiology and the American Brachytherapy Society practice parameter for transperineal permanent brachytherapy of prostate cancer. Brachytherapy 16:59-67, 2017.
PubMed
2) Spratt DE, Soni PD, McLaughlin PW, et al:American Brachytherapy Society Task Group Report:Combination of brachytherapy and external beam radiation for high-risk prostate cancer. Brachytherapy 16:1-12, 2017.
PubMed
3) Tanaka T, Yorozu A, Sutani S, et al:Predictive factors of long-term rectal toxicity following permanent iodine-125 prostate brachytherapy with or without supplemental external beam radiation therapy in 2216 patients. Brachytherapy 17:799-807, 2018.
PubMed
4) Stock RG, Stone NN, Cesaretti JA, et al:Biologically effective dose values for prostate brachytherapy:effects on PSA failure and posttreatment biopsy results. Int J Radiat Oncol Biol Phys 64:527-533, 2006.
PubMed
5) Bolla M, Collette L, Blank L, et al:Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study):a phase III randomised trial. Lancet 360:103-106, 2002.
PubMed
6) Konaka H, Egawa S, Saito S, et al:Tri-Modality therapy with I-125 brachytherapy, external beam radiation therapy, and short- or long-term hormone therapy for high-risk localized prostate cancer (TRIP):study protocol for a phase III, multicenter, randomized, controlled trial. BMC Cancer 12:110, 2012.
 
7) 斉藤史郎, 矢木康人, 中村 憲, ほか:前立腺癌に対する低線量率小線源療法-高リスク癌に対するトリモダリティー治療-. 泌尿器外科 35:21-26, 2022.
Medical*Online
8) Ohashi T, Yorozu A, Saito S, et al:Combined brachytherapy and external beam radiotherapy without adjuvant androgen deprivation therapy for high-risk prostate cancer. Radiat Oncol 9:13, 2014.
PubMed
9) Potters L, Klein EA, Kattan MW, et al:Monotherapy for stage T1-T2 prostate cancer:radical prostatectomy, external beam radiotherapy, or permanent seed implantation. Radiother Oncol 71:29-33, 2004.
PubMed
10) Morris WJ, Tyldesley S, Rodda S, et al:Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial):An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer. Int J Radiat Oncol Biol Phys 98:275-285, 2017.
PubMed
11) Morris WJ, Pickles T, Keyes M:Using a surgical prostate-specific antigen threshold of > 0.2 ng/mLto define biochemical failure for intermediate- and high-risk prostate cancer patients treated withdefinitive radiation therapy in the ASCENDE-RT randomized control trial. Brachytherapy 17:837-844, 2018.
 
12) Rodda S, Tyldesley S, Morris WJ, et al:ASCENDE-RT:An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys 98:286-295, 2017.
PubMed
13) Rodda S, Morris WJ, Hamm J, et al:ASCENDE-RT:An Analysis of Health-Related Quality of Life for a Randomized Trial Comparing Low-Dose-Rate Brachytherapy Boost With Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys 98:581-589, 2017.
PubMed
14) Ohashi T, Yorozu A, Saito S, et al:Urinary and Rectal Toxicity Profiles After Permanent Iodine-125 Implant Brachytherapy in Japanese Men:Nationwide J-POPS Multi-institutional Prospective Cohort Study. Int J Radiat Oncol Biol Phys 93:141-149, 2015.
PubMed
15) Ciezki JP, Weller M, Reddy CA, et al:A Comparison Between Low-Dose-Rate Brachytherapy With or Without Androgen Deprivation, External Beam Radiation Therapy With or Without Androgen Deprivation, and Radical Prostatectomy With or Without Adjuvant or Salvage Radiation Therapy for High-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys 97:962-975, 2017.
 
P.312 掲載の参考文献
1) Wilson RR:Radiological use of fast protons. Radiology 47:487-491, 1946.
PubMed
2) Ishikawa H, Tsuji H, Murayama S, et al:Particle therapy for prostate cancer:The past, present and future. Int J Urol 26:971-979, 2019.
PubMed
3) Zelefsky MJ, Yamada Y, Fuks Z, et al:Long-term results of conformal radiotherapy for prostate cancer:impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. Int J Radiat Oncol Biol Phys 71:1028-1033, 2008.
PubMed
4) Michalski J, Winter K, Roach M, et al:Clinical outcome of patients treated with 3D conformal radiation therapy (3D-CRT) for prostate cancer on RTOG 9406. Int J Radiat Oncol Biol Phys 83:e363-370, 2012.
PubMed
5) Li M, Li X, Yao L, et al:Clinical Efficacy and Safety of Proton and Carbon Ion Radiotherapy for Prostate Cancer:A Systematic Review and Meta-Analysis. Front Oncol 11:709530, 2021.
 
6) Shipley WU, Verhey LJ, Munzenrider JE, et al:Advanced prostate cancer:the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. Int J Radiat Oncol Biol Phys 32:3-12, 1995.
PubMed
7) Roach M 3rd, DeSilvio M, Valicenti R, et al:Whole-pelvis, "mini-pelvis, " or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial. Int J Radiat Oncol Biol Phys 66:647-653, 2006.
PubMed
8) Kuban DA, Tucker SL, Dong L, et al:Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 70:67-74, 2008.
 
9) Zietman AL, Bae K, Slater JD, et al:Randomized trial comparing conventional-dose with high-doseconformal radiation therapy in early-stage adenocarcinoma of the prostate:long-term results from proton radiation oncology group/american college of radiology 95-09. J Clin Oncol 28:1106-1111, 2010.
PubMed
10) Nihei K, Ogino T, Ishikura S, et al:Phase II feasibility study of high-dose radiotherapy for prostate cancer using proton boost therapy:first clinical trial of proton beam therapy for prostate cancer in Japan. Jpn J Clin Oncol 35:745-752, 2005.
PubMed
11) Schulte RW, Slater JD, Rossi CJ Jr, et al:Value and perspectives of proton radiation therapy for limited stage prostate cancer. Strahlenther Onkol 176:3-8, 2000.
PubMed
12) Nihei K, Ogino T, Onozawa M, et al:Multi-institutional Phase II study of proton beam therapy for organ-confined prostate cancer focusing on the incidence of late rectal toxicities. Int J Radiat Oncol Biol Phys 81:390-396, 2011.
PubMed
13) Ishikawa H, Hiroshima Y, Kanematsu N, et al:Carbon-ion radiotherapy for urological cancers. Int J Urol 29:1109-1119, 2022.
PubMed
14) Kupelian PA, Willoughby TR, Reddy CA, et al:Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer:Cleveland Clinic experience. Int J Radiat Oncol Biol Phys 68:1424-1430, 2007.
 
15) Cahlon O, Zelefsky MJ, Shippy A, et al:Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer:toxicity and biochemical outcomes. Int J Radiat Oncol Biol Phys 71:330-337, 2008.
PubMed
16) Guckenberger M, Lawrenz I, Flentje M:Moderately hypofractionated radiotherapy for localized prostate cancer:long-term outcome using IMRT and volumetric IGRT. Strahlenther Onkol 190:48-53, 2014.
PubMed
17) Lieng H, Pintilie M, Bayley A, et al:Long-term outcomes of a phase II trial of moderate hypofractionated image-guided intensity modulated radiotherapy (IG-IMRT) for localized prostate cancer. Radiother, Oncol 122:93-98, 2017.
PubMed
18) Shimizu D, Yamazaki H, Nishimura T, et al:Long-term tumor control and late toxicity in patients with prostate cancer receiving hypofractionated (2. 2 Gy) soft-tissue-matched image-guided intensity-modulated radiotherapy. Anticancer Res 37:5829-5835, 2017.
PubMed
19) Bryant C, Smith TL, Henderson RH, et al:Five-Year Biochemical Results, Toxicity, and Patient-Reported Quality of Life After Delivery of Dose-Escalated Image Guided Proton Therapy for Prostate Cancer. Int J Radiat Oncol Biol Phys 95:422-434, 2016.
PubMed
20) Iwata H, Ishikawa H, Takagi M, et al:Long-term outcomes of proton therapy for prostate cancer in Japan:a multi-institutional survey of the Japanese Radiation Oncology Study Group. Cancer Med 7:677-689, 2018.
 
21) Takagi M, Demizu Y, Fujii O, et al:Proton therapy for localized prostate cancer:long-term results from a single-center experience. Int J Radiat Oncol Biol Phys 109:964-974, 2021.
PubMed
P.318 掲載の参考文献
1) Kamada T, Tsujii H, Blakely EA, et al:Carbon ion radiotherapy in Japan:an assessment of 20 years of clinical experience. Lancet Oncol 16:e93-e100, 2015.
PubMed
2) Ishikawa H, Hiroshima Y, Kanematsu N, et al:Carbon-ion radiotherapy for urological cancers. Int J Urol 29:1109-1119, 2022.
PubMed
3) Tsuji H, Yanagi T, Ishikawa H, et al:Hypofractionated radiotherapy with carbon ion beams for prostate cancer. Int J Radiat Oncol Biol Phys 63:1153-1160, 2005.
PubMed
4) Tsubouchi T, Hamatani N, Takashina M, et al:Carbon ion radiotherapy using fiducial markers for prostate cancer in Osaka HIMAK:Treatment planning. J Appl Clin Med Phys 22:242-251, 2021.
PubMed
5) Ishikawa H, Tsuji H, Kamada T, et al:Carbon ion radiation therapy for prostate cancer:results of a prospective phase II study. Radiother Oncol 81:57-64, 2006.
PubMed
6) Okada T, Tsuji H, Kamada T, et al:Carbon ion radiotherapy in advanced hypofractionated regimens for prostate cancer:from 20 to 16 fractions. Int J Radiat Oncol Biol Phys 84:968-972, 2012.
PubMed
7) Nomiya T, Tsuji H, Maruyama K, et al:Phase I/II trial of definitive carbon ion radiotherapy for prostate cancer:evaluation of shortening of treatment period to 3 weeks. Br J Cancer 110:2389-2395, 2014.
 
8) Nomiya T, Tsuji H, Kawamura H, et al:A multi-institutional analysis of prospective studies of carbon ion radiotherapy for prostate cancer:A report from the Japan Carbon ion Radiation Oncology Study Group (J-CROS). Radiother Oncol 121:288-293, 2016.
 
9) Kawamura H, Kubo N, Sato H, et al:Moderately hypofractionated carbon ion radiotherapy for prostate cancer; a prospective observational study "GUNMA0702". BMC Cancer 20:75, 2020.
PubMed
10) Takakusagi Y, Katoh H, Kano K, et al:Preliminary result of carbon-ion radiotherapy using the spot scanning method for prostate cancer. Radiat Oncol 15:127, 2020.
PubMed
11) Sato H, Kasuya G, Ishikawa H, et al:Long-term clinical outcomes after 12-fractionated carbon-ion radiotherapy for localized prostate cancer. Cancer Sci 112:3598-3606, 2021.
PubMed
12) Sasamura K, Soyano T, Kozuka T, et al:Outcomes of intensity-modulated radiation therapy for intermediate- or high-risk prostate cancer:a single-institutional study. Jpn J Clin Oncol 52:170-178, 2022.
PubMed
13) Kishan AU, Wang PC, Upadhyaya SK, et al:SBRT and HDR brachytherapy produce lower PSA nadirs and different PSA decay patterns than conventionally fractionated IMRT in patients with low- or intermediate-risk prostate cancer. Pract Radiat Oncol 6:268-275, 2016.
PubMed
14) Eichkorn T, Karger CP, Brons S, et al:Results of a prospective randomized trial on long-term effectiveness of protons and carbon ions in prostate cancer:LEM I and α/β = 2 Gy overestimates the RBE. Radiother Oncol 173:223-230, 2022.
 
15) Wohlfahrt P, Mohler C, Stutzer K, et al:Dual-energy CT based proton range prediction in head and pelvic tumor patients. Radiother Oncol 125:526-533, 2017.
PubMed
P.323 掲載の参考文献
1) 国立がん研究センター:がん情報サービス「がん登録・統計」. [https://ganjoho.jp/reg_stat/].
 
2) Madersbacher S, Pedevilla M, Vingers L, et al:Effect of high-intensity focused ultrasound on human prostate cancer in vivo. Cancer Res 55:3346-3351, 1995.
PubMed
3) Yoshizawa S, Matsuura K, Takagi R, et al:Detection of tissue coagulation by decorrelation of ultrasonic echo signals in cavitation-enhanced high-intensity focused ultrasound treatment. J Ther Ultrasound 4:15, 2016.
PubMed
4) Chapelon JY, Margonari J, Vernier F, et al:In vivo effects of high-intensity ultrasound on prostatic adenocarcinoma Dunning R3327. Cancer Res 52:6353-6357, 1992.
PubMed
5) Oosterhof GO, Cornel EB, Smits GA, et al:Influence of high-intensity focused ultrasound on the development of metastases. Eur Urol 32:91-95, 1997.
PubMed
6) Gelet A, Chapelon JY, Margonari J, et al:Prostatic tissue destruction by high-intensity focused ultrasound:experimentation on canine prostate. J Endourol 7:249-253, 1993.
PubMed
7) Kincaide LF, Sanghvi NT, Cummings O, et al:Noninvasive ultrasonic subtotal ablation of the prostate in dogs. Am J Vet Res 57:1225-1227, 1996.
PubMed
8) Shoji S, Hiraiwa S, Uemura K, et al:Focal therapy with high-intensity focused ultrasound for the localized prostate cancer for Asian based on the localization with MRI-TRUS fusion image-guided transperineal biopsy and 12-cores transperineal systematic biopsy:prospective analysis of oncological and functional outcomes. Int J Clin Oncol 25:1844-1853, 2020.
PubMed
9) Hanada I, Shoji S, Takeda K, et al:Significant Impact of the Anterior Transition Zone Portion Treatment on Urinary Function After Focal Therapy with High-Intensity Focused Ultrasound for Prostate Cancer. J Endourol 35:951-960, 2021.
PubMed
10) Shoji S, Kuroda S, Uemura K, et al:Risk Factors for Severe Erectile Dysfunction after Focal Therapy with High-Intensity Focused Ultrasound for Prostate Cancer. Biomedicines 10:2876, 2022.
PubMed
11) Johnston MJ, Emara A, Noureldin M, et al:Focal High-intensity Focussed Ultrasound Partial Gland Ablation for the Treatment of Localised Prostate Cancer:A Report of Medium-term Outcomes From a Single-center in the United Kingdom. Urology 133:175-181, 2019.
PubMed
12) van Velthoven R, Aoun F, Marcelis Q, et al:A prospective clinical trial of HIFU hemiablation for clinically localized prostate cancer. Prostate Cancer Prostatic Dis 19:79-83, 2016.
 
13) Guillaumier S, Peters M, Arya M, et al:A Multicentre Study of 5-year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer. Eur Urol 74:422-429, 2018
 
14) He Y, Tan P, He M, et al:The primary treatment of prostate cancer with high-intensity focused ultrasound:A systematic review and meta-analysis. Medicine (Baltimore) 99:e22610, 2020.
PubMed
15) Shoji S, Kaya T, Tanaka Y, et al:Usefulness of LacdiNAc-glycosylated Prostate-specific Antigen Density for Predicting Pathological Findings of Magnetic Resonance Imaging-transrectal Ultrasound Fusion Image-guided Prostate Biopsy for the Patients With Highest Prostate Imaging Reporting and Data System Category >=3. J Urol 209:187-197, 2023.
 
P.329 掲載の参考文献
1) Fujihara A, Ukimura O:Focal therapy of localized prostate cancer. Int J Urol 29:1254-1263, 2022.
PubMed
2) Bahn D, de Castro Abreu AL, Gill IS, et al:Focal cryotherapy for clinically unilateral, low-intermediate risk prostate cancer in 73 men with a median follow-up of 3.7 years. Eur Urol 62:55-63, 2012.
PubMed
3) Oishi M, Gill IS, Tafuri A, et al:Hemigland Cryoablation of Localized Low, Intermediate and High Risk Prostate Cancer:Oncologic and Functional Outcomes at 5 Years. J Urol 202:1188-1198, 2019.
PubMed
4) Shah TT, Peters M, Eldred-Evans D, et al:Early-Medium-Term Outcomes of Primary Focal Cryotherapy to Treat Nonmetastatic Clinically Significant Prostate Cancer from a Prospective Multicentre Registry. Eur Urol 76:98-105, 2019.
PubMed
5) Chuang R, Kinnaird A, Kwan L, et al:Hemigland Cryoablation of Clinically Significant Prostate Cancer:Intermediate-Term Followup via Magnetic Resonance Imaging Guided Biopsy. J Urol 204:941-949, 2020.
PubMed
6) Wysock JS, Becher E, Gogaj R, et al:Early oncological control following partial gland cryo-ablation:a prospective experience specifying reflex MRI guided biopsy of the ablation zone. Prostate Cancer Prostatic Dis 24:114-119, 2021.
PubMed
7) ClinicalTrials. gov Identifier:NCT05500846:Targeted Cryoablation of Prostate Cancer Lesions:An Investigator-initiated Trial (PROCRY), ClinicalTrials. gov:U. S. National Library of Medicine, 2022. [https://clinicaltrials.gov/ct2/show/NCT05500846]
 
8) Cooper is, Lee AS:Cryostatic congelation:a system for producing a limited, controlled region of cooling or freezing of biologic tissues. J Nerv Ment Dis 133:259-263, 1961.
PubMed
9) 浮村 理, 藤原敦子:Focal therapy(癌標的化局所治療). 臨床泌尿器科 76:804-808, 2022.
 
10) Eastham JA, Auffenberg GB, Barocas DA, et al:Clinically Localized Prostate Cancer:AUA/ASTRO Guideline (2022) Part I, II, III, 2022. [https://www.auanet.org/guidelines-and-quality/guidelines/clinically-localized-prostate-cancer-aua/astro-guideline-2022]
 
11) 前立腺癌診療ガイドライン[2016年版](日本泌尿器科学会 編), メディカルレビュー社, 2016.
 
12) 日本泌尿器科学会 前立腺癌局所治療用医療機器の臨床評価ガイドラインワーキンググループ. 前立腺癌局所治療用医療機器の臨床評価方法に関するガイドライン(2021/4/20 公開)日本泌尿器科学会雑誌 第112巻2号:4月号 巻頭特集 1-21, 2021.
 
13) Inoue Y, Ushijima S, Shiraishi T, et al:Biochemical and magnetic resonance image response in targeted focal cryotherapy to ablate targeted biopsy-proven index lesion of prostate cancer. Int J Urol 26:317-319, 2019.
PubMed
14) 三木健太 , 木村章嗣 , 大沼 源, ほか:根治放射線照射後の再発前立腺癌病巣に対する救済凍結治療後の排尿・性機能への影響. 日本泌尿器科学会雑誌 109:184-193, 2018.
 
15) Oishi M, Gill IS, Ashrafi AN, et al:Primary Whole-gland Cryoablation for Prostate Cancer:Biochemical Failure and Clinical Recurrence at 5.6 Years of Follow-up. Eur Urol 75:208-214, 2019.
PubMed
P.335 掲載の参考文献
1) Mazariego CG, Egger S, King MT, et al:Fifteen year quality of life outcomes in men with localised prostate cancer:population based Australian prospective study. BMJ 371:m3503, 2020.
PubMed
2) Timilshina N, Komisarenko M, Martin LJ, et al:Factors Associated with Discontinuation of Active Surveillance among Men with Low-Risk Prostate Cancer:A Population-Based Study. J Urol 206:903-913, 2021.
PubMed
3) Matsuoka Y, Uehara S, Yoshida S, et al:Value of extra-target prostate biopsy for the detection of magnetic resonance imaging-missed adverse pathology according to the Prostate Imaging Reporting and Data System scores:Spatial analysis using magnetic resonance-ultrasound fusion images. Int J Urol 27:760-766, 2020.
 
4) Matsuoka Y, Numao N, Saito K, et al:Combination of diffusion-weighted magnetic resonance imaging and extended prostate biopsy predicts lobes without significant cancer:application in patient selection for hemiablative focal therapy. Eur Urol 65:186-192, 2014.
PubMed
5) Matsuoka Y, Numao N, Saito K, et al:Candidate selection for quadrant-based focal ablation through a combination of diffusion-weighted magnetic resonance imaging and prostate biopsy. BJU Int 117:94-101, 2016.
PubMed
6) Matsuoka Y, Uehara S, Yoshida S, et al:Three-dimensional analysis of systematic biopsy-derived prostate cancer upgrading over targeted biopsy:Potential of target margin and surrounding region sampling using magnetic resonance-ultrasound image fusion systems. Int J Urol 28:127-129, 2021.
PubMed
7) Kittel JA, Reddy CA, Smith KL, et al:Long-Term Efficacy and Toxicity of Low-Dose-Rate 125I Prostate Brachytherapy as Monotherapy in Low-, Intermediate-, and High-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys 92:884-893, 2015.
PubMed
8) 小線源治療部会ガイドラインに基づく密封小線源治療 診療・物理 QA マニュアル(日本放射線腫瘍学会小線源治療部会 編), p22-29, 金原出版, 2013.
 
9) Priester A, Natarajan S, Khoshnoodi P, et al:Magnetic Resonance Imaging Underestimation of Prostate Cancer Geometry:Use of Patient Specific Molds to Correlate Images with Whole Mount Pathology. J Urol 197:320-326, 2017.
PubMed
10) 日本泌尿器科学会 前立腺癌局所治療用医療機器の臨床評価ガイドラインワーキンググループ:前立腺癌局所治療用医療機器の臨床評価方法に関するガイドライン, p1-21, 2021.
 
11) Cosset JM, Cathelineau X, Wakil G, et al:Focal brachytherapy for selected low-risk prostate cancers:a pilot study. Brachytherapy 12:331-337, 2013.
PubMed
12) Matsuoka Y, Uehara S, Toda K, et al:Focal brachytherapy for localized prostate cancer:5.7-year clinical outcomes and a pair-matched study with radical prostatectomy. Urol Oncol 40:161. e15-161. e23, 2022.
 
13) Langley S, Uribe J, Uribe-Lewis S, et al:Hemi-ablative low-dose-rate prostate brachytherapy for unilateral localised prostate cancer. BJU Int 125:383-390, 2020.
PubMed
P.341 掲載の参考文献
1) Huggins C, Hodges CV:Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin 22:232-240, 1972.
PubMed
2) Schally AV, Arimura A, Kastin AJ, et al:Gonadotropin-releasing hormone:one polypeptide regulates secretion of luteinizing and follicle-stimulating hormones. Science 173:1036-1038, 1971.
PubMed
3) Labrie F, Dupont A, Belanger A, et al:New hormonal therapy in prostatic carcinoma:combined treatment with an LHRH agonist and an antiandrogen. Clin Invest Med 5:267-275, 1982.
 
4) Klotz L, Boccon-Gibod L, Shore ND, et al:The efficacy and safety of degarelix:a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int 102:1531-1538, 2008.
PubMed
5) Berthold DR, Sternberg CN, Tannock IF:Management of advanced prostate cancer after first-line chemotherapy. J Clin Oncol 23:8247-8252, 2005.
PubMed
6) Chi K, Hotte SJ, Joshua AM, et al:Treatment of mCRPC in the AR-axis-targeted therapy-resistant state. Ann Oncol 26:2044-2056, 2015.
PubMed
7) Khalaf DJ, Annala M, Taavitsainen S, et al:Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer:a multicentre, randomised, open-label, phase 2, crossover trial. Lancet Oncol 20:1730-1739, 2019.
PubMed
8) de Wit R, de Bono J, Sternberg CN, et al:Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. N Engl J Med 381:2506-2518, 2019.
 
9) Mulati Y, Fan Y, Yu W, et al:Novel Androgen Receptor Inhibitors in Non-Metastatic, Castration-Resistant Prostate Cancer:A Systematic Review and Network Meta-Analysis. Front Oncol 11:733202, 2021.
 
10) Miyake H, Matsushita Y, Watanabe H, et al:Prognostic Significance of Time to Castration Resistance in Patients With Metastatic Castration-sensitive Prostate Cancer. Anticancer Res 39:1391-1396, 2019.
PubMed
11) Wang L, Paller CJ, Hong H, et al:Comparison of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer:A Systematic Review and Network Meta-analysis. JAMA Oncol 7:412-420, 2021.
PubMed
12) Ratta R, Guida A, Scotte F, et al:PARP inhibitors as a new therapeutic option in metastatic prostate cancer:a systematic review. Prostate Cancer Prostatic Dis 23:549-560, 2020.
PubMed
13) Jian T, Zhan Y, Hu K, et al:Systemic triplet therapy for metastatic hormone-sensitive prostate cancer:A systematic review and network meta-analysis. Front Pharmacol 13:955925, 2022.
PubMed
14) Dathathri E, Isebia KT, Abali F, et al:Liquid Biopsy Based Circulating Biomarkers in Metastatic Prostate Cancer. Front Oncol 12:863472, 2022.
PubMed
15) Zhang J, Sun J, Bakht S, et al:Recent Development and Future Prospects of Molecular Targeted Therapy in Prostate Cancer. Curr Mol Pharmacol 15:159-169, 2022.
PubMed
P.346 掲載の参考文献
1) Huggins C, Hodges CV:Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1:293-297, 1941.
 
2) 前立腺癌診療ガイドライン[2016年版](日本泌尿器科学会 編), メディカルレビュー社, 2016.
 
3) Schally AV, Arimura A, Kastin AJ, et al:Gonadotropin-releasing hormone:one polypeptide regulates secretion of luteinizing and follicle-stimulating hormones. Science 173:1036-1038, 1971.
PubMed
4) Fujino M, Fukuda T, Shinagawa S, et al:Synthetic analogs of luteinizing hormone releasing hormone (LH-RH) substituted in position 6 and 10. Biochem Biophys Res Commun 60:406-413, 1974.
PubMed
5) Auclair C, Kelly PA, Labrie F, et al:Inhibition of testicular luteinizing hormone receptor level by treatment with a potent luteinizing hormone-releasing hormone agonist of human chorionic gonadotropin. Biochem Biophys Res Commun 76:855-862, 1977.
PubMed
6) 泌尿器科・病理・放射線科 前立腺癌取扱い規約[第5版](日本泌尿器科学会, 日本病理学会, 日本医学放射線学会 編), メディカルレビュー社, 2022.
 
7) Bruchovsky N, Goldenberg SL, Akakura K, et al:Luteinizing hormone-releasing hormone agonists in prostate cancer. Elimination of flare reaction by pretreatment with cyproterone acetate and low-dose diethylstilbestrol. Cancer 72:1685-1691, 1993.
PubMed
8) 阿曽佳郎, 亀山周二, 大森弘之, ほか:徐放性 LH-RH agonist 製剤, TAP-144-SR の前立腺癌に対する臨床第3相試験. 泌尿器科紀要 37:305-320, 1991.
 
9) Suzuki K, Namiki M, Fujimoto T, et al:Efficacy and safety of leuprorelin acetate 6-month depot in prostate cancer patients:a Phase III, randomized, open-label, parallel-group, comparative study in Japan. Jpn J Clin Oncol 45:1168-1174, 2015.
PubMed
10) Kaisary AV, Tyrrell CJ, Peeling WB, et al:Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. Br J Urol 67:502-508, 1991.
PubMed
11) Debruyne FM, Dijkman GA, Lee DC, et al:A new long acting formulation of the luteinizing hormone-releasing hormone analogue goserelin:results of studies in prostate cancer. J Urol 155:1352-1354, 1996.
 
12) Fernandez del Moral P, Dijkman GA, Debruyne FM, et al:Three-month depot of goserelin acetate:clinical efficacy and endocrine profile. Dutch South East Cooperative Urological Group. Urology 48:894-900, 1996.
 
13) Bolton EM, Lynch T:Are all gonadotrophin-releasing hormone agonists equivalent for the treatment of prostate cancer? A systematic review. BJU Int 122:371-383, 2018.
PubMed
14) Seidenfeld J, Samson DJ, Hasselblad V, et al:Single-therapy androgen suppression in men with advanced prostate cancer:a systematic review and meta-analysis. Ann Intern Med 132:566-577, 2000.
PubMed
15) Sarosdy MF, Schellhammer PF, Sharifi R, et al:Comparison of goserelin and leuprolide in combined androgen blockade therapy. Urology 52:82-88, 1998.
PubMed
P.351 掲載の参考文献
1) Huggins C, Hodges CV:Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin 22:232-240, 1972.
PubMed
2) Schally AV, Bowers CY:Purification of Luteinizing Hormone-releasing Factor from bovine hypothalamus. Endocrinology 75:608-614, 1964.
PubMed
3) Klotz L, Boccon-Gibod L, Shore ND, et al:The efficacy and safety of degarelix:a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int 102:1531-1538, 2008.
PubMed
4) Radu A, Pichon C, Camparo P, et al:Expression of follicle-stimulating hormone receptor in tumor blood vessels. N Engl J Med 363:1621-1630, 2010.
PubMed
5) Ozono S, Tsukamoto T, Naito S, et al:Efficacy and safety of 3-month dosing regimen of degarelix in Japanese subjects with prostate cancer:A phase III study. Cancer Sci 109:1920-1929, 2018.
PubMed
6) Albertsen PC, Klotz L, Tombal B, et al:Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. Eur Urol 65:565-573, 2014.
 
7) Wallach JD, Deng Y, McCoy RG, et al:Real-world Cardiovascular Outcomes Associated With Degarelix vs Leuprolide for Prostate Cancer Treatment. JAMA Netw Open 4:e2130587, 2021.
PubMed
8) Lopes RD, Higano CS, Slovin SF, et al:Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer:The Primary Results of the PRONOUNCE Randomized Trial. Circulation 144:1295-1307, 2021.
PubMed
9) Miyazawa Y, Kato H, Arai S, et al:Clinical endocrinological evaluation of the gonadal axis (testosterone, LH and FSH) in prostate cancer patients switched from a GnRH antagonist to a LHRH agonist. Basic Clin Androl 25:7, 2015.
PubMed
10) Shore ND, Saad F, Cookson MS, et al:Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer. N Engl J Med 382:2187-2196, 2020
PubMed
P.356 掲載の参考文献
1) Kelly WK, Scher HI:Prostate specific antigen decline after antiandrogen withdrawal:the flutamide withdrawal syndrome. J Urol 149:607-609, 1993.
PubMed
2) Leone G, Tucci M, Buttigliero C, et al:Antiandrogen withdrawal syndrome (AAWS) in the treatment of patients with prostate cancer. Endocr Relat Cancer 25:R1-R9, 2018.
PubMed
3) Korpal M, Korn JM, Gao X, et al:An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). Cancer Discov 3:1030-1043, 2013.
PubMed
4) Suzuki H, Okihara K, Miyake H, et al:Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. J Urol 180:921-927, 2008.
PubMed
5) Uemura H, Kobayashi K, Yokomizo A, et al:Enzalutamide + androgen deprivation therapy (ADT) versus flutamide + ADT in Japanese men with castration-resistant prostate cancer:AFTERCAB study. BJUI Compass 3:26-36, 2021.
PubMed
6) Nakano T, Kadono Y, Iwamoto H, et al:Therapeutic Effect of Ethinylestradiol in Castration-resistant Prostate Cancer. Anticancer Res 40:2291-2296, 2020.
PubMed
7) Tannock I, Gospodarowicz M, Meakin W, et al:Treatment of metastatic prostatic cancer with low-dose prednisone:evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 7:590-597, 1989.
PubMed
8) Moore MJ, Osoba D, Murphy K, et al:Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer. J Clin Oncol 12:689-694, 1994.
PubMed
9) Tannock IF, de Wit R, Berry WR, et al:Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512, 2004.
 
10) Venkitaraman R, Lorente D, Murthy V, et al:A randomised phase 2 trial of dexamethasone versus prednisolone in castration-resistant prostate cancer. Eur Urol 67:673-679, 2015.
 
11) Nishimura K, Nonomura N, Yasunaga Y, et al:Low doses of oral dexamethasone for hormone-refractory prostate carcinoma. Cancer 89:2570-2576, 2000.
PubMed
12) Attard G, Merseburger AS, Arlt W, et al:Assessment of the Safety of Glucocorticoid Regimens in Combination With Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer:A Randomized, Open-label Phase 2 Study. JAMA Oncol 5:1159-1167, 2019.
PubMed
13) Ni YC, Zhao JG, Zhang MN, et al:Predictors of efficacy of corticosteroid switching from abiraterone plus prednisone to dexamethasone in patients with metastatic castration-resistant prostate cancer. Asian J Androl 24:154-160, 2022.
PubMed
14) Derlin T, Sommerlath Sohns JM, Schmuck S, et al:Influence of short-term dexamethasone on the efficacy of177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer. Prostate 80:619-631, 2020.
 
P.362 掲載の参考文献
1) Klotz L, Boccon-Gibod L, Shore ND, et al:The efficacy and safety of degarelix:a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int 102:1531-1538, 2008.
PubMed
2) Sun D, Bai M, Jiang Y, et al:Roles of follicle stimulating hormone and its receptor in human metabolic diseases and cancer. Am J Transl Res 12:3116-3132, 2020.
PubMed
3) Walker LM, Tran S, Robinson JW:Luteinizing hormone--releasing hormone agonists:a quick reference for prevalence rates of potential adverse effects. Clin Genitourin Cancer 11:375-384, 2013.
PubMed
4) Nguyen PL, Alibhai SM, Basaria S, et al:Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol 67:825-836, 2015.
PubMed
5) Mitsuzuka K, Kyan A, Sato T, et al:Influence of 1 year of androgen deprivation therapy on lipid and glucose metabolism and fat accumulation in Japanese patients with prostate cancer. Prostate Cancer Prostatic Dis 19:57-62, 2016.
 
6) Wassersug RJ, Oliffe JL:The social context for psychological distress from iatrogenic gynecomastia with suggestions for its management. J Sex Med 6:989-1000, 2009.
PubMed
7) Saad F, Adachi JD, Brown JP, et al:Cancer treatment-induced bone loss in breast and prostate cancer. J Clin Oncol 26:5465-5476, 2008.
PubMed
8) Gomez-Aparicio MA, Lopez-Campos F, Pelari-Mici L, et al:Bone health and therapeutic agents in advanced prostate cancer. Front Biosci (Landmark Ed) 27:34, 2022.
 
9) Serpa Neto A, Tobias-Machado M, Esteves MA, et al:Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer:a systematic review and meta-analysis. Prostate Cancer Prostatic Dis 15:36-44, 2012.
PubMed
10) Smith MR, Egerdie B, Hernandez Toriz N, et al:Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 361:745-755, 2009.
PubMed
11) Bosco C, Bosnyak Z, Malmberg A, et al:Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer:a meta-analysis. Eur Urol 68:386-396, 2015.
PubMed
12) Iacovelli R, Ciccarese C, Bria E, et al:The Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate Cancer. Clin Genitourin Cancer 16:e645-e653, 2018.
PubMed
13) Abufaraj M, Iwata T, Kimura S, et al:Differential Impact of Gonadotropin-releasing Hormone Antagonist Versus Agonist on Clinical Safety and Oncologic Outcomes on Patients with Metastatic Prostate Cancer:A Meta-analysis of Randomized Controlled Trials. Eur Urol 79:44-53, 2021.
PubMed
14) Challa AA, Calaway AC, Cullen J, et al:Cardiovascular Toxicities of Androgen Deprivation Therapy. Curr Treat Options Oncol 22:47, 2021.
PubMed
15) Shim M, Bang WJ, Oh CY, et al:Androgen deprivation therapy and risk of cognitive dysfunction in men with prostate cancer:is there a possible link? Prostate Int 10:68-74, 2022.
 
P.366 掲載の参考文献
1) Scher HI, Halabi S, Tannock I, et al:Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone:recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26:1148-1159, 2008.
 
2) 泌尿器科・病理・放射線科 前立腺癌取扱い規約 [第5版](日本泌尿器科学会, 日本病理学会, 日本医学放射線学会 編), p96, メディカルレビュー社, 2022.
 
3) Therasse P, Arbuck SG, Eisenhauer EA, et al:New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000.
 
4) Byar DP, Corle DK:Hormone therapy for prostate cancer:results of the Veterans Administration Cooperative Urological Research Group studies. NCI Monogr (7):165-170, 1988.
PubMed
5) Oefelein MG Feng A, Scolieri MJ, , et al:Reassessment of the definition of castrate levels of testosterone:Implications for clinical decision making. Urology 56:1021-1024, 2000.
PubMed
6) Morote J, Orsola A, Planas J, et al:Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. J Urol 178:1290-1295, 2007.
PubMed
7) Morote J, Comas I, Planas J, et al:Serum Testosterone Levels in Prostate Cancer Patients Undergoing Luteinizing Hormone-Releasing Hormone Agonist Therapy. Clin Genitourin Cancer 16:e491-e496, 2018.
PubMed
8) Efstathiou E, Titus M, Tsavachidou D, et al:Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. J Clin Oncol 30:637-643, 2012.
 
9) Bryce AH, Alumkal JJ, Armstrong A, et al:Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer:post hoc analysis of PREVAIL. Prostate Cancer Prostatic Dis 20:221-227, 2017.
PubMed
10) Corfield J, Perera M, Bolton D, et al:68Ga-prostate specific membrane antigen (PSMA) positron emission tomography (PET) for primary staging of high-risk prostate cancer:a systematic review. World J Urol 36:519-527, 2018.
 
P.372 掲載の参考文献
1) Helgstrand JT, Roder MA, Klemann N, et al:Trends in incidence and 5-year mortality in men with newly diagnosed, metastatic prostate cancer-A population-based analysis of 2 national cohorts. Cancer 124:2931-2938, 2018.
PubMed
2) Sweeney CJ, Chen YH, Carducci M, et al:Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med 373:737-746, 2015.
PubMed
3) Kyriakopoulos CE, Chen YH, Carducci MA, et al:Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer:Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. J Clin Oncol 36:1080-1087, 2018.
 
4) Fizazi K, Tran N, Fein L, et al:Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE):final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol 20:686-700, 2019.
PubMed
5) James ND, Clarke NW, Cook A, et al:Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy:5-year follow-up results from the STAMPEDE randomised trial (NCT00268476). Int J Cancer 151:422-434, 2022.
PubMed
6) Armstrong AJ, Szmulewitz RZ, Petrylak DP, et al:ARCHES:A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol 37:2974-2986, 2019.
 
7) Davis ID, Martin AJ, Zielinski RR, et al:Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC). J Clin Oncol 40:LBA5004, 2022.
 
8) Chi KN, Chowdhury S, Bjartell A, et al:Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer:Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study. J Clin Oncol 39:2294-2303, 2021.
PubMed
9) Fizazi K, Foulon S, Carles J, et al:Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1):a multicentre, open-label, randomised, phase 3 study with a 2x2 factorial design. Lancet 399:1695-1707, 2022.
 
10) Smith MR, Hussain M, Saad F, et al:Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. N Engl J Med 386:1132-1142, 2022.
 
11) Antonarakis ES, Piulats JM, Gross-Goupil M, et al:Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer:Multicohort, Open-Label Phase II KEYNOTE-199 Study. J Clin Oncol 38:395-405, 2020.
PubMed
12) Palmbos PL, Daignault-Newton S, Tomlins SA, et al:A Randomized Phase II Study of Androgen Deprivation Therapy with or without Palbociclib in RB-positive Metastatic Hormone-Sensitive Prostate Cancer. Clin Cancer Res 27:3017-3027, 2021.
PubMed
13) Sweeney C, Bracarda S, Sternberg CN, et al:Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150):a multicentre, randomised, double-blind, phase 3 trial. Lancet 398:131-142, 2021.
PubMed
14) de Bono J, Mateo J, Fizazi K, et al:Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med 382:2091-2102, 2020.
PubMed
15) Sartor O, de Bono J, Chi KN, et al:Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med 385:1091-1103, 2021.
PubMed
16) Hofman MS, Emmett L, Sandhu S, et al:[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP):a randomised, open-label, phase 2 trial. Lancet 397:797-804, 2021.
PubMed
17) Parker CC, James ND, Brawley CD, et al:Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE):a randomised controlled phase 3 trial. Lancet 392:2353-2366, 2018.
 
18) Akamatsu S, Kubota M, Uozumi R, et al:Development and Validation of a Novel Prognostic Model for Predicting Overall Survival in Treatment-naive Castration-sensitive Metastatic Prostate Cancer. Eur Urol Oncol 2:320-328, 2019.
PubMed
19) Mateo J, Seed G, Bertan C, et al:Genomics of lethal prostate cancer at diagnosis and castration resistance. J Clin Invest 130:1743-1751, 2020.
PubMed
P.379 掲載の参考文献
1) 泌尿器科・病理・放射線科 前立腺癌取扱い規約[第5版](日本泌尿器科学会, 日本病理学会, 日本医学放射線学会 編), メディカルレビュー社, 2022.
 
2) Mateo J, Fizazi K, Gillessen S, et al:Managing Nonmetastatic Castration-resistant Prostate Cancer. Eur Urol 75:285-293, 2019.
PubMed
3) Smith MR, Kabbinavar F, Saad F, et al:Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 23:2918-2925, 2005.
PubMed
4) Smith MR, Saad F, Oudard S, et al:Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer:exploratory analyses by baseline prostate-specific antigen doubling time. J Clin Oncol 31:3800-3806, 2013.
PubMed
5) Smith MR, Saad F, Chowdhury S, et al:Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer N. Engl J Med 378:1408-1418, 2018.
PubMed
6) Hussain M, Fizazi K, Saad F, et al:Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med 378:2465-2474, 2018.
PubMed
7) Fizazi K, Shore N, Tammela TL, et al:Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med 380:1235-1246, 2019.
PubMed
8) Xie W, Regan MM, Buyse M, et al:Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer. J Clin Oncol 35:3097-3104, 2017.
 
9) Smith MR, Saad F, Chowdhury S, et al:Apalutamide and Overall Survival in Prostate Cancer. Eur Urol 79:150-158, 2021.
PubMed
10) Sternberg CN, Fizazi K, Saad F, et al:Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med 382:2197-2206, 2020.
PubMed
11) Fizazi K, Shore N, Tammela TL, et al:Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide. N Engl J Med 383:1040-1049, 2020.
PubMed
12) Tombal B, Saad F, Penson D, et al:Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER):a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 20:556-569, 2019.
PubMed
13) Saad F, Cella D, Basch E, et al:Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer:an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial. Lancet Oncol 19:1404-1416, 2018.
 
14) Smith MR, Shore N, Tammela TL, et al:Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer:An analysis of the phase III ARAMIS trial. Eur J Cancer 154:138-146, 2021.
PubMed
15) Hakozaki Y, Yamada Y, Kawai T, et al:Time to castration resistance is a novel prognostic factor of cancer specific survival in patients with nonmetastatic castration resistant prostate cancer. Sci Rep 12:16202, 2022
PubMed
P.384 掲載の参考文献
1) Petrylak DP, Tangen CM, Hussain MH, et al:Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513-1520, 2004.
PubMed
2) Ryan CJ, Smith MR, de Bono JS, et al:Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368:138-148, 2013.
PubMed
3) Beer TM, Armstrong AJ, Rathkopf DE, et al:Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371:424-433, 2014.
PubMed
4) Golshayan AR, Antonarakis ES:Enzalutamide:an evidence-based review of its use in the treatment of prostate cancer. Core Evid 8:27-35, 2013
PubMed
5) Cone EB, Reese S, Marchese M, et al:Cardiovascular toxicities associated with abiraterone compared to enzalutamide-A pharmacovigilance study. EClinicalMedicine 36:100887, 2021.
PubMed
6) de Wit R, de Bono J, Sternberg CN, et al:Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. N Engl J Med 381:2506-2518, 2019.
 
7) European Medicines Agency(EMA):EMA restricts use of prostate cancer medicine Xofigo. Pressrelease, 27/07/2018. [https://www.ema.europa.eu/en/news/ema-restricts-use-prostate-cancer-medicine-xofigo]
 
8) Smith M, Parker C, Saad F, et al:Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223):arandomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 20:408-419, 2019.
PubMed
9) Matsumoto T, Shiota M, Blas L, et al:Role of Olaparib in the Management of Metastatic Castration-Resistant Prostate Cancer:A Japanese Clinician's Perspective. Cancer Manag Res 14:2389-2397, 2022.
PubMed
10) Mottet N, Cornford P, van den Bergh RCN, et al:EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer update. Eur Urol 79:243-262, 2022.
 
11) Sartor O, de Bono J, Chi KN, et al:Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med 385:1091-1103, 2021.
PubMed
12) Hofman MS, Emmett L, Sandhu S, et al:TheraP:177 Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel-Overall survival after median follow-up of 3 years (ANZUP 1603). J Clin Oncol 40(16 Suppl):Abstract 5000, 2022.
 
13) Shen YC, Hsu HC, Lin TM, et al:H1-Antihistamines Reduce the Risk of Hepatocellular Carcinoma in Patients With Hepatitis B Virus, Hepatitis C Virus, or Dual Hepatitis B Virus-Hepatitis C Virus Infection. J Clin Oncol 40:1206-1219, 2022.
PubMed
14) Smith MR, Hussain M, Saad F, et al:Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. N Engl J Med 386:1132-1142, 2022.
 
15) Fizazi K, Foulon S, Carles J, et al:Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1):a multicentre, open-label, randomised, phase 3 study with a 2x2 factorial design. Lancet 399:1695-1707, 2022.
 
16) Chi KN, Rathkopf DE, Smith MR, et al:Phase 3 MAGNITUDE study:first results of niraparib (NIRA) with Abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair(HRR) gene alterations. J Clin Oncol 40(6 Suppl):Abstract 12, 2022.
 
17) Saad FA, Armstrong AJ, Thiery-Vuillemin A, et al:PROpel:phase III trial of olaparib (ola) and Abiraterone (abi) versus placebo (pbo) and abi as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 40(6 Suppl):Abstract 11, 2022.
 
18) Antonarakis ES, Piulats JM, Gross-Goupil M, et al:Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer:multicohort, open-label Phase II KEYNOTE-199 study. J Clin Oncol 38:395-405, 2020.
PubMed
P.390 掲載の参考文献
1) Rehman Y, Rosenberg JE:Abiraterone acetate:oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer. Drug Des, Devel Ther 6:13-18, 2012.
PubMed
2) Hoy SM:Abiraterone acetate:a review of its use in patients with metastatic castration-resistant prostate cancer. Drugs 73:2077-2091, 2013.
PubMed
3) Fizazi K, Scher HI, Molina A, et al:Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer:final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 13:983-992, 2012.
PubMed
4) Ryan CJ, Smith MR, Fizazi K, et al:Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302):final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 16:152-160, 2015.
PubMed
5) Ryan CJ, Smith MR, de Bono JS, et al:Interim analysis(IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate(AA) in chemotherapy-naive patients(pts) with metastatic castration-resistant prostate cancer(mCRPC). J Clin Oncol 30(18 Suppl):LBA4518, 2012.
 
P.398 掲載の参考文献
1) Tran C, Ouk S, Clegg NJ, et al:Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324:787-790, 2009.
PubMed
2) Scher HI, Beer TM, Higano CS, et al:Antitumour activity of MDV3100 in castration-resistant prostate cancer:a phase 1-2 study. Lancet 375:1437-1446, 2010.
PubMed
3) Scher HI, Fizazi K, Saad F, et al:Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367:1187-1197, 2012.
PubMed
4) Akaza H, Uemura H, Tsukamoto T, et al:A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer. Int J Clin Oncol 21:773-782, 2016.
PubMed
5) Beer TM, Armstrong AJ, Rathkopf DE, et al:Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371:424-433, 2014.
PubMed
6) Hussain M, Fizazi K, Saad F, et al:Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med 378:2465-2474, 2018.
PubMed
7) Armstrong AJ, Szmulewitz RZ, Petrylak DP, et al:ARCHES:A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol 37:2974-2986, 2019.
 
8) Davis ID, Martin AJ, Stockler MR, et al:Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. N Engl J Med 381:121-131, 2019.
PubMed
9) Kimura G, Yonese J, Fukagai T, et al:Enzalutamide in Japanese patients with chemotherapy-naive, metastatic castration-resistant prostate cancer:A post-hoc analysis of the placebo-controlled PREVAIL trial. Int J Urol 23:395-403, 2016.
PubMed
10) Sternberg CN, Fizazi K, Saad F, et al:Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med 382:2197-2206, 2020.
PubMed
11) Armstrong AJ, Azad AA, Iguchi T, et al:Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol 40:1616-1622, 2022.
PubMed
12) Iguchi T, Kimura G, Fukasawa S, et al:Enzalutamide with androgen deprivation therapy in Japanese men with metastatic hormone-sensitive prostate cancer:A subgroup analysis of the phase III ARCHES study. Int J Urol 28:765-773, 2021.
PubMed
13) Davis ID, Martin AJ, Zielinski RR, et al:Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC). J Clin Oncol 40(17 Suppl):Abstract LBA5004, 2022.
 
14) Beer TM, Miller K, Tombal B, et al:The association between health-related quality-of-life scores and clinical outcomes in metastatic castration-resistant prostate cancer patients:Exploratory analyses of AFFIRM and PREVAIL studies. Eur J Cancer 87:21-29, 2017.
PubMed
15) Tombal B, Saad F, Penson D, et al:Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER):a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 20:556-569, 2019.
PubMed
16) Stenzl A, Dunshee C, De Giorgi U, et al:Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer:An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study. Eur Urol 78:603-614, 2020.
 
17) 井口太郎, 安田早也香, 二宮典子, ほか:去勢抵抗性前立腺癌患者におけるイクスタンジの副作用マネジメント. 泌尿器外科 28:1685-1691, 2015.
Medical*Online
18) Agarwal N, Azad A, Shore ND, et al:Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer:TALAPRO-2 phase III study design. Future Oncol 18:425-436, 2002
 
P.404 掲載の参考文献
1) Clegg NJ, Wongvipat J, Joseph JD, et al:ARN-509:a novel antiandrogen for prostate cancer treatment. Cancer Res 72:1494-1503, 2012.
PubMed
2) Ryan CJ, Smith MR, Fizazi K, et al:Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302):final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 16:152-160, 2015.
PubMed
3) Smith MR, Saad F, Oudard S, et al:Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer:exploratory analyses by baseline prostate-specific antigen doubling time. J Clin Oncol 31:3800-3806, 2013.
PubMed
4) Smith MR, Saad F, Chowdhury S, et al:Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. N Engl J Med 378:1408-1418, 2018.
PubMed
5) Smith MR, Saad F, Chowdhury S, et al:Apalutamide and Overall Survival in Prostate Cancer. Eur Urol 79:150-158, 2021.
PubMed
6) Sweeney CJ, Chen YH, Carducci M, et al:Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med 373:737-746, 2015.
PubMed
7) Fizazi K, Tran N, Fein L, et al:Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE):final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol 20:686-700, 2019.
PubMed
8) Uemura H, Koroki Y, Iwaki Y, et al:Skin rash following Administration of Apalutamide in Japanese patients with Advanced Prostate Cancer:an integrated analysis of the phase 3 SPARTAN and TITAN studies and a phase 1 open-label study. BMC Urol 20:139, 2020.
 
9) Chi KN, Chowdhury S, Bjartell A, et al:Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer:Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study. J Clin Oncol 39:2294-2303, 2021.
PubMed
P.410 掲載の参考文献
1) 青木 淳, 広中 隆, 堀尾知代:新規アンドロゲン受容体阻害薬ダロルタミドの特徴および臨床試験成績:(第2回)非臨床. 泌尿器外科 33:521-528, 2020.
Medical*Online
2) Smith MR, Saad F, Oudard S, et al:Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer:Exploratory analyses by baseline prostate-specific antigen doubling time. J Clin Oncol 31:3800-3806, 2013.
PubMed
3) Fizazi K, Shore N, Tammela TL, et al:Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med 380:1235-1246, 2019.
PubMed
4) Fizazi K, Shore N, Smith MR, et al:Tolerability and treatment response to darolutamide (DARO) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) in the phase III ARAMIS trial[Abstract 633P]. Ann Oncol 31(Suppl 4):S522, 2020.
 
5) Morgans AK, Sweeney C, Wallis CJD, et al:Progression patterns by types of metastatic spread, prostate-specific antigen (PSA), and clinical symptoms:Post-hoc analyses of ARAMIS. J Clin Oncol 40(16 Suppl):Abstract 5044, 2022.
 
6) Smith MR, Hussain M, Saad F, et al:Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. N Engl J Med 386:1132-1142, 2022.
 
P.415 掲載の参考文献
1) 医薬品インタビューフォーム:タキソイド系抗悪性腫瘍剤 日本薬局方 注射用ドセタキセル:タキソテール(日本標準商品分類番号 87424)2021年6月改訂(第16版).
 
2) Tannock IF, de Wit R, Berry WR, et al:Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512, 2004.
 
3) 前立腺癌診療ガイドライン[2016 年版](日本泌尿器科学会 編), p223-226, メディカルレビュー社, 2016.
 
4) Berthold DR, Pond GR, Soban F, et al:Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer:updated survival in the TAX 327 study. J Clin Oncol 26:242-245, 2008.
PubMed
5) Aggarwal R, Harris A, Formaker C, et al:Response to subsequent docetaxel in a patient cohort withmetastatic castration-resistant prostate cancer after abiraterone acetate treatment. Clin GenitourinCancer 12:e167-e172, 2014.
 
6) Azad AA, Leibowitz-Amit R, Eigl BJ, et al:A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer. Prostate 74:1544-1550, 2014.
PubMed
7) Miyake H, Sugiyama T, Aki R, et al:Comparison of Alternative Androgen Receptor-axis-targeted Agent (ARATA) and Docetaxel as Second-line Therapy for Patients With Metastatic Castration-resistant Prostate Cancer With Progression After Initial ARATA in Real-world Clinical Practice in Japan. Clin Genitourin Cancer 16:219-225, 2018.
PubMed
8) Fizazi K, Tran N, Fein L, et al:Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE):final overall survivalanalysis of a randomised, double-blind, phase 3 trial. Lancet Oncol 20:686-700, 2019.
 
9) Fizazi K, Foulon S, Carles J, et al:Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1):a multicentre, open-label, randomised, phase 3 study with a 2x2 factorial design. Lancet 399:1695-1707, 2022.
 
10) Smith MR, Hussain M, Saad F, et al:Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. N Engl J Med 386:1132-1142, 2022.
 
11) Mera T, Saijo N, Akaza H:[Safety and efficacy of docetaxel in prostate cancer patients:based on the post-marketing surveillance in Japan]. Gan To Kagaku Ryoho 39:551-562, 2012.
PubMed
12) Lewis LD, Miller AA, Owzar K, et al:The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia:CALGB 60805 (Alliance) . Pharmacogenet Genomics 23:29-33, 2013.
PubMed
13) Kita Y, Shimizu Y, Inoue T, et al:Reduced-dose docetaxel for castration-resistant prostate cancer has no inferior impact on overall survival in Japanese patients. Int J Clin Oncol 18:718-723, 2013.
PubMed
14) Kume H, Kawai T, Nagata M, et al:Intermittent docetaxel chemotherapy is feasible for castration-resistant prostate cancer. Mol Clin Oncol 3:303-307, 2015.
PubMed
15) Droz JP, Aapro M, Balducci L, et al:Management of prostate cancer in older patients:updated recommendations of a working group of the International Society of Geriatric Oncology. Lancet Oncol 15:e404-414, 2014
 
P.420 掲載の参考文献
1) Oudard S, Fizazi K, Sengelov L, et al:Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer:A Randomized Phase III Trial-FIRSTANA. J Clin Oncol 35:3189-3197, 2017.
PubMed
2) de Wit R, de Bono J, Sternberg CN, et al:Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. N Engl J Med 381:2506-2518, 2019.
 
3) Hussain M, Mateo J, Fizazi K, et al:Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. N Engl J Med 383:2345-2357, 2020.
PubMed
4) Sartor O, de Bono J, Chi KN, et al:Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med 385:1091-1103, 2021.
PubMed
5) Hofman MS, Emmett L, Violet J, et al:TheraP:a randomized phase 2 trial of 177Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603). BJU Int 124(Suppl 1)::5-13, 2019.
 
6) Eisenberger M, Hardy-Bessard AC, Kim CS, et al:Phase III Study Comparing a Reduced Dose of Cabazitaxel (20mg/m2) and the Currently Approved Dose (25mg/m2) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA. J Clin Oncol 35:3198-3206, 2017.
 
7) Matsuyama H, Matsubara N, Kazama H, et al:Real-world efficacy and safety of two doses of cabazitaxel (20 or 25mg/m2) in patients with castration-resistant prostate cancer:results of a Japanese post-marketing surveillance study. BMC Cancer 20:649, 2020.
PubMed
8) Terada N, Kamoto T, Tsukino H, et al:The efficacy and toxicity of cabazitaxel for treatment of docetaxel-resistant prostate cancer correlating with the initial doses in Japanese patients. BMC Cancer 19:156, 2019.
 
9) Matsumoto T, Shiota M, Nakamura M, et al:Efficacy and safety of cabazitaxel therapy in elderly (>=75years) patients with castration-resistant prostate cancer:A multiinstitutional study. Prostate Int 9:96-100, 2021.
 
10) Delanoy N, Robbrecht D, Eisenberger M, et al:Pain Progression at Initiation of Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC):A Post Hoc Analysis of the PROSELICA Study. Cancers (Basel) 13:1284, 2021.
PubMed
11) Ito T, Kanao K, Takahara K, et al:Optimal Timing of Cabazitaxel Introduction for Japanese Patients With Metastatic Castration-resistant Prostate Cancer. Anticancer Res 39:3089-3094, 2019.
PubMed
12) Kosaka T, Hongo H, Mizuno R, et al:Risk stratification of castration-resistant prostate cancer patients treated with cabazitaxel. Mol Clin Oncol 9:683-688, 2018.
PubMed
13) Miyake H, Sato R, Watanabe K, et al:Prognostic significance of third-line treatment for patients with metastatic castration-resistant prostate cancer:comparative assessments between cabazitaxel and other agents. Int J Clin Oncol 26:1745-1751, 2021.
PubMed
14) Shiota M, Nakamura M, Yokomizo A, et al:Prognostic significance of lactate dehydrogenase in cabazitaxel chemotherapy for castration-resistant prostate cancer:a multi-institutional study. Anticancer Drugs 31:298-303, 2020.
PubMed
15) Corn PG, Heath EI, Zurita A, et al:Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers:a randomised, open-label, phase 1-2 trial. Lancet Oncol 20:1432-1443, 2019.
PubMed
P.426 掲載の参考文献
1) Schuller M, Butler RE, Ariza A, et al:Molecular basis for DarT ADP-ribosylation of a DNA base. Nature 596:597-602, 2021.
PubMed
2) Li P, Lei Y, Qi J, et al:Functional roles of ADP-ribosylation writers, readers and erasers. Front Cell Dev Biol 10:941356, 2022.
 
3) Pandey N, Black BE:Rapid Detection and Signaling of DNA Damage by PARP-1. Trends Biochem Sci 46:744-757, 2021.
PubMed
4) Groelly FJ, Fawkes M, Dagg RA, et al:Targeting DNA damage response pathways in cancer. Nat Rev Cancer 23:78-94, 2023.
PubMed
5) Lord CJ, Ashworth A:PARP inhibitors:Synthetic lethality in the clinic. Science 355:1152-1158, 2017.
PubMed
6) Bryant HE, Schultz N, Thomas HD, et al:Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434:913-917, 2005.
PubMed
7) Farmer H, McCabe N, Lord CJ, et al:Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434:917-921, 2005.
PubMed
8) Chu YY, Yam C, Yamaguchi H, et al:Biomarkers beyond BRCA:promising combinatorial treatment strategies in overcoming resistance to PARP inhibitors. J Biomed Sci 29:86, 2022.
PubMed
9) de Bono J, Mateo J, Fizazi K, et al:Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med 382:2091-2102, 2020.
PubMed
10) Hussain M, Mateo J, Fizazi K, et al:Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. N Engl J Med 383:2345-2357, 2020.
PubMed
11) Momozawa Y, Iwasaki Y, Hirata M, et al:Germline Pathogenic Variants in 7636 Japanese Patients With Prostate Cancer and 12 366 Controls. J Natl Cancer Inst 112:369-376, 2020.
PubMed
12) Pritchard CC, Mateo J, Walsh MF, et al:Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. N Engl J Med 375:443-453, 2016.
PubMed
13) Chi KN, Barnicle A, Sibilla C, et al:Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound. Clin Cancer Res 29:81-91, 2023.
PubMed
14) Taza F, Holler AE, Fu W, et al:Differential Activity of PARP Inhibitors in BRCA1- Versus BRCA2-Altered Metastatic Castration-Resistant Prostate Cancer. JCO Precis Oncol 5:PO. 21. 00070, 2021.
 
15) Carreira S, Porta N, Arce-Gallego S, et al:Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial. Cancer Discov 11:2812-2827, 2021.
PubMed
16) Loehr A, Hussain A, Patnaik A, et al:Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib. Eur Urol 83:200-209, 2023
PubMed
17) Cahuzac M, Peant B, Mes-Masson AM, et al:Development of Olaparib-Resistance Prostate Cancer Cell Lines to Identify Mechanisms Associated with Acquired Resistance. Cancers (Basel) 14:3877, 2022.
PubMed
18) Yazinski SA, Comaills V, Buisson R, et al:ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells. Genes Dev 31:318-332, 2017.
PubMed
P.432 掲載の参考文献
1) Gundem G, Van Loo P, Kremeyer B, et al:The evolutionary history of lethal metastatic prostate cancer. Nature 520:353-357, 2015.
PubMed
2) Pezaro C, Omlin A, Lorente D, et al:Visceral disease in castration-resistant prostate cancer. Eur Urol 65:270-273, 2014.
PubMed
3) Suominen MI, Fagerlund KM, Rissanen JP, et al:Radium-223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of Cancer Cells and Bone Microenvironment in Mouse Models. Clin Cancer Res 23:4335-4346, 2017
PubMed
4) Parker C, Nilsson S, Heinrich D, et al:Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369:213-223, 2013.
PubMed
5) Hoskin P, Sartor O, O'Sullivan JM, et al:Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use:a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol 15:1397-1406, 2014.
 
6) Uemura H, Uemura H, Nagamori S, et al:Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases. Int J Clin Oncol 24:557-566, 2019.
PubMed
7) Castello A, Macapinlac HA, Lopci E, et al:Prostate-specific antigen flare induced by 223RaCl2 in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging 45:2256-2263, 2018.
PubMed
8) Miyoshi Y, Tsutsumi S, Yasui M, et al:A novel prediction model for the completion of six cycles of radium-223 treatment and survival in patients with metastatic castration-resistant prostate cancer. World J Urol 39:3323-3328, 2021.
PubMed
9) Hashimoto K, Miyoshi Y, Shindo T, et al:Dynamic changes of bone metastasis predict bone-predominant status to benefit from radium-223 dichloride for patients with castration-resistant prostate cancer. Cancer Med 9:8579-8588, 2020.
PubMed
10) Kawahara T, Miyoshi Y, Ninomiya S, et al:Administration of radium-223 and the prognosis in Japanese bone metastatic castration-resistant prostate cancer patients:A large database study. Int J Urol 29:1079-1084, 2022.
PubMed
11) Smith M, Parker C, Saad F, et al:Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223):a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 20:408-419, 2019.
PubMed
12) Trieu J, Chang M, Rojas V, et al:Lower Fracture Rates in Patients Treated with Radium-223, Abiraterone or Enzalutamide, When Given Concurrently with Bone Health Agents:A Real-World Analysis. Clin Genitourin Cancer 20:399-403, 2022.
PubMed
13) Jacene H, Gomella L, Yu EY, et al:Hematologic Toxicity From Radium-223 Therapy for Bone Metastases in Castration-Resistant Prostate Cancer:Risk Factors and Practical Considerations. Clin Genitourin Cancer 16:e919-e926, 2018.
PubMed
P.438 掲載の参考文献
1) Smith MR, Hussain M, Saad F, et al:Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. N Engl J Med 386:1132-1142, 2022.
 
2) Fizazi K, Foulon S, Carles J, et al:Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1):a multicentre, open-label, randomised, phase 3 study with a 2x2 factorial design. Lancet 399:1695-1707, 2022.
 
3) Saad F, Efstathiou E, Attard G, et al:Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS):a randomised, placebo-controlled, double-blind, multinational, phase 3 study. Lancet Oncol 22:1541-1559, 2021.
PubMed
4) Clarke NW, Armstrong AJ, Thiery-Vuillemin A, et al:Abiraterone and Olaparib for metastatic castration-resistant prostate cancer. NEJM Evid 1, 2022. (DOI:10.1056/EVIDoa2200043)
 
5) Suzuki H, Kamiya N, Imamoto T, et al:Current topics and perspectives relating to hormone therapy for prostate cancer. Int J Clin Oncol 13:401-410, 2008.
PubMed
6) James ND, Sydes MR, Clarke NW, et al:Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE):survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 387:1163-1177, 2016.
 
7) Fizazi K, Tran N, Fein L, et al:Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med 377:352-360, 2017.
PubMed
8) Suzuki H, Shin T, Fukasawa S, et al:Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer:final subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. Jpn J Clin Oncol 50:810-820, 2020.
PubMed
9) Davis ID, Martin AJ, Stockler MR, et al:Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. N Engl J Med 381:121-131, 2019.
PubMed
10) Armstrong AJ, Szmulewitz RZ, Petrylak DP, et al:ARCHES:A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol 37:2974-2986, 2019.
 
11) Chi KN, Agarwal N, Bjartell A, et al:Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med 381:13-24, 2019.
PubMed
12) Chen K, O'Brien J, McVey A, et al:Combination treatment in metastatic prostate cancer:is the bar too high or have we fallen short? Nat Rev Urol 20:116-123, 2023.
PubMed
13) Yanagisawa T, Rajwa P, Thibault C, et al:Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer:A Systematic Review and Meta-analysis. Eur Urol 82:584-598, 2022.
PubMed
14) Gillessen S, Armstrong A, Attard G, et al:Management of patients with advanced prostate cancer:Report from the Advanced Prostate Cancer Consensus Conference 2021. Eur Urol 82:115-141, 2022.
PubMed
15) Schaeffer EM, Srinivas S, Adra N, et al:NCCN GuidelinesRInsights:Prostate Cancer, Version 1. 2023. J Natl Compr Canc Netw 20:1288-1298, 2022
PubMed
P.443 掲載の参考文献
1) Wong CH, Siah KW, Lo AW:Estimation of clinical trial success rates and related parameters. Biostatistics 20:273-286, 2019.
PubMed
2) Fizazi K, Cook N, Barthelemy P, et al:Phase 1 results of the ODM-208 first-in-human phase 1-2 trial in patients with metastatic castration-resistant prostate cancer (CYPIDES). J Clin Oncol 40(Suppl 6):18, 2022.
 
3) Fizazi K, Bernard-Tessier A, Barthelemy P, et al:1364MO Preliminary phase II results of the CYPIDES study of ODM-208 in metastatic castration-resistant prostate (mCRPC) cancer patients. Ann Oncol 33(Suppl 7):S616-S652, 2022.
 
4) Modi S, Saura C, Yamashita T, et al:Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N Engl J Med 382:610-621, 2020.
PubMed
5) Shitara K, Bang YJ, Iwasa S, et al:Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. N Engl J Med 382:2419-2430, 2020.
PubMed
6) Modi S, Jacot W, Yamashita T, et al:Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med 387:9-20, 2022.
PubMed
7) Guo C, Figueiredo I, Gurel B, et al:B7-H3 as a Therapeutic Target in Advanced Prostate Cancer. Eur Urol 83:224-238, 2023.
 
8) Doi T, Patel M, Falchook GS, et al:453O DS-7300 (B7-H3 DXd antibody-drug conjugate [ADC])shows durable antitumor activity in advanced solid tumors:Extended follow-up of a phase I/II study. Ann Oncol 33(Suppl 7):S197-S224, 2022.
 
9) Tran B, Horvath L, Dorff T, et al:609O Results from a phase I study of AMG 160, a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTER) immune therapy for metastatic castration-resistant prostate cancer (mCRPC). Ann Oncol 31(Suppl 4):S507, 2022.
 
10) Santomasso BD, Nastoupil LJ, Adkins S, et al:Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy:ASCO Guideline. J Clin Oncol 39:3978-3992, 2021.
PubMed
P.452 掲載の参考文献
1) Johansson JE, Adami HO, Andersson SO, et al:High 10-year survival rate in patients with early, untreated prostatic cancer. JAMA 267:2191-2196, 1992.
PubMed
2) Chodak GW, Thisted RA, Gerber GS, et al:Results of conservative management of clinically localized prostate cancer. N Engl J Med 330:242-248, 1994.
PubMed
3) Choo R, Klotz L, Danjoux C, et al:Feasibility study:watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol 167:1664-1669, 2002.
PubMed
4) Carter HB, Walsh PC, Landis P, et al:Expectant management of nonpalpable prostate cancer with curative intent:preliminary results. J Urol 167:1231-1234, 2002.
PubMed
5) Kakehi Y, Kamoto T, Shiraishi T, et al:Prospective evaluation of selection criteria for active surveillance in Japanese patients with stage T1cN0M0 prostate cancer. Jpn J Clin Oncol 38:122-128, 2008.
PubMed
6) Hugosson J, Roobol MJ, Mansson M, et al:A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer. Eur Urol 76:43-51, 2019.
PubMed
7) Hamdy FC, Donovan JL, Lane JA, et al:10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. N Engl J Med 375:1415-1424, 2016.
 
8) Wilt TJ, Jones KM, Barry MJ, et al:Follow-up of Prostatectomy versus Observation for Early Prostate Cancer. N Engl J Med 377:132-142, 2017.
PubMed
9) Klotz L, Vesprini D, Sethukavalan P, et al:Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol 33:272-277, 2015.
PubMed
10) Tosoian JJ, Mamawala M, Epstein JI, et al:Intermediate and Longer-Term Outcomes From a Prospective Active-Surveillance Program for Favorable-Risk Prostate Cancer. J Clin Oncol 33:3379-3385, 2015.
PubMed
11) 平間裕美, 杉元幹史, 小川 修, ほか:前立腺 骨転移・他 低リスク前立腺癌に対する(PSA)監視療法の長期成績-厚生労働省班研究 11-10 より-. 日本癌治療学会学術集会抄録集, 54回, WS6-1, 2016.
 
12) Musunuru HB, Yamamoto T, Klotz L, et al:Active Surveillance for Intermediate Risk Prostate Cancer:Survival Outcomes in the Sunnybrook Experience. J Urol 196:1651-1658, 2016.
PubMed
13) Savdie R, Aning J, So AI, et al:Identifying intermediate-risk candidates for active surveillance of prostate cancer. Urol Oncol 35:605. e1-605. e8, 2017.
 
14) Masic S, Cowan JE, Washington SL, et al:Effects of Initial Gleason Grade on Outcomes during Active Surveillance for Prostate Cancer. Eur Urol Oncol 1:386-394, 2018.
PubMed
15) Godtman RA, Holmberg E, Khatami A, et al:Long-term Results of Active Surveillance in the Goteborg Randomized, Population-based Prostate Cancer Screening Trial. Eur Urol 70:760-766, 2016.
PubMed
16) Thomsen FB, Jakobsen H, Langkilde NC, et al:Active Surveillance for Localized Prostate Cancer:Nationwide Observational Study. J Urol 201:520-527, 2019.
PubMed
17) Enikeev D, Morozov A, Taratkin M, et al:Active Surveillance for Intermediate-Risk Prostate Cancer:Systematic Review and Meta-analysis of Current Protocols and Outcomes. Clin Genitourin Cancer 18:e739-e753, 2020.
PubMed
18) NCCN Clinical Practice Guidelines in Oncology(NCCN Guidelines(R)):Prostate Cancer, version 1. 2023.
 
19) EAU Oncology Guidelines "Prostate Cancer", 2021.
 
20) Eastham JA, Auffenberg GB, Barocas DA, et al:Clinically Localized Prostate Cancer:AUA/ASTRO Guideline, 2022.
 
21) CQ2 監視療法中の経過観察方法と治療開始基準は何か? 前立腺癌診療ガイドライン[2016年版](日本泌尿器科学会 編), p105-106, メディカルレビュー社, 2016.
 
22) Hoffman KE, Penson DF, Zhao Z, et al:Patient-Reported Outcomes Through 5 Years for Active Surveillance, Surgery, Brachytherapy, or External Beam Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer. JAMA 323:149-163, 2020
 
23) Donovan JL, Hamdy FC, Lane JA, et al:Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med 375:1425-1437, 2016.
 
24) Punnen S, Cowan JE, Chan JM, et al:Long-term health-related quality of life after primary treatment for localized prostate cancer:results from the CaPSURE registry. Eur Urol 68:600-608, 2015.
PubMed
25) Chen RC, Basak R, Meyer AM, et al:Association Between Choice of Radical Prostatectomy, External Beam Radiotherapy, Brachytherapy, or Active Surveillance and Patient-Reported Quality of Life Among Men With Localized Prostate Cancer. JAMA 317:1141-1150, 2017.
PubMed
26) Zelefsky MJ, Poon BY, Eastham J, et al:Longitudinal assessment of quality of life after surgery, conformal brachytherapy, and intensity-modulated radiation therapy for prostate cancer. Radiother Oncol 118:85-91, 2016.
PubMed
27) Venderbos LDF, Aluwini S, Roobol MJ, et al:Long-term follow-up after active surveillance or curative treatment:quality-of-life outcomes of men with low-risk prostate cancer. Qual Life Res 26:1635-1645, 2017.
PubMed
28) Hirama H, Sugimoto M, Miyatake N, et al:Health-related quality of life in Japanese low-risk prostate cancer patients choosing active surveillance:3-year follow-up from PRIAS-JAPAN. World J Urol 39:2491-2497, 2021.
PubMed
29) Rajwa P, Pradere B, Quhal F, et al:Reliability of Serial Prostate Magnetic Resonance Imaging to Detect Prostate Cancer Progression During Active Surveillance:A Systematic Review and Meta-analysis. Eur Urol 80:549-563, 2021.
PubMed
30) Chesnut GT, Vertosick EA, Benfante N, et al:Role of Changes in Magnetic Resonance Imaging or Clinical Stage in Evaluation of Disease Progression for Men with Prostate Cancer on Active Surveillance. Eur Urol 77:501-507, 2020.
 
31) Loeb S, Tosoian JJ:Biomarkers in active surveillance. Transl Androl Urol 7:155-159, 2018.
PubMed
32) Lin DW, Newcomb LF, Brown MD, et al:Evaluating the Four Kallikrein Panel of the 4Kscore for Prediction of High-grade Prostate Cancer in Men in the Canary Prostate Active Surveillance Study. Eur Urol 72:448-454, 2017.
PubMed
33) Hirama H, Sugimoto M, Ito K, et al:The impact of baseline [-2]proPSA-related indices on the prediction of pathological reclassification at 1 year during active surveillance for low-risk prostate cancer:the Japanese multicenter study cohort. J Cancer Res Clin Oncol 140:257-263, 2014.
PubMed
34) Kato T, Hirama H, Mitsuzuka K, et al:Reclassification prediction of first-year protocol biopsy on active surveillance of prostate cancer by p2PSA-related parameters:from PRIAS-JAPAN. Prostate Cancer Prostatic Dis 25:666-671, 2022.
PubMed
35) Carter HB, Helfand B, Mamawala M, et al:Germline Mutations in ATM and BRCA1/2 Are Associated with Grade Reclassification in Men on Active Surveillance for Prostate Cancer. Eur Urol 75:743-749, 2019.
PubMed
36) Nguyen PL, Haddad Z, Ross AE, et al:Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens. Eur Urol 72:845-852, 2017.
PubMed
37) Nguyen PL, Shin H, Yousefi K, et al:Impact of a Genomic Classifier of Metastatic Risk on Postprostatectomy Treatment Recommendations by Radiation Oncologists and Urologists. Urology 86:35-40, 2015.
PubMed
38) Eure G, Germany R, Given R, et al:Use of a 17-Gene Prognostic Assay in Contemporary Urologic Practice:Results of an Interim Analysis in an Observational Cohort. Urology 107:67-75, 2017.
 
39) Lokman U, Erickson AM, Vasarainen H, et al:PTEN Loss but Not ERG Expression in Diagnostic Biopsies Is Associated with Increased Risk of Progression and Adverse Surgical Findings in Men with Prostate Cancer on Active Surveillance. Eur Urol Focus 4:867-873, 2018.
PubMed
P.458 掲載の参考文献
1) Huang JF, Shen J, Li X, et al:Incidence of patients with bone metastases at diagnosis of solid tumors in adults:a large population-based study. Ann Transl Med 8:482, 2020.
PubMed
2) Norgaard M, Jensen AO, Jacobsen JB, et al:Skeletal related events, bone metastasis and survival of prostate cancer:a population based cohort study in Denmark (1999 to 2007). J Urol 184:162-167, 2010.
PubMed
3) Rades D, Conde-Moreno AJ, Cacicedo J, et al:Metastatic Spinal Cord Compression:A Survival Score Particularly Developed for Elderly Prostate Cancer Patients. Anticancer Res 35:6189-6192, 2015.
PubMed
4) Fizazi K, Massard C, Smith M, et al:Bone-related Parameters are the Main Prognostic Factors for Overall Survival in Men with Bone Metastases from Castration-resistant Prostate Cancer. Eur Urol 68:42-50, 2015.
PubMed
5) Pan Y, Jin H, Chen W, et al:Docetaxel with or without zoledronic acid for castration-resistant prostate cancer. Int Urol Nephrol 46:2319-2326, 2014.
PubMed
6) Yoneda T, Hiraga T:Crosstalk between cancer cells and bone microenvironment in bone metastasis. Biochem Biophys Res Commun 328:679-687, 2005.
PubMed
7) Nakagawa N, Kinosaki M, Yamaguchi K, et al:RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun 253:395-400, 1998.
PubMed
8) Yasuda H, Shima N, Nakagawa N, et al:Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 95:3597-3602, 1998.
PubMed
9) Fleisch H:Bisphosphonates:Mechanisms of Action. Endocr Rev 19:80-100, 1998.
 
10) Saad F, Gleason DM, Murray R, et al:Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96:879-882, 2004.
PubMed
11) Fizazi K, Carducci M, Smith M, et al:Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer:a randomised, double-blind study. Lancet 377:813-822, 2011.
PubMed
12) Smith MR, Coleman RE, Klotz L, et al:Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer:comparison of skeletal-related events and symptomatic skeletal events. Ann Oncol 26:368-374, 2015.
PubMed
13) Kamba T, Kamoto T, Maruo S, et al:A phase III multicenter, randomized, controlled study of combined androgen blockade with versus without zoledronic acid in prostate cancer patients with metastatic bone disease:results of the ZAPCA trial. Int J Clin Oncol 22:166-173, 2017.
PubMed
14) Ueno S, Mizokami A, Fukagai T, et al:Efficacy of combined androgen blockade with zoledronic acidtreatment in prostate cancer with bone metastasis:the ZABTON-PC (zoledronic acid/androgenblockade trial on prostate cancer) study. Anticancer Res 33:3837-3844, 2013.
 
15) Smith MR, Saad F, Coleman R, et al:Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer:results of a phase 3, randomised, placebo-controlled trial. Lancet 379:39-46, 2012.
PubMed
16) Smith MR, Saad F, Oudard S, et al:Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer:exploratory analyses by baseline prostate-specific antigen doubling time. J Clin Oncol 31:3800-3806, 2013.
PubMed
17) Smith MR, Halabi S, Ryan CJ, et al:Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases:results of CALGB 90202 (alliance). J Clin Oncol 32:1143-1150, 2014.
 
18) Bamias A, Kastritis E, Bamia C, et al:Osteonecrosis of the jaw in cancer after treatment with bisphosphonates:incidence and risk factors. J Clin Oncol 23:8580-8587, 2005.
PubMed
19) Takahashi M, Ozaki Y, Kizawa R, et al:Atypical femoral fracture in patients with bone metastasis receiving denosumab therapy:a retrospective study and systematic review. BMC Cancer 19:980, 2019.
 
20) Himelstein AL, Foster JC, Khatcheressian JL, et al:Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases:A Randomized Clinical Trial. JAMA 317:48-58, 2017.
PubMed
21) Clemons M, Ong M, Stober C, et al:A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer. Eur J Cancer 142:132-140, 2021.
PubMed
22) Mucke T, Deppe H, Hein J, et al:Prevention of bisphosphonate-related osteonecrosis of the jaws in patients with prostate cancer treated with zoledronic acid - A prospective study over 6 years. J Craniomaxillofac Surg 44:1689-1693, 2016.
PubMed
23) Ripamonti CI, Maniezzo M, Campa T, et al:Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol 20:137-145, 2009.
PubMed
24) Ruggiero SL, Dodson TB, Fantasia J, et al:American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw-2014 update. J Oral Maxillofac Surg 72:1938-1956, 2014.
 
25) Ruggiero SL, Dodson TB, Aghaloo T, et al:American Association of Oral and Maxillofacial Surgeons' Position Paper on Medication-Related Osteonecrosis of the Jaws-2022 Update. J Oral Maxillofac Surg 80:920-943, 2022.
 
26) Stopeck AT, Fizazi K, Body JJ, et al:Safety of long-term denosumab therapy:results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer. Support Care Cancer 24:447-455, 2016.
PubMed
P.465 掲載の参考文献
1) 宇井睦人:緩和ケアポケットマニュアル[改訂2版], p51-61, 南山堂, 2022.
 
2) がん仏痛の薬物療法に関するガイドライン[2020年版](日本緩和医療学会ガイドライン統括委員会編), p22-92, 金原出版, 2020.
 
3) Caraceni A, Hanks G, Kaasa S, et al:Use of opioid analgesics in the treatment of cancer pain:evidence-based recommendations from the EAPC. Lancet Oncol 13:e58-68, 2012.
PubMed
4) Fallon M, Giusti R, Aielli F, al:Management of cancer pain in adult patients:ESMO Clinical Practice Guidelines. Ann Oncol 29(Suppl 3):iv166-iv191, 2018.
 
P.472 掲載の参考文献
1) European Association of Urology (EAU):EAU Guidelines on Prostate Cancer, 2021. [https://uroweb.org/guidelines/prostate-cancer]
 
2) National Comprehensive Cancer Network (NCCN):NCCN Guidelines:Prostate Cancer, Version 1. 2023. [https://www.nccn.org/guidelines/guidelines-detail?category=1]
 
3) Moris L, Cumberbatch MG, Van den Broeck T, et al:Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer:An International Multidisciplinary Systematic Review. Eur Urol 77:614-627, 2020.
PubMed
4) Stranne J, Brasso K, Brennhovd B, et al:SPCG-15:a prospective randomized study comparing primary radical prostatectomy and primary radiotherapy plus androgen deprivation therapy for locally advanced prostate cancer. Scand J Urol 52:313-320, 2018.
PubMed
5) Saika T, Miura N, Fukumoto T, et al:Role of robot-assisted radical prostatectomy in locally advanced prostate cancer. Int J Urol 25:30-35, 2018.
PubMed
6) Eastham JA, Heller G, Halabi S, et al:Cancer and Leukemia Group B 90203 (Alliance):Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer. J Clin Oncol 38:3042-3050, 2020.
PubMed
7) Narita S, Tsuchiya N, Kumazawa T, et al:Short-term clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade, followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with high-risk localized prostate cancer. World J Surg Oncol 10:1, 2012.
PubMed
8) Narita S, Nara T, Kanda S, et al:Radical Prostatectomy With and Without Neoadjuvant Chemohormonal Pretreatment for High-Risk Localized Prostate Cancer:A Comparative Propensity Score Matched Analysis. Clin Genitourin Cancer 17:e113-e122, 2019.
PubMed
9) 相澤理人:局所進行性前立腺癌に対する外部放射線治療の実際(粒子線治療も含む). 臨床泌尿器科 76:830-836, 2022.
 
10) Zapatero A, Guerrero A, Maldonado X, et al:High-dose radiotherapy and risk-adapted androgen deprivation in localised prostate cancer (DART 01/05):10-year results of a phase 3 randomised, controlled trial. Lancet Oncol 23:671-681, 2022.
PubMed
11) Pommier P, Chabaud S, Lagrange JL, et al:Is There a Role for Pelvic Irradiation in Localized Prostate Adenocarcinoma? Update of the Long-Term Survival Results of the GETUG-01 Randomized Study. Int J Radiat Oncol Biol Phys 96:759-769, 2016.
 
12) Roach M, Moughan J, Lawton CAF, et al:Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413):long-term results of a randomised, phase 3 trial. Lancet Oncol 19:1504-1515, 2018.
 
13) Rodda S, Tyldesley S, Morris WJ, et al:ASCENDE-RT:An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys 98:286-295, 2017.
PubMed
14) Morris WJ, Tyldesley S, Rodda S, et al:Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial):An Analysis of Survival Endpoints fora Randomized Trial Comparing a Low-Dose-Rate Brachy therapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer. Int J Radiat Oncol Biol Phys 98:275-285, 2017.
 
15) Attard G, Murphy L, Clarke NW, et al:Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer:a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet 399:447-460, 2022.
 
16) Barata PC, Sartor AO:Metastatic castration-sensitive prostate cancer:Abiraterone, docetaxel, or.... Cancer 125:1777-1788, 2019.
 
17) Gillessen S, Attard G, Beer TM, et al:Management of Patients with Advanced Prostate Cancer:Report of the Advanced Prostate Cancer Consensus Conference 2019. Eur Urol 77:508-547, 2020.
PubMed
18) Guckenberger M, Lievens Y, Bouma AB, et al:Characterisation and classification of oligometastatic disease:a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol 21:e18-e28, 2020.
PubMed
19) Yoshida S, Matsushima H, Fujii Y:Classification of oligometastatic prostate cancer with additional consideration for hormone sensitivity. World J Urol 40:871-873, 2022.
PubMed
20) Boeve LMS, Hulshof MCCM, Vis AN, et al:Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial:Data from the HORRAD Trial. Eur Urol 75:410-418, 2019.
 
21) Parker CC, James ND, Brawley CD, et al:Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE):a randomised controlled phase 3 trial. Lancet 392:2353-2366, 2018.
 
22) Patrikidou A, Brureau L, Casenave J, et al:Locoregional symptoms in patients with de novo metastatic prostate cancer:Morbidity, management, and disease outcome. Urol Oncol 33:202. e9-17, 2015.
 
23) Ost P, Reynders D, Decaestecker K, et al:Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence:A Prospective, Randomized, Multicenter Phase II Trial. J Clin Oncol 36:446-453, 2018.
PubMed
24) Phillips R, Shi WY, Deek M, et al:Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer:The ORIOLE Phase 2 Randomized Clinical Trial. JAMA Oncol 6:650-659, 2020.
PubMed
25) Hofman MS, Lawrentschuk N, Francis RJ, et al:Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA):a prospective, randomised, multicentre study. Lancet 395:1208-1216, 2020.
 
26) Gillessen S, Bossi A, Davis ID, et al:Management of Patients with Advanced Prostate Cancer. Part I:Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment:Report of the Advanced Prostate Cancer Consensus Conference 2022. Eur Urol 83:267-293, 2023.
PubMed
27) De Visschere PJL, Standaert C, Futterer JJ, et al:A Systematic Review on the Role of Imaging in Early Recurrent Prostate Cancer. Eur Urol Oncol 2:47-76, 2019.
PubMed
28) Lecouvet FE, Geukens D, Stainier A, et al:Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer:diagnostic and cost-effectiveness and comparison with current detection strategies. J Clin Oncol 25:3281-3287, 2007.
PubMed
29) Lecouvet FE, Simon M, Tombal B, et al:Whole-body MRI (WB-MRI) versus axial skeleton MRI (AS-MRI) to detect and measure bone metastases in prostate cancer (PCa). Eur Radiol 20:2973-2982, 2010.
PubMed
30) Robertson NL, Sala E, Benz M, et al:Combined Whole Body and Multiparametric Prostate Magnetic Resonance Imaging as a 1-Step Approach to the Simultaneous Assessment of Local Recurrence and Metastatic Disease after Radical Prostatectomy. J Urol 198:65-70, 2017.
 
31) 吉田宗一郎, 藤井靖久:前立腺癌の新規画像診断法としての全身 MRI:PSMA-PET/CT と比較した位置付けと使用法. 泌尿器外科 35:416-423, 2022.
Medical*Online
32) Dyrberg E, Hendel HW, Huynh THV, et al:68Ga-PSMA-PET/CT in comparison with 18F-fluoride-PET/CT and whole-body MRI for the detection of bone metastases in patients with prostate cancer:a prospective diagnostic accuracy study. Eur Radiol 29:1221-1230, 2019.
 
33) Wu H, Xu T, Wang X, et al:Diagnostic Performance of 68Gallium Labelled Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography and Magnetic Resonance Imaging for Staging the Prostate Cancer with Intermediate or High Risk Prior to Radical Prostatectomy:A Systematic Review and Meta-analysis. World J Mens Health 38:208-219, 2020.
PubMed
P.480 掲載の参考文献
1) Sweat SD, Pacelli A, Murphy GP, et al:Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology 52:637-640, 1998.
PubMed
2) Eiber M, Maurer T, Souvatzoglou M, et al:Evaluation of Hybrid v x Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy. J Nucl Med 56:668-674, 2015.
 
3) Rahbar K, Ahmadzadehfar H, Kratochwil C, et al:German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients. J Nucl Med 58:85-90, 2017.
PubMed
4) Haberkorn U, Eder M, Kopka K, et al:New Strategies in Prostate Cancer:Prostate-Specific Membrane Antigen (PSMA) Ligands for Diagnosis and Therapy. Clin Cancer Res 22:9-15, 2016.
PubMed
5) Huggins C, Hodges CV:Studies on Prostatic Cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1:293-297, 1941.
 
6) Schally AV, Arimura A, Kastin AJ, et al:Gonadotropin-releasing hormone:one polypeptide regulates secretion of luteinizing and follicle-stimulating hormones. Science 173:1036-1038, 1971.
PubMed
7) Labrie F, Dupont A, Belanger A, et al:New hormonal therapy in prostatic carcinoma:combined treatment with an LHRH agonist and an antiandrogen. Clin Invest Med 5:267-275, 1982.
 
8) Mori K, Miura N, Mostafaei H, et al:Sequential therapy of abiraterone and enzalutamide in castration-resistant prostate cancer:a systematic review and meta-analysis. Prostate Cancer Prostatic Dis 23:539-548, 2020.
PubMed
9) Fendler WP, Rahbar K, Herrmann K, et al:177Lu-PSMA Radioligand Therapy for Prostate Cancer. J Nucl Med 58:1196-1200, 2017.
 
10) Hofman MS, Violet J, Hicks RJ, et al:[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial):a single-centre, single-arm, phase 2 study. Lancet Oncol 19:825-833, 2018.
 

V 特論

P.490 掲載の参考文献
1) Sung H, Ferlay J, Siegel RL, et al:Global Cancer Statistics 2020:GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 71:209-249, 2021.
PubMed
2) 厚生労働省:「令和3年(2021)人口動態統計月報年計(概数)の概況」. [https://www.mhlw.go.jp/toukei/saikin/hw/jinkou/geppo/nengai21/index.html]
 
3) 国立がん研究センター:がん情報サービス「がん統計」(厚生労働省人口動態統計).
 
4) 国立がん研究センター:がん情報サービス「がん統計」(全国がん登録).
 
5) 国立がん研究センター:がん情報サービス「がん統計」(全国がん罹患モニタリング集計(MCIJ)).
 
6) Robinson D, Van Allen EM, Wu YM, et al:Integrative clinical genomics of advanced prostate cancer. Cell 161:1215-1228, 2015.
PubMed
7) Yatani R, Chigusa I, Akazaki K, et al:Geographic pathology of latent prostatic carcinoma. Int J Cancer 29:611-616, 1982.
PubMed
8) Fleshner N, Bagnell PS, Klotz L, et al:Dietary fat and prostate cancer. J Urol 171:S19-S24, 2004.
PubMed
P.497 掲載の参考文献
1) Young HH:XV. Cancer of the Prostate:A Clinical, Pathological and Post-Operative Analysis of 111 Cases. Ann Surg 50:1144-1233, 1909.
PubMed
2) Kovi J, Jackson MA, Heshmat MY:Ductal spread in prostatic carcinoma. Cancer 56:1566-1573, 1985.
PubMed
3) McNeal JE, Yemoto CE:Spread of adenocarcinoma within prostatic ducts and acini. Morphologic and clinical correlations. Am J Surg Pathol 20:802-814, 1996.
PubMed
4) Tsuzuki T:Intraductal carcinoma of the prostate:a comprehensive and updated review. Int J Urol 22:140-145, 2015.
PubMed
5) Haffner MC, Weier C, Xu MM, et al:Molecular evidence that invasive adenocarcinoma can mimic prostatic intraepithelial neoplasia (PIN) and intraductal carcinoma through retrograde glandular colonization. J Pathol 238:31-41, 2016.
PubMed
6) WHO Classification of Tumours, 5th ed, Vol 8, Urinary and Male Genital Tumours(ed by the WHO Classification of Tumours Editorial Board), IARC, Lyon, 2022.
 
7) Guo CC, Epstein JI:Intraductal carcinoma of the prostate on needle biopsy:Histologic features and clinical significance. Mod Pathol 19:1528-1535, 2006.
 
8) Cohen RJ, Wheeler TM, Bonkhoff H, et al:A proposal on the identification, histologic reporting, and implications of intraductal prostatic carcinoma. Arch Pathol Lab Med 131:1103-1109, 2007.
PubMed
9) Fine SW, Al-Ahmadie HA, Chen YB, et al:Comedonecrosis Revisited:Strong Association With Intraductal Carcinoma of the Prostate. Am J Surg Pathol 42:1036-1041, 2018.
PubMed
10) Porter LH, Lawrence MG, Ilic D, et al:Systematic Review Links the Prevalence of Intraductal Carcinoma of the Prostate to Prostate Cancer Risk Categories. Eur Urol 72:492-495, 2017.
PubMed
11) Kato M, Hirakawa A, Kobayashi Y Ms, et al:The influence of the presence of intraductal carcinoma of the prostate on the grade group system's prognostic performance. Prostate 79:1065-1070, 2019.
PubMed
12) Kimura K, Tsuzuki T, Kato M, et al:Prognostic value of intraductal carcinoma of the prostate in radical prostatectomy specimens. Prostate 74:680-687, 2014.
PubMed
13) Kweldam CF, Kummerlin IP, Nieboer D, et al:Prostate cancer outcomes of men with biopsy Gleason score 6 and 7 without cribriform or intraductal carcinoma. Eur J Cancer 66:26-33, 2016.
 
14) Aizawa R, Tsuzuki T, Haga H, et al:Clinical significance of IDC-P as predictive factor after intensity-modulated radiation therapy. Cancer Sci 113:2425-2433, 2022.
 
15) Kato M, Tsuzuki T, Kimura K, et al:The presence of intraductal carcinoma of the prostate in needle biopsy is a significant prognostic factor for prostate cancer patients with distant metastasis at initial presentation. Mod Pathol 29:166-173, 2016.
PubMed
16) McKay RR, Ye H, Xie W, et al:Evaluation of Intense Androgen Deprivation Before Prostatectomy:A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone. J Clin Oncol 37:923-931, 2019.
PubMed
17) Yamamoto A, Kato M, Matsui H, et al:Efficacy of docetaxel in castration-resistant prostate cancer patients with intraductal carcinoma of the prostate. Int J Clin Oncol 23:584-590, 2018.
PubMed
18) Yamamoto A, Kato M, Hattori K, et al:Propensity score-matched comparison of docetaxel and androgen receptor axis-targeted agents in patients with castration-resistant intraductal carcinoma of the prostate. BJU Int 125:702-708, 2020.
PubMed
19) National Comprehensive Cancer Network(NCCN):NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines(R)):Prostate Cancer, Version 1. 2023. [https://www.nccn.org/professionals/physician_gls/pdf/prostate_blocks.pdf]
 
20) European Association of Urology(EAU):EAU Guideline, Prostate Cancer, 2022. [https://uroweb.org/guidelines/prostate-cancer]
 
21) Pritchard CC, Mateo J, Walsh MF, et al:Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. N Engl J Med 375:443-453, 2016.
PubMed
22) Isaacsson Velho P, Silberstein JL, Markowski MC, et al:Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostatecancer. Prostate 78:401-407, 2018.
 
23) Taylor RA, Fraser M, Rebello RJ, et al:The influence of BRCA2 mutation on localized prostatecancer. Nat Rev Urol 16:281-290, 2019.
 
24) Giri VN, Knudsen KE, Kelly WK, et al:Implementation of Germline Testing for Prostate Cancer:Philadelphia Prostate Cancer Consensus Conference 2019. J Clin Oncol 38:2798-2811, 2020.
PubMed
25) Lozano R, Salles DC, Sandhu S, et al:Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer. Eur J Cancer 147:74-83, 2021.
PubMed
26) Hussain M, Mateo J, Fizazi K, et al:Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. N Engl J Med 383:2345-2357, 2020.
PubMed
27) Kweldam CF, Kummerlin IP, Nieboer D, et al:Disease-specific survival of patients with invasive cribriform and intraductal prostate cancer at diagnostic biopsy. Mod Pathol 29:630-636, 2016.
PubMed
28) van Leenders GJLH, Kweldam CF, Hollemans E, et al:Improved Prostate Cancer Biopsy Grading by Incorporation of Invasive Cribriform and Intraductal Carcinoma in the 2014 Grade Groups. Eur Urol 77:191-198, 2020.
PubMed
29) McNeal JE, Reese JH, Redwine EA, et al:Cribriform adenocarcinoma of the prostate. Cancer 58:1714-1719, 1986.
PubMed
30) Gleason DF:Classification of prostatic carcinomas. Cancer Chemother Rep 50:125-128, 1966.
PubMed
31) Rijstenberg LL, Hansum T, Kweldam CF, et al:Large and small cribriform architecture have similar adverse clinical outcome on prostate cancer biopsies. Histopathology 80:1041-1049, 2022.
PubMed
32) van der Kwast TH, van Leenders GJ, Berney DM, et al:ISUP Consensus Definition of Cribriform Pattern Prostate Cancer. Am J Surg Pathol 45:1118-1126, 2021.
PubMed
33) Epstein JI, Amin MB, Beltran H, et al:Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am J Surg Pathol 38:756-767, 2014.
PubMed
34) Beltran H, Prandi D, Mosquera JM, et al:Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med 22:298-305, 2016.
PubMed
35) Aggarwal R, Huang J, Alumkal JJ, et al:Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer:A Multi-institutional Prospective Study. J Clin Oncol 36:2492-2503, 2018.
PubMed
36) Abida W, Cyrta J, Heller G, et al:Genomic correlates of clinical outcome in advanced prostate cancer. Proc Natl Acad Sci USA 116:11428-11436, 2019.
PubMed
37) Marusyk A, Janiszewska M, Polyak K:Intratumor Heterogeneity:The Rosetta Stone of Therapy Resistance. Cancer Cell 37:471-484, 2020.
PubMed
38) Cheng Q, Butler W, Zhou Y, et al:Pre-existing Castration-resistant Prostate Cancer-like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy. Eur Urol 81:446-455, 2022.
 
39) Chan JM, Zaidi S, Love JR, et al:Lineage plasticity in prostate cancer depends on JAK/STAT inflammatory signaling. Science 377:1180-1191, 2022.
PubMed
40) Deng S, Wang C, Wang Y, et al:Ectopic JAK-STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance. Nat Cancer 3:1071-1087, 2022.
PubMed
41) 都築豊徳:大きく変わる前立腺がんの病理診断. 日本医師会雑誌 145:1601-1604, 2016.
 
42) Anderson BB, Oberlin DT, Razmaria AA, et al:Extraprostatic Extension Is Extremely Rare for Contemporary Gleason Score 6 Prostate Cancer. Eur Urol 72:455-460, 2017.
PubMed
43) Eggener SE, Berlin A, Vickers AJ, et al:Low-Grade Prostate Cancer:Time to Stop Calling It Cancer. J Clin Oncol 40:3110-3114, 2022.
 
44) Epstein JI, Kibel AS:Renaming Gleason Score 6 Prostate to Noncancer:A Flawed Idea Scientifically and for Patient Care. J Clin Oncol 40:3106-3109, 2022.
PubMed
45) Iczkowski KA, Molina M, Egevad L, et al:Low-grade prostate cancer should still be labelled cancer. BJU Int 130:741-743, 2022.
PubMed
46) Netto GJ, Amin MB, Comperat EM, et al:Prostate Adenocarcinoma Grade Group 1:Rationale for Retaining a Cancer Label in the 2022 World Health Organization Classification. Eur Urol 83:301-303, 2023.
PubMed
47) Bulten W, Kartasalo K, Chen PC, et al:Artificial intelligence for diagnosis and Gleason grading of prostate cancer:the PANDA challenge. Nat Med 28:154-163, 2022.
PubMed
P.506 掲載の参考文献
1) Bill-Axelson A, Holmberg L, Garmo H, et al:Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med 370:932-942, 2014.
 
2) Walsh PC, Donker PJ:Impotence following radical prostatectomy:insight into etiology and prevention. J Urol 128:492-497, 1982.
PubMed
3) Lepor H, Gregerman M, Crosby R, et al:Precise localization of the autonomic nerves from the pelvic plexus to the corpora cavernosa:a detailed anatomical study of the adult male pelvis. J Urol 133:207-212, 1985.
 
4) Kiyoshima K, Yokomizo A, Yoshida T, et al:Anatomical features of periprostatic tissue and its surroundings:a histological analysis of 79 radical retropubic prostatectomy specimens. Jpn J Clin Oncol 34:463-468, 2004.
PubMed
5) Costello AJ, Brooks M, Cole OJ:Anatomical studies of the neurovascular bundle and cavernosal nerves. BJU Int 94:1071-1076, 2004.
PubMed
6) Takenaka A, Murakami G, Soga H, et al:Anatomical analysis of the neurovascular bundle supplying penile cavernous tissue to ensure a reliable nerve graft after radical prostatectomy. J Urol 172:1032-1035, 2004.
PubMed
7) Lunacek A, Schwentner C, Fritsch H, et al:Anatomical radical retropubic prostatectomy:'curtain dissection' of the neurovascular bundle. BJU Int 95:1226-1231, 2005.
PubMed
8) Menon M, Shrivastava A, Kaul S, et al:Vattikuti Institute prostatectomy:contemporary technique and analysis of results. Eur Urol 51:648-658, 2007.
PubMed
9) Alsaid B, Bessede T, Diallo D, et al:Division of autonomic nerves within the neurovascular bundles distally into corpora cavernosa and corpus spongiosum components:immunohistochemical confirmation with three-dimensional reconstruction. Eur Urol 59:902-909, 2011.
PubMed
10) Costello AJ, Dowdle BW, Namdarian B, et al:Immunohistochemical study of the cavernous nerves in the periprostatic region. BJU Int 107:1210-1215, 2011.
PubMed
11) Kim ED, Nath R, Slawin KM, et al:Bilateral nerve grafting during radical retropubic prostatectomy:extended follow-up. Urology 58:983-987, 2001.
PubMed
12) Tewari AK, Srivastava A, Huang MW, et al:Anatomical grades of nerve sparing:a risk-stratified approach to neural-hammock sparing during robot-assisted radical prostatectomy (RARP). BJU Int 108:984-992, 2011.
PubMed
13) Ganzer R, Stolzenburg JU, Neuhaus J, et al:Anatomical study of pelvic nerves in relation to seminal vesicles, prostate and urethral sphincter:immunohistochemical staining, computerized planimetry and 3-dimensional reconstruction. J Urol 193:1205-1212, 2015.
PubMed
14) Hinata N, Murakami G, Miyake H, et al:Histological study of the cavernous nerve mesh outside the periprostatic region:anatomical basis for erectile function after nonnerve sparing radical prostatectomy. J Urol 193:1052-1059, 2015.
PubMed
15) Schatloff O, Chauhan S, Sivaraman A, et al:Anatomic grading of nerve sparing during robot-assisted radical prostatectomy. Eur Urol 61:796-802, 2012.
PubMed
16) Hinata N, Sejima T, Takenaka A:Progress in pelvic anatomy from the viewpoint of radical prostatectomy. Int J Urol 20:260-270, 2013.
PubMed
17) Tewari AK, Ali A, Metgud S, et al:Functional outcomes following robotic prostatectomy using athermal, traction free risk-stratified grades of nerve sparing. World J Urol 31:471-480, 2013.
PubMed
18) Srivastava A, Chopra S, Pham A, et al:Effect of a risk-stratified grade of nerve-sparing technique on early return of continence after robot-assisted laparoscopic radical prostatectomy. Eur Urol 63:438-444, 2013.
 
19) Stolzenburg JU, Kallidonis P, Do M, et al:A comparison of outcomes for interfascial and intrafascial nerve-sparing radical prostatectomy. Urology 76:743-748, 2010.
 
20) Rifaioglu MM, Davarci M, Ozgur T, et al:Histopathologic evaluation of neurovascular bundles and periprostatic tissue in interfascial and intrafascial nerve-sparing radical prostatectomy technique:a cadaveric anatomic study. Urology 82:948-954, 2013.
PubMed
21) Ong AM, Su LM, Varkarakis I, et al:Nerve sparing radical prostatectomy:effects of hemostatic energy sources on the recovery of cavernous nerve function in a canine model. J Urol 172(4Pt1):1318-1322, 2004.
 
22) Ahlering TE, Eichel L, Chou D, et al:Feasibility study for robotic radical prostatectomy cautery-free neurovascular bundle preservation. Urology 65:994-997, 2005.
PubMed
23) Kowalczyk KJ, Huang AC, Hevelone ND, et al:Stepwise approach for nerve sparing without countertraction during robot-assisted radical prostatectomy:technique and outcomes. Eur Urol 60:536-547, 2011.
PubMed
24) Myers RP:Detrusor apron, associated vascular plexus, and avascular plane:relevance to radical retropubic prostatectomy-anatomic and surgical commentary. Urology 59:472-479, 2002.
PubMed
25) Hinata N, Miyake H, Murakami G, et al:Bladder Neck Muscle Degeneration in Patients with Prostatic Hyperplasia. J Urol 195:206-212, 2016.
PubMed
26) McNeal J:The prostate gland:morphology and pathobiology. Monogr Urol 9:36, 1988.
 
27) Ayala AG, Ro JY, Babaian R, et al:The prostatic capsule:does it exist? Its importance in the staging and treatment of prostatic carcinoma. Am J Surg Pathol 13:21-27, 1989.
PubMed
28) Galfano A, Ascione A, Grimald, S, et al:A new anatomic approach for robot-assisted laparoscopic prostatectomy:a feasibility study for completely intrafascial surgery. Eur Urol 58:457-461, 2010.
 
29) Menon M, Dalela D, Jamil M, et al:Functional Recovery, Oncologic Outcomes and Postoperative Complications after Robot-Assisted Radical Prostatectomy:An Evidence-Based Analysis Comparing the Retzius Sparing and Standard Approaches. J Urol 199:1210-1217, 2018.
PubMed
30) Wagaskar VG, Mittal A, Sobotka S, et al:Hood Technique for Robotic Radical Prostatectomy-Preserving Periurethral Anatomical Structures in the Space of Retzius and Sparing the Pouch of Douglas, Enabling Early Return of Continence Without Compromising Surgical Margin Rates. Eur Urol 80:213-221, 2021.
PubMed
31) Moore, KL, Agur AMR, Dalley AF:Essential Clinical Anatomy, 4th ed, Lippincott Williams & Wilkins, Baltimore, 2011.
 
32) Tanagho EA, Pugh RC:The anatomy and function of the ureterovesical junction. Br J Urol 35:151-165, 1963.
PubMed
33) Dorschner W, Stolzenburg JU, Dieterich F:A new theory of micturition and urinary continence based on histomorphological studies. 2. The musculus sphincter vesicae:continence or sexual function? Urol Int 52:154-158, 1994.
PubMed
34) Federative Committee on Anatomical Terminology(FCAT):Terminologia Anatomica. International Anatomical Terminology, Georg Thieme Verlag KG, Stuttgart, 1998.
 
35) Tewari A, El-Hakim A, Rao S, et al:Identification of the retrotrigonal layer as a key anatomical landmark during robotically assisted radical prostatectomy. BJU Int 98:829-832, 2006.
PubMed
36) Patel VR, Coelho RF, Rocco B, et al:Positive surgical margins after robotic assisted radical prostatectomy:a multi-institutional study. J Urol 186:511-516, 2011.
PubMed
37) Atug F, Castle EP, Srivastav SK, et al:Positive surgical margins in robotic-assisted radical prostatectomy:impact of learning curve on oncologic outcomes. Eur Urol 49:866-872, 2006.
PubMed
38) Swindle P, Eastham JA, Ohori M, et al:Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol 179:S47-S51, 2008.
PubMed
39) Schlomm T, Heinzer H, Steuber T, et al:Full functional-length urethral sphincter preservation during radical prostatectomy. Eur Urol 60:320-329, 2011.
PubMed
40) McNeal JE:Normal histology of the prostate. Am J Surg Pathol 12:619-633, 1988.
PubMed
41) Myers RP, Goellner JR, Cahill DR:Prostate shape, external striated urethral sphincter and radical prostatectomy:the apical dissection. J Urol 138:543-550, 1987.
PubMed
42) Oelrich TM:The urethral sphincter muscle in the male. Am J Anat 158:229-246, 1980.
 
43) Walz J, Burnett AL, Costello AJ, et al:A critical analysis of the current knowledge of surgical anatomy related to optimization of cancer control and preservation of continence and erection in candidates for radical prostatectomy. Eur Urol 57:179-192, 2010.
PubMed
44) Myers RP, Cheville JC, Pawlina W:Making anatomic terminology of the prostate and contiguous structures clinically useful:historical review and suggestions for revision in the 21st century. Clin Anat 23:18-29, 2010.
PubMed
45) Murakami G, Nakajima F, Sato TJ, et al:Individual variations in aging of the male urethral rhabdosphincter in Japanese. Clin Anat 15:241-252, 2002.
PubMed
46) Elbadawi A, Mathews R, Light JK, et al:Immunohistochemical and ultrastructural study of rhabdosphincter component of the prostatic capsule. J Urol 158:1819-1828, 1997.
PubMed
47) Guru KA, Perlmutter AE, Sheldon MJ, et al:Apical margins after robot-assisted radical prostatectomy:does technique matter? J Endourol 23:123-127, 2009.
 
48) Lei Y, Alemozaffar M, Williams SB, et al:Athermal division and selective suture ligation of the dorsal vein complex during robot-assisted laparoscopic radical prostatectomy:description of technique and outcomes. Eur Urol 59:235-243, 2011.
PubMed
49) Myers RP:Improving the exposure of the prostate in radical retropubic prostatectomy:longitudinal bunching of the deep venous plexus. J Urol 142:1282-1284, 1989.
PubMed
50) Eichelberg C, Erbersdobler A, Michl U, et al:Nerve distribution along the prostatic capsule. Eur Urol 51:105-111, 2007.
PubMed
51) Lee SB, Hong SK, Choe G, et al:Periprostatic distribution of nerves in specimens from non-nerve-sparing radical retropubic prostatectomy. Urology 72:878-881, 2008.
PubMed
52) Ganzer R, Blana A, Gaumann A, et al:Topographical anatomy of periprostatic and capsular nerves:quantification and computerised planimetry. Eur Urol 54:353-360, 2008.
PubMed
53) Hisasue S, Hashimoto K, Kobayashi K, et al:Baseline erectile function alters the cavernous nerve quantity and distribution around the prostate. J Urol 184:2062-2067, 2010.
PubMed
54) Huri E, Sargon MF, Tatar I, et al:Novel Anatomic Mapping of Pelvic Plexus at Prostatic and Periprostatic Region on Fresh Frozen Cadaveric Setting. Urol J 14:5064-5067, 2017.
PubMed
55) Rodrigues TM, Mitre AI, da Silva LFF, et al:Periprostatic innervation:New issues based on segmental analysis of 10 human cadaver pelvic blocs. Prostate 77:1151-1159, 2017.
PubMed
56) Stanford JL, Feng Z, Hamilton AS, et al:Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer:the Prostate Cancer Outcomes Study. JAMA 283:354-360, 2000.
PubMed
57) Barre C:Open radical retropubic prostatectomy. Eur Urol 52:71-80, 2007.
PubMed
58) Krishnan R, Katz D, Nelson CJ, et al:Erectile function recovery in patients after non-nerve sparing radical prostatectomy. Andrology 2:951-954, 2014.
PubMed
P.515 掲載の参考文献
1) Minds 診療ガイドライン作成マニュアル 2020 ver.3.0 (Minds 診療ガイドライン作成マニュアル編集委員会 編), 日本医療機能評価機構, 2021.
 

書評

最近チェックした商品履歴

Loading...